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Abstract
Population-based administrative databases are valuable data sources for scientiﬁc
research. A common problem of studies based on secondary data is, however, missing
confounder information. For instance in pharmacoepidemiological studies based on
claims data of statutory health insurances, information on the potentially important
confounders body mass index (BMI) and smoking behaviour is lacking. Obtaining
additional information from another data source, e.g. from survey data, for at least
a subsample of the study population resolves this problem. Two-phase designs can
be employed for the combined analysis of both data sources. In logistic two-phase
studies a dichotomous outcome and some covariate information are available for the
whole population in phase 1 whereas the full vector of covariates is only observed
for a subsample in phase 2. Information of phase 1 is utilised in the analysis of
the phase 2 sample via stratiﬁcation by phase 1 covariates. This approach allows
for an unbiased parameter estimation and can improve eﬃciency of the estimation
of covariates included in the stratiﬁcation. An additional gain in eﬃciency can be
achieved if the stratiﬁcation is also used for sampling of the phase 2 data set and
the most informative subjects are sampled with a high probability.
Two-phase designs have been developed for ﬁeld studies. Field studies usually
comprise very few covariates in phase 1 because ascertainment of each additional
covariate for the whole population is associated with additional costs. In these tra-
ditional two-phase studies, the stratiﬁcation is simply deﬁned by cross-classiﬁcation
of all available phase 1 covariates. Two-phase database studies include a multitude
of phase 1 covariates. Cross-classiﬁcation of all available covariates would therefore
lead to a tremendously high number of strata and, due to the restricted size of the
phase 2 sample, to empty cells. Since two-phase methods cannot be applied in pres-
ence of empty cells, new stratiﬁcation strategies are needed which account for all
relevant phase 1 covariates but do not result in empty cells.
The aim of this thesis is the development of strategies for the eﬃcient use of
phase 1 information in logistic two-phase studies comprising a multitude of phase
1 covariates. An alternative stratiﬁcation strategy is proposed, which is based on
percentiles of a disease score. In this context, the disease score includes as a sum-
mary measure information on several phase 1 covariates in the stratiﬁcation. The
core of the thesis is the development of a design criterion which allows the identiﬁ-
cation of eﬃcient stratiﬁcations at the planning stage of the study when only phase
1 information is available. Both the new stratiﬁcation strategy and the design crite-
rion are applied to an empirical two-phase database study investigating the risk of
serious bleedings associated with phenprocoumon exposure. Additionally, the novel
approaches are evaluated in a simulation study mimicking the empirical study. It
is shown that those stratiﬁcations assessed as eﬃcient by the design criterion result
in the smallest standard errors for the estimates of most phase 1 covariates in the
simulation study. The best stratiﬁcations regarding unbiased and eﬃcient param-
eter estimation are deﬁned by cross-classiﬁcation of variables used for sampling of
the phase 2 data and percentiles of the disease score. Moreover, empirically based
recommendations for the planning of future two-phase studies are deduced from the
results of the simulation study.
An outlook on survey methodological approaches for the analysis of partially
missing data completes the thesis. The multiple imputation approach is applied
to the empirical study and compared to results of the two-phase analyses. It be-
comes evident that multiple imputation is much more eﬃcient with respect to the
estimation of coeﬃcients for phase 1 covariates than two-phase methods. However,
biased estimates are observed in a simulation study, when the imputation model does
not suﬃciently account for the selective sampling of the phase 2 data. A ﬁnal as-
sessment of the comparison between two-phase methods and survey methodological
approaches is still missing.
Zusammenfassung
Administrative Datenbanken sind wertvolle Datenquellen für populationsbasierte
Studien. Ein großes Problem dieser Sekundärdaten ist jedoch, dass oft nicht alle
für die Studie notwendigen Informationen in den Daten enthalten sind. In phar-
makoepidemiologischen Studien, die auf Basis von Abrechnungsdaten der gesetzli-
chen Krankenversicherungen durchgeführt werden, fehlen z.B. Informationen über
wichtige verzerrende Faktoren (Confounder) wie den Body Mass Index (BMI) und
das Rauchverhalten. Daten über fehlende Confounder müssen separat erhoben wer-
den oder aus anderen Datenquellen zugespielt werden. Da es häuﬁg nicht möglich
ist, die zusätzlichen Daten für die gesamte Studienpopulation zu erheben, muss
die Auswertungsmethode mit partiell fehlender Information umgehen können. Zwei-
Phasen-Designs ermöglichen eine eﬃziente gemeinsame Auswertung beider Daten-
quellen. Das Design lässt sich sinnvoll anwenden, wenn gewisse Information, z.B.
über den Krankheitsstatus und einige Kovariablen, für eine breite Studiengesamt-
heit verfügbar ist (Phase 1), während zusätzliche oder genauere Information nur
für eine Teilmenge (Phase 2) vorliegt. In der Analyse der Phase-2-Stichprobe wird
Information über die Kovariablenverteilung in den Phase-1-Daten genutzt, wodurch
die Standardfehler der Parameterschätzungen der Phase-1-Variablen und korrelier-
ter Phase-2-Variablen reduziert werden. Diese Nutzung von Phase-1-Information
erfolgt über eine Stratiﬁzierung der Datensätze nach Phase-1-Variablen. Ein zusätz-
licher Eﬃzienzgewinn kann dadurch erreicht werden, dass die Stratiﬁzierung nicht
nur zur Auswertung, sondern zuvor auch zur Selektion der Phase-2-Stichprobe ver-
wendet wird, sodass ‘informative’ Personen mit einer höheren Wahrscheinlichkeit
ausgewählt werden.
Zwei-Phasen-Designs wurden ursprünglich für Feldstudien entwickelt. Feldstu-
dien enthalten in Phase 1 nur sehr wenige Variablen, da die Erhebung jeder zu-
sätzlichen Variable mit Kosten verbunden ist. Die Stratiﬁzierung wird in traditio-
nellen Zwei-Phasen-Studien einfach als Kreuzklassiﬁkation aller Phase-1-Variablen
deﬁniert. In Datenbankstudien steht hingegen eine Vielzahl an Phase-1-Variablen
zur Verfügung, die in die Stratiﬁzierung eingeschlossen werden können. Kreuzklassi-
ﬁkation aller Phase-1-Variablen führt in dieser Situation zu einer sehr großen Anzahl
von Straten und, aufgrund des begrenzten Umfangs der Phase-2-Stichprobe, zu un-
besetzten Zellen. Da Zwei-Phasen-Methoden nicht für Stratiﬁzierungen mit leeren
Straten angewendet werden können, wird eine Stratiﬁzierungsstrategie benötigt, die
zwar einerseits viele Phase-1-Variablen einschließt, andererseits aber nicht zu leeren
Zellen führt.
Das Ziel dieser Arbeit ist die Entwicklung von Strategien zur eﬃzienten Nutzung
von Phase-1-Information in logistischen Zwei-Phasen-Studien, die eine Vielzahl von
Phase-1-Variablen enthalten. Dazu wird zunächst ein zur Kreuzklassiﬁkation alter-
natives Stratiﬁzierungsverfahren vorgeschlagen, das auf der Verwendung von Disease
Scores beruht. Die Disease Scores werden dabei als zusammenfassendes Maß vieler
Phase-1-Variablen genutzt. Im Hauptteil der Arbeit wird ein Designkriterium entwi-
ckelt, das den Vergleich verschiedener Stratiﬁzierungen in Hinblick auf eine eﬃziente
Parameterschätzung ermöglicht. Sowohl das neue Stratiﬁzierungsverfahren als auch
das Designkriterium werden in einer empirischen Zwei-Phasen-Datenbankstudie, die
das Risiko schwerer Blutungen nach Phenprocoumoneinnahme untersucht, angewen-
det und in einer auf der empirischen Studie basierenden Simulationsstudie überprüft.
Es zeigt sich, dass die mit dem Designkriterium als eﬃzient eingestuften Stratiﬁ-
zierungen in der Simulationsstudie tatsächlich für viele Phase-1-Variablen zu den
kleinsten Standardfehlern der geschätzten Parameter führen. Bezüglich der Eﬃzi-
enz und der gleichzeitigen Vermeidung von Verzerrungen in der Parameterschätzung
sind Stratiﬁzierungen, die aus einer Kreuzklassiﬁkation von Perzentilen des Disease
Scores und von Variablen bestehen, die zur Selektion der Phase-2-Stichprobe genutzt
wurden, in dieser Datenkonstellation am besten geeignet. Aus den Ergebnissen der
Simulationsstudie lassen sich außerdem Empfehlungen für die Planung zukünftiger
Zwei-Phasen-Studien ableiten.
Die Arbeit schließt mit einem Ausblick auf surveymethodologische Ansätze, die
ebenfalls für die Analyse unvollständiger Datensätze eingesetzt werden können. Ins-
besondere wird der Multiple-Imputation-Ansatz auf die empirische Studie ange-
wandt und mit den Ergebnissen der Zwei-Phasen-Analyse verglichen. Die Schät-
zung mittels Multiple Imputation resultiert in dieser Studie im Vergleich zu Zwei-
Phasen-Analysen in wesentlich kleineren Standardfehlern für die geschätzten Eﬀekte
der Phase-1-Variablen. In einer Simulationsstudie wird jedoch gezeigt, dass die Pa-
rameterschätzer bei Verwendung falscher Imputationsmodelle verzerrt sind. Eine
abschließende Beurteilung der surveymethodologischen Verfahren im Vergleich zur
Zwei-Phasen-Analyse ist noch nicht erfolgt.
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Chapter 1
Introduction
Population-based administrative databases are a valuable data source for scientiﬁc
research. Examples for such databases in Germany are the micro data of the Ger-
man Federal Employment Agency (BA) and the claims data of the statutory health
insurances (SHI). These data sources are often used for empirical research, either as
a data source for database studies, as a sampling frame for survey studies, or as a
source of additional information to be linked with survey data. A common problem
in database studies based on secondary data is, however, missing confounder in-
formation, which can be resolved by obtaining additional information for at least
a subset of the study sample. In this context, the combined use of administrative
data and other data sources is reasonable. Currently, there are some examples of
studies combining population-based administrative data with survey data or other
secondary data. For instance in the panel study ‘The Labour Market and Social
Security’ (PASS), the register on unemployment beneﬁt II recipients was used as
the sampling frame for one of the two samples included in the panel (Rudolph and
Trappmann, 2007). In PASS, information on postal code, unemployment beneﬁt
receipt and the number of so-called ‘Bedarfsgemeinschaften’ was extracted from the
administrative data for each household and used for the selection of the study sam-
ple. Another example is the study ‘lidA - leben in der Arbeit. German Cohort
Study on Work, Age and Health’ in which interview data is planned to be linked
to administrative data of the BA and to health insurance data to investigate the
inﬂuence of work-related factors on the health of workers of advanced age (March
et al., 2012).
1
In both examples, the available information from the administrative data source is
not fully considered in the design and analysis of the studies. In the main analysis of
PASS, information from the administrative data is only utilised to generate sampling
weights which means that only that part of information is used on which the sample
selection was based. Further analyses investigating non-response and memory error
incorporate additional variables from the administrative data (Kreuter et al., 2010).
However, these analyses are based on subjects included in both data sources and
ignore information for subjects not included in the intersection of the data sources.
In the lidA study, it is also planned to base the study exclusively on subjects included
in the survey who agreed to the data linkage.
To use the available data sources more eﬃciently in such studies, two-phase de-
signs can be employed. Two-phase designs were ﬁrst suggested by Neyman, 1938
who proposed a two-step approach of sampling in a ﬁeld survey with the aim to
investigate a characteristic which is expensive to obtain but for which an easily col-
lectable surrogate exists. In the ﬁrst step of sampling, the surrogate is obtained for
a large population. In the second step of sampling, a stratiﬁed random sample is
drawn from the large population where the surrogate is used to deﬁne the strata.
The characteristic of interest is only obtained for the stratiﬁed subsample but the
analysis of the characteristic also utilises the distribution of the surrogate in the
large population, thereby enhancing the eﬃciency of the estimator. More than 40
years later, the two-phase design was introduced into the ﬁeld of epidemiology by
Walker, 1982 and White, 1982. During the late 1980s and the 1990s methodolog-
ical work has been published regarding the estimation in two-phase studies with
binary outcome (e.g., Breslow and Cain, 1988; Flanders and Greenland, 1991; Schill
et al., 1993), though the design was rarely used in practice. Also in the late 1990s,
Schaubel et al., 1997 suggested the use of the two-phase design for epidemiological
studies in which the population is obtained from an administrative database and
confounder information is collected from surveys or other data sources. The few
published examples of two-phase studies based on administrative or registry data
employ simple two-phase designs using the main exposure of interest as a single
stratiﬁcation variable (Collet et al., 1998; Sharpe et al., 2000; Martel et al., 2009).
These studies ignore information, e.g. on age and sex, which is also available in the
administrative data for the full population.
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Figure 1.1: Concept of a two-phase case-control design
The aim of this thesis is to investigate two-phase designs for case-control studies
based on administrative databases which use the maximum amount of available
phase 1 information for the eﬃcient estimation of the adjusted exposure eﬀect of
the exposure under study. Incorporation of the phase 1 information in the two-phase
analysis is accomplished by the performed stratiﬁcation which is therefore the key
element of a two-phase design. To further illustrate the role of stratiﬁcation, the
concept of a two-phase case-control design is depicted in Figure 1.1. Two types
of stratiﬁcation can be distinguished: A stratiﬁcation deﬁned before the phase 2
sample is drawn is called a priori stratiﬁcation; if the stratiﬁcation is deﬁned to
analyse an already existing phase 2 sample it is called post stratiﬁcation. The post
stratiﬁcation can be based on any set of variables available in phase 1. As will be
seen in Chapter 3, the estimation methods do not diﬀerentiate between a priori and
post stratiﬁcation. For design considerations, however, the distinction is worthwhile.
Figure 1.1 shows a two-phase case-control study in which an a priori stratiﬁcation
is deﬁned based on a binary covariate, which is in most applications the exposure
of main interest. The a priori stratiﬁcation classiﬁes the phase 1 data set into four
strata: exposed cases, unexposed cases, exposed controls and unexposed controls.
From each of the four strata, a random sample is selected with a speciﬁed probability,
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here denoted by p1, . . . , p4. The resulting phase 2 data set is further stratiﬁed by
additional phase 1 variables, i.e. by those variables that are available for everyone
in the phase 1 sample. The phase 2 data set is then analysed with respect to the
complete covariate pattern which is only known for subjects included in the phase
2 sample and taking into account the stratum distribution in the phase 1 data set.
The choice of the stratiﬁcation and the choice of the selection probabilities have a
substantial impact on the eﬃciency of the parameter estimates obtained from the
two-phase analysis.
In this thesis, an empirical study on the risk of bleeding associated with phenpro-
coumon exposure is used as a recurring theme to illustrate the impact of diﬀerent
analysis approaches in two-phase database studies. Chapter 2 starts with a descrip-
tion of two ordinary case-control studies on phenprocoumon exposure and bleedings
which are published in Behr et al., 2010 (Appendix B) and Garbe et al., 2013 (Ap-
pendix C) and which serve as a motivation for the empirical two-phase study. The
chapter also introduces the two underlying data sources: claims data included in
the German Pharmacoepidemiological Research Database (GePaRD) and interview
data obtained in a health survey. In anticipation of the theoretical discussion of
two-phase database studies in the following chapters, ﬁrst results of the empirical
two-phase study are reported based on the publication of Behr et al., 2012 (Appendix
D) in Pharmacoepidemiology and Drug Safety. Chapter 3 provides details on the pa-
rameter estimation in two-phase studies. After deﬁning the notation and the study
design, likelihood-based estimation methods for two-phase studies are introduced.
The main part of the chapter is devoted to the derivation of maximum likelihood es-
timators in case-control and two-phase case-control studies using a proﬁle likelihood
approach. The focus of Chapter 4 lies on the identiﬁcation of stratiﬁcations which
use the available phase 1 information eﬃciently. The chapter starts with a discus-
sion on the limitations of cross-classiﬁcation, i.e. of the stratiﬁcation strategy used
in traditional two-phase ﬁeld studies, which can also be observed in the empirical
study (Behr et al., 2012; Appendix D). An alternative stratiﬁcation strategy based
on percentiles of a disease score is proposed by Behr and Schill, 2013 (Appendix E)
in a paper that will be submitted to a methodological epidemiology journal. The
core of the chapter as well as of the thesis is the development of a design criterion for
the identiﬁcation of the most eﬃcient stratiﬁcations with respect to small standard
errors of the parameter estimates. This part of the thesis has not yet been sum-
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marised in a manuscript and is therefore described in detail. Both novel approaches,
the new stratiﬁcation strategy and the design criterion, are applied in the empirical
study as well as in a simulation study based on this study. Chapter 5 gives a ﬁrst
impression of approaches beyond two-phase methods. In particular, results of the
two-phase analysis using the most eﬃcient stratiﬁcation identiﬁed in Chapter 4 are
compared with results of the survey methodological approach multiple imputation.
Chapter 6 concludes with a discussion of the presented work with regard to design
considerations of future two-phase studies comprising a rich phase 1 data set.
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Chapter 2
The empirical study: Two-phase
case-control study on the risk of
serious bleedings associated with
phenprocoumon treatment
2.1 Motivation
The Leibniz Institute for Prevention Research and Epidemiology - BIPS established
a research database which consists in its current form of administrative data from
four German statutory health insurances to study the use, eﬀectiveness and safety of
pharmaceutics and vaccines (for a detailed description of the German Pharmacoepi-
demiological Research Database, in short GePaRD, see Section 2.2.1). One of the
ﬁrst research projects that was initiated based on this database investigated the risk
of serious bleedings associated with phenprocoumon exposure. The research project
was intended to fulﬁl two purposes. First, the knowledge gap concerning the mag-
nitude of the bleeding risk related to phenprocoumon treatment should be closed.
Second, with serious bleedings being a well-known complication of oral anticoagu-
lants the suitability of the database for pharmacoepidemiological studies should be
investigated.
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A series of nested case-control studies was conducted to assess the overall bleeding
risk and the risk of bleeding in speciﬁc locations (gastrointestinal, intracerebral,
subarachnoid and urogenital bleedings) for phenprocoumon treatment. Except for
the outcome deﬁnition and the selection of potential confounders, the designs of
the case-control studies were very similar. The study on intracerebral bleedings
has been published in Pharmacoepidemiology and Drug Safety (Behr et al., 2010;
Appendix B). Details on the design of the case-control studies are described in that
publication. The study on subarachnoid bleedings has been submitted to Stroke
(Garbe et al., 2013; Appendix C). In addition, the risk of bleeding was assessed for
drug interactions with phenprocoumon (Jobski et al., 2011). In the next section, the
focus is on an unpublished study investigating the overall risk of serious bleeding
which motivated the conduct of the two-phase case-control study. After giving a
brief summary of the background and the study design, the results are described in
more detail.
2.1.1 Case-control study on the overall bleeding risk
Before the new classes of oral anticoagulants were launched to the market in 2008,
coumarins were the most widely used oral anticoagulants. Phenprocoumon is a
coumarin which accounts for more than 99% of the coumarin prescriptions in Ger-
many whereas outside of Germany warfarin is used instead (Hein and Schwabe,
2007). For this reason, there have been no epidemiological studies investigating
the bleeding risk for phenprocoumon alone and only a few studies investigating the
combined use of warfarin and phenprocoumon (e.g., Johnsen et al., 2003; Groen-
baek et al., 2008). To estimate the overall risk of serious bleeding associated with
phenprocoumon exposure a case-control study was conducted nested in a cohort of
more than 265,000 subjects who were insured at the regional healthcare provider
AOK Bremen/Bremerhaven between 2004 and 2006. Cohort entry was deﬁned as
the ﬁrst day after six months of continuous insurance time in the study period and
cohort exit was determined as the end of the insurance period, the date of hospital-
isation due to serious bleedings, the date of death, or the end of the study period
whichever came ﬁrst. Claims data from the GePaRD (see Section 2.2.1) was used
to identify cases by hospital discharge diagnoses of serious bleedings and to obtain
covariate information for cases and their respective controls which were matched by
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age and sex with a ratio of ten controls per case using a risk-set sampling approach.
Phenprocoumon exposure was assessed on the index day, i.e. the day of hospitalisa-
tion for cases and the day resulting in the same duration of follow-up for controls.
To be more precise, exposure on the index day was deﬁned as a phenprocoumon
prescription overlapping the index day where the duration of a prescription was es-
timated by the amount of prescribed substance divided by the estimated average
daily dose. Adjusted bleeding odds ratios (OR) and 95% conﬁdence intervals were
estimated for phenprocoumon exposure in a multivariable conditional logistic regres-
sion model including comorbid diseases and concomitant medications as covariates
as well as interaction terms between phenprocoumon exposure and the covariates,
age and sex, respectively. A list of all covariates and details on their deﬁnition are
given in a paper recently published in Pharmacoepidemiology and Drug Safety (Behr
et al., 2012; Appendix D).
A total of 2,113 cases of serious bleedings and 21,128 matched controls were
identiﬁed in the cohort. The mean age in the case-control sample was 68 years
(standard deviation (STD)=17.3 years) and slightly more women (54%) than men
were included. Most cases were hospitalised due to gastrointestinal bleedings (56%)
and cerebral bleedings (17%). Regarding phenprocoumon exposure, more cases
(10%) than controls (3%) were exposed on the index day. The prevalence of comorbid
conditions and concurrent medications was generally higher among cases than among
controls, e.g., diabetes was prevalent in 17% of the cases and 11% of the controls
(Table 2.1).
The results of the multivariable regression model are presented in Table 2.2. The
multivariable analysis revealed a signiﬁcantly increased risk of serious bleedings as-
sociated with phenprocoumon exposure. As indicated by the signiﬁcant interaction
terms, the magnitude of the risk depended on age and sex and was 4.6-fold increased
for a 68 years old male phenprocoumon user compared to a respective male not tak-
ing phenprocoumon. The risk associated with phenprocoumon was approximately
two times higher for females and decreased for older age. Because of the matched
design of the study age and sex could not be evaluated as independent risk factors
for serious bleedings. Most of the considered covariates were identiﬁed as signiﬁcant
risk factors for serious bleedings. Among these, medications aﬀecting the coagula-
tion, such as platelet aggregation inhibitors, heparin, and analgesics, were associated
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Table 2.1: Characteristics of cases and controls for selected comorbid con-
ditions and concurrent medications
Cases Controls
N=2,113 N=21,128
Comorbid conditions
Alcohol dependence 164 (7.76%) 407 (1.93%)
Bleeding history 58 (2.74%) 93 (0.44%)
Diabetes mellitus 360 (17.04%) 2,365 (11.19%)
Diverticular disease 219 (10.36%) 1,163 (5.50%)
Hypertension 1,355 (64.13%) 11,168 (52.86%)
Liver failure 324 (15.33%) 2,252 (10.66%)
Renal failure 324 (15.33%) 1,388 (6.57%)
Concurrent medications
Analgesics, antirheumatics, ASA 477 (22.57%) 2,239 (10.60%)
Diuretics 726 (34.36%) 3,834 (18.15%)
H2-receptor antagonists 69 (3.27%) 318 (1.51%)
Platelet aggregation inhibitors, heparin 334 (15.33%) 1,154 (5.46%)
Proton pump inhibitors 372 (17.61%) 1,164 (5.51%)
SSRIs 36 (1.70%) 118 (0.56%)
ASA: acetylsalicylic acid, SSRI: selective serotonin reuptake inhibitor
with an approximately two-fold increased risk.
The observed interaction between phenprocoumon exposure and sex has not been
described in the literature previously. Whether the elevation of risk is causally re-
lated to female sex cannot be concluded from this study because the higher bleeding
risk can also be related to the usually lower body mass index (BMI) in women. Since
information on BMI is not included in the administrative data, the risk of bleeding
could not be adjusted for it which is a relevant limitation of the study. Furthermore,
claims data does only include information on prescriptions which are reimbursed by
the health care provider. Especially painkillers like acetylsalicylic acid (ASA) are
often bought over-the-counter (OTC) leading to an underestimation of exposure to
analgesics and potentially diluting the appropriate estimation of the bleeding risk
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Table 2.2: Results of the multivariable conditional logistic regression analysis for
serious bleedings
Multivariable model Odds 95% Conﬁdence p-value
Ratiob Interval
Phenprocoumon exposure 4.60 2.93-7.23 <.001
Interaction: phen. * sex 1.86 1.27-2.72 0.001
Interaction: phen. * agea 0.98 0.96-1.00 0.029
Comorbid conditions
Alcohol dependence 3.67 2.96-4.55 <.001
Bleeding history 3.91 2.68-5.69 <.001
Diabetes mellitus 1.13 0.98-1.29 0.082
Diverticular disease 1.63 1.36-1.94 <.001
Interaction: phen. * diverticular disease 0.58 0.32-1.05 0.070
Hypertension 1.16 1.03-1.31 0.017
Interaction: phen. * hypertension 0.82 0.52-1.30 0.391
Liver failure 1.39 1.22-1.58 <.001
Renal failure 1.67 1.42-1.96 <.001
Interaction: phen. * renal failure 0.60 0.37-0.96 0.035
Concurrent medications
Analgesics, antirheumatics, ASA 1.88 1.66-2.12 <.001
Diuretics 1.60 1.42-1.80 <.001
H2-receptor antagonists 1.38 1.03-1.85 0.029
Platelet aggregation inhibitors, heparin 2.22 1.92-2.58 <.001
Proton pump inhibitors 2.16 1.87-2.49 <.001
SSRIs 1.93 1.26-2.96 0.002
a Age centred at 68 years.
b Also adjusted for corticosteroid use, cancer, and chronic obstructive pulmonary disease (COPD).
ASA: acetylsalicylic acid, SSRI: selective serotonin reuptake inhibitor
for these substances.
To overcome these limitations, additional information was obtained from a sub-
sample of insurance members in a health survey described in Section 2.2.2 where a
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two-phase design was used for the combined analysis of both data sources. The de-
sign and the main results of the two-phase study are brieﬂy described in Section 2.3.
More details of the study are published in Behr et al., 2012 (Appendix D). Since this
two-phase study is used to illustrate design aspects of two-phase studies throughout
the thesis, the underlying data sources are described in the next sections.
2.2 Data sources
2.2.1 The administrative claims database
The German Pharmacoepidemiological Research Database (GePaRD) currently com-
prises claims data of the years 2004-2009 from four statutory health insurances with
about 17 million members during this time period. The content and structure of
the insurance claims data is regulated by the Code of Social Law V which allows
pooling of the data from diﬀerent health care providers according to the structure
presented in Figure 2.1. The data can be subdivided into four blocks corresponding
to distinct data-generating processes which are regulated by diﬀerent paragraphs of
the Code of Social Law. The ﬁrst block consists of the basic claims data comprising
demographic characteristics of the insurance member and information on insurance
periods. The second block of data arises from hospital stays and includes inpatient
diagnoses and inpatient medical procedures. Since inpatient service is reimbursed
by lump sums according to the main discharge diagnosis, inpatient pharmaceutical
treatment is not recorded in the claims data. The third block contains outpatient
treatment data such as information about the treating physician, outpatient diag-
noses and outpatient medical procedures. The fourth block consists of outpatient
prescription data including all prescriptions which were ﬁlled by the patient in a
pharmacy and were reimbursed by the health care provider. Thus, no information
on OTC medication and on non-refundable medication is available in the claims
data. The four blocks are linked by pseudonymous subject identiﬁers.
All diagnoses are coded according to the German modiﬁcation of the International
Statistical Classiﬁcation of Diseases version 10 (ICD-10-GM). Medical procedures
are coded using the OPS classiﬁcation system for surgeries and medical procedures.
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Figure 2.1: Structure of GePaRD
The prescription data can be linked by using the central pharmaceutical reference
number (PZN) to information included in a pharmaceutical reference database main-
tained at the BIPS that comprises the ATC code, trade name, generic name, and
the Deﬁned Daily Dose (DDD) for each substance.
Pigeot and Ahrens, 2008 investigated the usefulness of German SHI data for the
conduct of pharmacoepidemiological studies in a pilot database covering 3.6 million
subjects. They compared the age and sex distribution and hospital admission rates
for speciﬁc diseases obtained from the claims data with the respective values of the
oﬃcial statistics and found good agreement. They concluded that claims data can
be used to deﬁne confounder information on medical conditions and on concomitant
medication but also alluded to the limitation of the data to identify lifestyle-related
confounders such as smoking.
2.2.2 Additional information obtained in a health survey
For the empirical study on the overall bleeding risk related to phenprocoumon use
additional information on lifestyle- and health-related factors was obtained in com-
puter-assisted telephone interviews (CATI) for a subsample of insurants included
in the case-control study described in Section 2.1. The health survey was con-
ducted in collaboration with the regional statutory health insurance AOK Bre-
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men/Bremerhaven who contacted randomly selected insurance members (see Section
2.3) by mail and asked for their willingness to participate in the survey. Members
who agreed to participate had to send their telephone number together with a signed
informed consent to the BIPS and were afterwards called by the ﬁeld work unit of
the BIPS. The data collection and data handling process was described in a data
protection concept which was reviewed and accepted by the data protection oﬃcers
of the SHI and of the University of Bremen. In addition, the ethical committee of
the University of Bremen did not raise ethical concerns regarding the conduct of the
study.
Table 2.3: Response proportion in the health survey
Batch 1 Batch 2 Total
Letters sent 1,619 1,661 3,280
Response 382 (23.59%) 229 (13.78%) 611 (18.62%)
Interviews conducted 312 (19.27%) 193 (11.5%) 505 (15.35%)
Since claims data of the year 2007 became available shortly before the survey
started, the selection of insurants was based on claims data from 2004 until 2006 and
preliminary data from 2007. Several exclusion criteria were applied to ensure that all
persons were able to participate in the telephone interview. Persons were excluded if
they were younger than 18 years or older than 75 years, if they quit membership in
the SHI, if they had a diagnosis of dementia between 2004 and 2007, or if they died.
Two batches of 2,000 insurants each were selected and contacted consecutively. In
the initial batch of 2,000 persons, all persons with serious bleedings and all persons
with phenprocoumon exposure were included to achieve a balanced design with
respect to phenprocoumon exposure and serious bleedings. The remaining persons
were selected randomly from the set of unexposed persons without bleedings. After
insurants had been selected for the two batches, the SHI removed also those persons
who lived in nursing homes, who had left the SHI after 2007 or died after 2007. All
interviews were conducted between October 2009 and January 2010. A total of 505
interviews could be completed which corresponds to a response proportion of 15%
(Table 2.3). The response proportions for the two batches are summarised in Table
2.3.
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The following information was requested in the telephone interviews:
• Personal information about the date of birth, height, weight and the general
health status,
• hospital stays since 2004 including the reason for hospitalisation and the length
of stay,
• administration and indication of speciﬁc drug substances since 2006, i.e., phen-
procoumon, acetylsalicylic acid (ASA), diclofenac, ibuprofen and St. John’s
wort which is an antidote for phenprocoumon,
• treated and untreated gastric disorders since 2006, e.g., gastrointestinal bleed-
ings, gastric ulcer, reﬂux,
• other non-traumatic bleedings since 2004 which needed medical treatment,
• smoking history and current smoking behaviour.
The survey data was checked for internal plausibility and for external plausibility
by comparing the survey information with claims data for those items which were
available in both data sources. Very few inconsistencies were detected in the internal
plausibility checks. The comparison with the claims data revealed that bleedings
were reported with a low sensitivity whereas the sensitivity and the speciﬁcity were
high for phenprocoumon exposure. In contrast, prescriptions of the well-known
substance ASA were overreported and prescriptions of the less known pain killers
ibuprofen and diclofenac were underreported. As bleeding information can be reli-
ably obtained from the claims data the low reporting quality of bleedings imposed
no restrictions on the two-phase study described in the next section. However, in-
formation on OTC use of ASA and St. John’s wort and on other pain killers was
deemed to be not reliable due to the observed response errors for the prescribed
drugs. As a consequence, this information was not included in the two-phase study.
2.3 The two-phase study
A two-phase study was conducted to consider the additional confounder information
on BMI and smoking from the survey data for the estimation of the adjusted bleeding
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risk associated with phenprocoumon use based on the case-control database study.
This section describes the design of the two-phase study and gives a short overview
about the results. Details on the results are presented in Behr et al., 2012 (Appendix
D).
2.3.1 Study design
The design of the two-phase case-control study was very similar to the database
study presented in Section 2.1 using the same case deﬁnition and the same rules for
the identiﬁcation of phenprocoumon exposure as well as the derivation of covariates.
The underlying cohort was deﬁned in an extended data set consisting of claims
data of the AOK Bremen/Bremerhaven from 2004 until 2007. In addition to the
inclusion criterion of continuous membership in the SHI for at least six months, the
same exclusion criteria were applied as for the sample selection of the health survey.
Cohort entry and cohort exit were deﬁned as in the database study. However, in
contrast to this study, controls were not matched by age, sex and follow-up time
but were randomly selected from the set of cohort members who did not become a
case during the study with a case:control ratio of 1:20. Since the phase 2 subsample,
i.e. the insurants who were asked to participate in the health survey, had been
selected from preliminary data before the phase 1 case-control sample was drawn,
it had to be ensured that all survey participants were also part of the case-control
sample. Therefore, all subjects in the set of potential controls who completed the
telephone interview were included in the case-control sample. For each control, a
random index date was chosen from the period between cohort entry and cohort
exit. Additional information on BMI and smoking behaviour was available from
the health survey for a subset of 502 subjects. The remaining three subjects who
participated in the survey had to be excluded because two of them were not entitled
to receive beneﬁts from the SHI during the study period. Interview data of the third
subject was of very low quality (i.e., most items were missing, in particular no dates
were available).
The setup of the two-phase study is depicted in Figure 2.2. The phase 2 sample
was planned as a stratiﬁed random sample with approximately equal numbers of
exposed cases, unexposed cases, exposed controls and unexposed controls. Aiming
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at a balanced phase 2 data set of 1,000 subjects and assuming a response proportion
of 25%, 4,000 subjects were selected with sampling fractions of one for cases and
exposed controls and of 0.08 for unexposed controls. The actual phase 2 sample size
was only half of the planned sample size and the actual sampling fractions diﬀered
widely from the planned sampling fractions (Figure 2.2). Because of the unequal
sampling fractions, the phase 2 sample was not representative for the phase 1 sample.
Figure 2.2: Setup of the two-phase study on serious bleedings associ-
ated with phenprocoumon use
As will be explained in Chapter 3, overall representativeness of the phase 2 sample
is not required for adopting the two-phase approach but representativeness of each
stratum has to be ensured to fulﬁl the Missing-at-Random (MAR) assumption.
Since unintended selection processes might have led to distorted phase 2 strata, a
non-response analysis was conducted to identify prognostic factors for participation
in the survey. The logistic regression analysis modelling the probability of selection
into the phase 2 sample revealed case status and phenprocoumon exposure as the
most relevant prognostic factors which was expected due to the stratiﬁed sampling
scheme. Furthermore, age at cohort entry was identiﬁed as an important predictor
with a higher selection probability for older age. Signiﬁcant but weak associations
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were found for sex, use of statins and diverticular disease. All other covariates
were removed from the model by the applied backward selection procedure due
to non-signiﬁcance (p ≥ 0.05). The results of the non-response analysis are given
in Table 2.4. Taking these results into account, a stratiﬁcation was constructed
by cross-classifying age (< 50 years, 50− < 65 years, and ≥ 65 years), sex, and
phenprocoumon exposure into 12 strata. Use of statins and diverticular disease
were not considered in the stratiﬁcation because of the relatively low prevalence
of both factors (3.6% for statins, 0.7% for diverticular disease) and the only weak
association.
Table 2.4: Results of the logistic regression analysis modelling
the probability of selection into phase 2
Backward selection model OR (95% CI) p-value
Case-control status 5.35 (4.31 - 6.64) < .001
Phenprocoumon exposure 7.33 (5.57 - 9.64) < .001
Sex (reference: male) 1.25 (1.03 - 1.50) 0.021
Age (reference: < 50 years)
≥ 50− < 65 years 3.64 (2.87 - 4.63) < .001
≥ 65 years 4.20 (3.21 - 5.50) < .001
Diverticular disease 1.82 (1.01 - 3.25) 0.045
Statin use 1.56 (1.16 - 2.10) 0.003
A two-phase logistic model was ﬁt to estimate the risk of bleeding associated
with phenprocoumon use adjusted for the phase 1 covariates age, sex, hypertension,
and diabetes mellitus as well as for the phase 2 covariates BMI and smoking. Odds
ratios and corresponding 95% conﬁdence intervals (CI) were estimated by using the
maximum likelihood (ML) approach described by Breslow and Holubkov, 1997a and
taking into account the stratiﬁcation speciﬁed above. The theoretical background
of ML estimation in two-phase studies is given in Chapter 3. Further details on the
statistical analysis are speciﬁed in Behr et al., 2012 (Appendix D). The results of
the two-phase analysis were compared to risk estimates from a logistic regression
analysis based on the full phase 1 data set adjusted for the same phase 1 covariates
but without consideration of BMI and smoking. In addition, a full phase 1 model
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was used to estimate the risk for phenprocoumon adjusted for all available phase 1
variables.
2.3.2 Results
For the phase 1 case-control sample 1,248 cases and 24,960 controls were selected
from 186,438 subjects included in the study cohort. The phase 2 sample consisted
of 155 cases and 343 controls with complete information on BMI and smoking1.
Similar estimators for the risk of bleeding associated with phenprocoumon use were
observed in the two-phase analysis (OR=4.96, 95% CI: 2.91-8.45), the correspond-
ing phase 1 analysis (OR=4.14, 95% CI: 2.95-5.81), and in the full phase 1 model
(OR=3.93, 95% CI: 2.75-5.61). Regression coeﬃcients for age and the estimated
interaction between age and phenprocoumon exposure were also of similar size in
all models (cf. Table 3 and Table 5 in Appendix D). The interaction between sex
and phenprocoumon exposure was not statistically signiﬁcant (p < 0.05) in the full
phase 1 model (OR=1.33, 95% CI: 0.83-2.15) but in the reduced phase 1 model
(OR=1.59, 95% CI: 1.01-2.49) and in the two-phase analysis (OR=1.75, 95% CI:
1.07-2.86). Nevertheless, the odds ratios related to this interaction consistently in-
dicated an increased risk of bleeding for women taking phenprocoumon compared to
men taking phenprocoumon. Moreover, the two-phase model revealed an increased
risk of bleeding for BMI ≥ 30 kg/m2 and smoking with odds ratios of 1.57 (95%
CI: 1.00-2.47) and 2.30 (95% CI: 1.50-3.53), respectively. There was no evidence for
an interaction between BMI and phenprocoumon exposure. The eﬀects of hyper-
tension and diabetes mellitus could not be estimated with suﬃcient precision in the
two-phase analysis.
2.3.3 Discussion
Additional adjustment for BMI and smoking in the two-phase analysis did not alter
the estimated bleeding risk associated with phenprocoumon exposure. This study
conﬁrmed the increased risk for female phenprocoumon users which was observed
1One control without information on BMI and one case and two controls without information
on smoking were excluded from the two-phase analysis.
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in the case-control study described in Section 2.1.1 although the risk was less pro-
nounced in the two-phase study.
On the one hand the two-phase analysis yielded accurate and precise risk estimators
for phenprocoumon exposure and age, on the other hand two-phase estimators for
covariates like hypertension and diabetes mellitus were inconclusive. Since inclu-
sion of phase 1 information on these covariates in the stratiﬁcation may improve
the precision of the estimators, subsequent analyses were conducted to explore the
performance of alternative stratiﬁcations in this study. The results of these analyses
are presented and discussed in Chapter 4.
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Chapter 3
Two-phase methodology for
case-control studies
Several likelihood-based methods have been developed for the parameter estimation
in logistic two-phase studies. Three of these approaches, the full maximum likelihood
(ML), the pseudo likelihood (PL) and the weighted likelihood (WL) estimation,
are outlined in this chapter. After introducing the notation and the two-phase
setting considered in this thesis, the ML estimator is derived for simple case-control
studies and for two-phase case-control studies by using a proﬁle likelihood approach.
Moreover, the relation between the ML estimator and the PL estimator is brieﬂy
discussed. As an alternative to the proﬁle likelihood approach, the EM-algorithm
is described as a computational approach for ML estimation in two-phase studies.
Finally, the WL method is established which is known to be less eﬃcient than ML
estimation. The WL approach is introduced here because its easily interpretable
covariance formula allows for the deﬁnition of a design criterion that is derived in
Chapter 4. The chapter concludes with some remarks on the implementation of
these methods in SAS and R software.
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3.1 Notation
Throughout the thesis, a binary disease model with a linear-logistic form is con-
sidered. LetD denote a binary disease indicator that equals one for diseased subjects
(cases) and zero for subjects free of disease (controls) and let X be a p-dimensional
covariate vector. The model for contracting the disease given the covariate vector
X is therefore:
Pr(D = 1|X = x) = (1 + e−(α+βTx))−1 (3.1)
where Pr() stands for probability. It is well known that the β -part of the param-
eter vector θT = (α,βT ) can be estimated from data collected in retrospective or
prospective studies. The intercept α, which indicates the baseline disease probabil-
ity, can only be estimated in retrospective studies if additional information on the
marginal disease probability is available. The focus here lies on the retrospective
case-control design, a situation in which the covariate distribution is observed con-
ditional on the disease status, i.e. data of the form (X|D) is observed. To be more
precise, suppose a case-control study is conducted with N subjects, N1 cases and N0
controls, N = N1+N0, in which covariate values x are sampled from the conditional
distribution of X given D. The likelihood contribution of a subject with covariate
vector x and disease status d is then given by Pr(X = x|D = d).
In the setting considered in this thesis, the case-control study is nested within
a cohort using data from a population-based administrative database which allows
for the estimation of the marginal disease probabilities π1 = Pr(D = 1) and π0 =
Pr(D = 0). Although the claims data regarded here comprises a multitude of
covariates the complete covariate vector X might not be entirely available. Then, a
two-phase study is reasonable, in which the claims data constitutes the phase 1 data
set and phase 2 data comprises additional information from another data source
for a subset of n subjects. Suppose that the phase 1 data includes information
about the disease status D and about covariates Y. With Z denoting the additional
covariate information collected only for the phase 2 sample, the complete vector
of explanatory variables is given by XT = (YT ,ZT ). A stratiﬁcation S can be
constructed as a function of Y, which is then used to stratify the case-control sample
in 2×J strata, where Sij is the jth stratum of cases (if i = 1) or of controls (if i = 0)
for j = 1, . . . , J . Assume that the phase 2 data set is a stratiﬁed random sample,
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for which nij individuals have been sampled randomly from the Nij individuals in
stratum Sij for i ∈ {0, 1} and j = 1, . . . , J . In this situation, the MAR-assumption
holds in each stratum.
In the following, the subscript i is used to denote the disease status (i ∈ {0, 1}),
j is used to denote the stratum (j ∈ {1, . . . , J}) and k denotes a single subject
(k ∈ {1, . . . , N}). Furthermore, •+ means summation over the respective index.
Before introducing the methodology for a two-phase study, the concept of param-
eter estimation via a proﬁle likelihood is explained for the simple case-control study
in the next section.
3.2 Estimation via the proﬁle likelihood
3.2.1 Estimation in case-control studies
Although the likelihood for the retrospective case-control study contains terms of the
form Pr(X|D), Prentice and Pyke, 1979 have shown that the semiparametric max-
imum likelihood estimator (MLE) of β can be obtained from the ordinary (prospec-
tive) logistic regression model (see Equation (3.1)). Arguments are mainly based
on Bayes’ theorem (i.e. Pr(D|X) = Pr(X|D)Pr(D)Pr(X)−1) leaving the covariate
distribution Pr(X) unspeciﬁed.
An alternative approach to prove the results of Prentice and Pyke was given by
Scott and Wild, 2001 who used the proﬁle likelihood to obtain a semiparametric
estimator of β . For this purpose, they had to consider the estimator of θ = (α,βT )T
which can only be derived from prospective sampling. In fact, the argument of
prospective sampling is only needed for the estimation of the intercept parameter α
which will be discussed later. Thus, the semiparametric MLE of θ will be derived
in the following, where the MLE of α cannot formally be derived in a case-control
sample and will therefore be discarded. Suppose that the N observations in the case-
control sample are realisations of (D1,X1), . . . , (DN ,XN) i.i.d. random variables
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with density f(d|x¯;θ)g(x) where
f(d|x¯;θ) =
(
exp(θT x¯)
1 + exp(θT x¯)
)d(
1
1 + exp(θT x¯)
)1−d
, (3.2)
d ∈ {0, 1}, x¯T = (1,xT ) ∈ Rp+1, θ ∈ Rp+1, and g(x) is the density of the marginal
distribution of X which is left unspeciﬁed. In the following, (D,X) will be written
instead of (D1,X1), . . . , (DN ,XN) and x and x¯ will be used interchangeably. The
ﬁrst component of x is one whenever x is used in combination with θ. Then, the
likelihood for the case-control study is given by
L(θ, g) =
N∏
k=1
f(dk|xk;θ)g(xk)π−dk1 π−(1−dk)0 . (3.3)
The probabilities π0 = Pr(D = 0) and π1 = Pr(D = 1) in (3.3) cannot be omitted
from the likelihood function because they are related to f and g by:
πi =
∫
f(D = i|x;θ)dG(x), i = 0, 1, (3.4)
with G denoting the marginal distribution function of X.
Since only the estimation of θ is of interest, the proﬁle likelihood, that treats g
as nuisance parameter, simpliﬁes the parameter estimation. The proﬁle likelihood
of L is deﬁned as
LP (θ) = max
g
L(θ, g).
To maximise the proﬁle likelihood LP or the proﬁle log-likelihood lP , the density g is
assumed to be discrete where the support of G consists of the M observed distinct
values of X, {x˜1, . . . , x˜M}. Let nim denote the number of subjects with disease
status i and covariate value x˜m and let δm denote the probability of x˜m. Using (3.4)
and summing over cases and controls as well as over the distinct covariate values
the log-likelihood evolves from (3.3) as follows:
l(θ, δ) =
N∑
k=1
log f(dk|x˜k;θ) +
N∑
k=1
log g(xk)−
N∑
k=1
dk log(π1)−
N∑
k=1
(1− dk) log(π0) = (3.5)
1∑
i=0
M∑
m=1
nim log f(D = i|x˜m;θ) +
M∑
m=1
n+m log δm −
1∑
i=0
Ni log
(
M∑
l=1
f(D = i|x˜l;θ)δl
)
.
The proﬁle likelihood is obtained (for ﬁxed θ) by maximising (3.5) over δ taking into
consideration the constraint
∑
m δm = 1 by using a Lagrange multiplier. Scott and
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Wild showed (cf. Appendix A.1) that the Lagrange multiplier λ for this constrained
maximisation problem is λ = 0 and that the estimator δˆm fulﬁls the equation
δm = τm(θ) =
n+m∑
i
Nif(D=i|x˜m;θ)
πi
, m = 1, . . . ,M. (3.6)
Since the Lagrange multiplier vanishes from the optimisation problem, it is obvious
that the solution of l(θ, δ) = 0 automatically fulﬁls the constraint, which has also
been noted by Prentice and Pyke.
Using (3.5) and (3.6), the proﬁle log-likelihood lP (θ) can be transformed to
lP (θ) = l
∗(θ) =
N∑
k=1
log f ∗(dk|xk;θ) (3.7)
with f ∗(D = i|x;θ) = μif(D = i|x;θ)∑
h μhf(D = h|x;θ)
, μi =
Ni
πi
, i ∈ {0, 1}.
The function l∗ corresponds to the log-likelihood of a prospective pseudo model that
would arise from data which is sampled from the joint distribution (D,X) but is
only recorded with probability μi
N
= Ni
Nπi
for d = i. It follows for the pseudo model
that
logitf ∗(D = 1|x;θ) = logitf(D = 1|x;θ) + log(κ)
= α + log(κ) + βTx, κ =
N1
π1
N0
π0
. (3.8)
Hence, the same parameter vector β and an intercept α∗ which is related to the
intercept α in f by α∗ = α + log(κ) can be estimated by using the prospective
model f ∗. In practice this can be done by applying an ordinary logistic regression
model. Of note, the intercept α can only be estimated with additional information
on κ. For details on the derivation of (3.7) and (3.8) see Appendix A.2.
The MLE θˆ maximising the proﬁle likelihood LP is the (p+ 1)-dimensional com-
ponent of the solution of
∂lP (θ)
∂θ
=
∂l∗(Φ)
∂Φ
= 0,
where ΦT = (θT , κ). This follows from (3.7) and because of
∂l∗(Φ)
∂κ
= 0 (see Appendix A.3).
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Remarkably, the dimension of the nuisance parameters could be reduced from M
for (δ1, . . . , δM) to 1 for κ.
Using results of Gill et al., 1988, it can be shown that the above results which
have been developed for a discrete distribution of X are also valid for continuous
covariates. A detailed argumentation is given in Holubkov, 1995. The strong con-
sistency of βˆ has been proven by Prentice and Pyke, 1979. Furthermore, Scott and
Wild, 2001 demonstrated that the usual large sample results for maximum likelihood
estimates also apply for βˆ by showing that Φˆ
T
= (θˆ
T
, κˆ) is approximately normally
distributed with expectation Φ0 and covariance matrix
Cov(Φˆ) = J∗(Φ0)−1Cov(S∗(Φ0))J∗(Φ0)−1 = J∗(Φ0)−1 − keeT
where Φ0 is the true parameter value, k = κ2
(
1
N1
+ 1
N0
)
, e = (0, . . . , 0, 1)T , S∗(Φ) =
∂l∗(Φ)
∂Φ
is the score function and J∗(Φ) = −E
(
∂2l∗
∂Φ∂ΦT
)
is the expected pseudo infor-
mation matrix. Since the expected pseudo information matrix coincides with the
observed information matrix for the logistic model, the observed information matrix
I∗(Φ) = ∂
2l∗
∂Φ∂ΦT
can be used as well.
3.2.2 Estimation in two-phase studies
In this section, the semiparametric maximum likelihood estimation introduced for
simple case-control studies in the last section is extended to the more complex two-
phase design. This will provide a theoretical basis for the parameter estimation in
database studies with a case-control design augmented by additional information.
In a ﬁrst step, the sampling scheme from which the data arises is described and the
corresponding likelihood function is derived. Based on this likelihood function, a
semiparametric MLE is derived following the approach described by Scott and Wild,
2001. At the end of this section the relation between the semiparametric MLE and
the pseudo likelihood estimator, which has been developed by Breslow and Cain,
1988, is established following the arguments of Scott and Wild, 1997.
Likelihood function for the two-phase database study: Consider a two-
phase case-control study in which the phase 1 data set is obtained from a population-
based claims database and the phase 2 data comprises additional information orig-
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inating from another data source for a subset of subjects. The phase 1 case-control
sample can then be considered as a random sample of N0 controls and N1 cases from
a ﬁnite population of size N with N0 controls and N1 cases. From data of the form
(D,X), the phase 1 data set is sampled from the conditional distribution (X|D).
Cases and controls are sampled with probability pIi = Pr(RI = 1|D = i) with RI be-
ing the indicator for selection into phase 1. Furthermore, assume that the stratum,
sk, is known for each individual k with sk = (i, j) if (dk,xk) ∈ Sij and that (D,X) is
observed for all individuals in phase 2. Let (D,X) have the density f(d|x;θ)g(x) as
speciﬁed in the previous section. Moreover, assume that the probability of being se-
lected for the phase 2 sample depends only on the stratum, i.e., the MAR-assumption
is fulﬁlled with Pr(RII = 1|sk,xk) = Pr(RII = 1|sk), k = 1, . . . , N, where RII
is the indicator for selection into phase 2. Let Pr(RII = 1|sk = (i, j)) = pIIij be
the selection probability for an individual k in stratum Sij. Then, it follows for the
density of the observed and unobserved data for subject k that
Pr(dk,xk, sk, r
I
k, r
II
k ) = Pr(r
I
k|dk,xk, sk, rIIk )Pr(dk,xk, sk, rIIk )
= Pr(rIk|dk)Pr(rIIk |dk,xk, sk)Pr(dk,xk, sk)
= Pr(rIk|dk)Pr(rIIk |sk)Pr(dk,xk, sk), (3.9)
where rIk and rIIk denote the subject-speciﬁc values of RI and RII . Suppose that
neither pIi nor pIIij contain any information on the parameter vector θ. Then, pIi and
pIIij can be omitted from the likelihood function for estimating θ. The contribution
to the likelihood for the Ni −Ni individuals not selected into phase 1 (i.e., rIk = 0)
is Pr(D = i) = πi for i ∈ {0, 1}. The contribution of the Nij −nij subjects included
in the phase 1 sample but not selected into the phase 2 sample (i.e., rIIk = 0) is
Pr((dk,xk) ∈ Sij) for i ∈ {0, 1} and j = 1, . . . , J . The contribution to the likelihood
function for individuals in phase 2 with full covariate information is Pr(dk,xk) =
f(dk|xk;θ)g(xk). According to (3.9) and the above, the likelihood can be written as
L(θ, g) =
1∏
i=0
πNi−Nii
J∏
j=1
Pr((D,X) ∈ Sij)Nij−nij
nij∏
k=1
f(dk|xk;θ)g(xk). (3.10)
Semiparametric likelihood estimation: The semiparametric MLE is derived
by applying the proﬁle likelihood approach described by Scott and Wild, 2001 to the
likelihood function (3.10). Compared with the likelihood function used by Scott and
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Wild, the likelihood function given in (3.10) includes an additional term to account
for sampling phase 1 data from a ﬁnite population.
To obtain the proﬁle log-likelihood lP (θ) it is again assumed that the marginal
distribution function G of X has ﬁnite support {x˜1, . . . , x˜M} and that g(x˜m) = δm.
Let n++m denote the number of subjects with covariate value x˜m in the phase 2
sample and nijm the respective number of subjects in stratum Sij. The ﬁrst step is
then to solve the following constrained maximisation problem for ﬁxed θ:
max
g
l(θ, g) =max
g
[
1∑
i=0
(Ni −Ni) log(
M∑
m=1
f(D = i|x˜m;θ)δm)
+
1∑
i=0
J∑
j=1
(Nij − nij) log
(
M∑
m=1
Q∗ij(x˜m)δm
)
+
1∑
i=0
J∑
j=1
M∑
m=1
nijm log f(D = i|x˜m;θ) +
M∑
m=1
n++m log δm
]
(3.11)
with respect to the constraint
∑
m δm = 1. The ﬁrst term in (3.11) results from
Equation (3.4). For simpliﬁcation of the notation, the stratum probability Q∗ij for a
given covariate vector x˜m is introduced in (3.11) with
Q∗ij(x˜m) = Pr((D,X) ∈ Sij|x˜m).
Note that Qij =
∑
mQ
∗
ij(x˜m)δm is the marginal stratum probability for stratum Sij.
The solution of (3.11) is derived as in the previous section by introducing a Lagrange
multiplier λ. It is shown in Appendix (A.4) that λ = −N and that the estimator
δˆ fulﬁls the following system of equations
δm =τm(θ) =
n++m
N −∑i Ni−Niπi f(D = i|x˜m;θ)−∑i∑j(Nij − nij)Q∗ij(x˜m)Qij , (3.12)
m = 1, . . . ,M.
After inserting (3.12) in (3.11) and omitting additive constants the proﬁle log-
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likelihood is given by
lP (θ)
=l∗(θ, τ (θ)) (3.13)
=
1∑
i=0
(Ni −Ni) log πi +
1∑
i=0
J∑
j=1
(Nij − nij) logQij
+
1∑
i=0
J∑
j=1
M∑
m=1
nijm log f(D = i|x˜m;θ)
−
1∑
i=0
J∑
j=1
M∑
m=1
nijm log
(
N −
1∑
i=0
Ni −Ni
πi
f(D = i|x˜m;θ)−
1∑
i=0
J∑
j=1
Nij − nij
Qij
Q∗ij(x˜m)
)
with Qij and πi such that they maximise l∗ and fulﬁl
0 < Qij < 1,
1∑
i=0
J∑
j=1
Qij = 1
and
0 < πi < 1, π1 + π0 = 1,
respectively. Setting
ρij = log
(
Qij
Q1J
)
, ij ∈ {0, 1} × {1, . . . , J}, ij = 1J, ρ1J = 0,
and solving
∂l∗
∂ρ
= 0
with respect to the 2J-dimensional vector
ρ = (ρ01, . . . , ρ1J−1, logit(π1))T
yields an estimator that fulﬁls the constraints on Qij and πi (see Appendix (A.5)).
Obviously, ρ depends on θ via Qij.
The second step to obtain the semiparametric MLE is to ﬁnd the MLE θˆ which
maximises l∗(θ, τ (θ)) or equivalently l∗(θ,ρ(θ)). Seber and Wild (1989, Theorem 2.2,
pp. 39) have shown that the MLE θˆ can be obtained as solution Φˆ = (θˆ
T
, ρˆ(θ)T )T
of
∂l∗(Φ)
∂Φ
= 0,
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if ρˆ(θ) solves
∂l∗(θ,ρ(θ))
∂ρ
= 0
for any ﬁxed θ.
Moreover, the information of the proﬁle log-likelihood IP is given by
IP = −
(
∂2lP
∂θ∂θT
)
= −
(
∂2l∗(θ,ρ)
∂θ∂θT
− ∂
2l∗(θ,ρ)
∂θ∂ρT
(
∂2l∗(θ,ρ)
∂ρ∂ρT
)−1
∂2l∗(θ,ρ)
∂ρ∂θT
)
.
Using the standard rule for the inverse of a partitioned matrix, the inverse proﬁle
information I−1P can be derived from the (p+1)× (p+1) submatrix of I(Φ)−1 where
I(Φ) = − ∂
2l∗
∂Φ∂ΦT
=
(
Iθθ Iθρ
Iρθ Iρρ
)
.
If I(Φ) is positive deﬁnite at Φˆ, l∗ has a local maximum at Φˆ. However, Scott and
Wild, 2001 noted that this assumption is often violated in practice. As a solution
they proposed to maximise the proﬁle likelihood function directly by applying the
Newton-Raphson algorithm to solve the proﬁle likelihood for θ with an inner Newton-
Raphson loop that maximises the proﬁle likelihood with respect to ρ(θ).
Relation to the pseudo likelihood: A pseudo model can be established for the
two-phase case-control situation analogously to the simple case-control situation.
For simpliﬁcation, the ﬁrst term of the likelihood function (3.10) will be ignored in
the following. This will only aﬀect the estimation of the intercept parameter because
the Ni−Ni subjects not selected for the case-control sample only contribute disease
information but no information about the association between disease and covari-
ates. Calculations along the lines of Appendix A.4 yield λ = N . As a consequence,
δˆ(θ) solves the following system of equations:
δm = τm(θ) =
n++m
N
∑
i
∑
j μijQ
∗
ij(x˜m)
(3.14)
with μij = 1− Nij − nij
NQij
, m = 1, . . . ,M.
If X fully determines Sij for j = 1, . . . , J , which is true for the considered study
situation, Q∗ij(x) in (3.14) can be substituted by f(D = i|x;θ) for (D,X) ∈ Sij.
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With this substitution and following the arguments given in Scott and Wild, 1997
a pseudo model f ∗ can be deﬁned as
f ∗(D = i|x;θ) = μijf(D = i|x;θ)∑
i
∑
j μijf(D = i|x;θ)
. (3.15)
Furthermore, it follows that
μij
1− μij =
μij
Nij−nij
NQij
= μij
(
Nij − nij
N
∑
mQ
∗
ij(x˜m)δm
)−1
=
μij
Nij − nij
(
N
∑
m
Q∗ij(x˜m)
n++m
N
∑
i
∑
j μijQ
∗
ij(x˜m)
)
=
∑
l n++lf
∗(D = i|x˜l;θ)
Nij − nij (3.16)
where the index l is such that x˜l ∈ Sij. Then, μij can be rewritten as
μij =
nij − γij
Nij − γij with γij = nij −
∑
l
n++lf
∗(D = i|x˜l;θ). (3.17)
Since the parameters γij are the diﬀerences between the observed stratum counts
and the expected stratum counts under the pseudo model, they can be interpreted
as measures for the model ﬁt of the pseudo model.
Using (3.14), (3.15) and (3.16), the proﬁle log-likelihood can be written as (see
Appendix A.6)
l˜P (θ) = l˜
∗(θ,γ(θ))
=
1∑
i=0
J∑
j=1
M∑
m=1
nijm log f
∗(D = i|x˜m;θ)−
1∑
i=0
J∑
j=1
nij log(nij − γij)
+
1∑
i=0
J∑
j=1
Nij log(Nij − γij). (3.18)
Note, that l˜P in (3.18) and lP in (3.13) diﬀer by the term which is related to the
disease probability in the ﬁnite population.
Scott and Wild, 1997 have shown that when solving
∂l˜∗(θ,γ(θ))
∂θ
= 0
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all parts including the partial derivatives of γ vanish. Thus, the maximum likelihood
estimator of l˜P corresponds to the maximum likelihood estimator of the pseudo
model, i.e. it solves
∂
∂θ
1∑
i=0
J∑
j=1
M∑
m=1
log f ∗(D = i|x˜m;θ) = 0.
Furthermore, f ∗ has a logistic form with
f ∗(d|x;θ) =
⎛⎝ exp
(
log
(
μ1j
μ0j
)
+ θTx
)
1 + exp
(
log
(
μ1j
μ0j
)
+ θTx
)
⎞⎠d⎛⎝ 1
1 + exp
(
log
(
μ1j
μ0j
)
+ θTx
)
⎞⎠1−d .
To calculate the maximum likelihood estimator in practice, Scott and Wild proposed
the following algorithm: Starting with ﬁxed values μˆ0ij the pseudo model is ﬁtted
with respect to θ. Using the estimator θˆ
a
, updated values μˆaij are calculated by
the inner loop and the loop starts with ﬁtting the pseudo model with the updated
values to estimate θˆ
a+1
. If μˆ0ij =
nij
Nij
are used as starting values, the estimator of
the ﬁrst iteration yields the pseudo likelihood estimator which has been proposed
by Breslow and Cain, 1988. Details on the implementation of methods for the
parameter estimation in two-phase studies in current software packages are given in
Section 3.4.
Large sample theory: The estimation procedure described in this section for
covariates with discrete distributions can be extended to continuous covariates with
the same arguments that were raised for simple case-control studies. Since the stan-
dard constrained ML theory (Aitchison and Silvey, 1958) cannot be applied in this
setting, the asymptotic properties of θˆ have to be derived speciﬁcally for continuous
covariates. As already mentioned for the simple case-control study, the intercept α
cannot be estimated without bias when using the usual parametrisation. Since the
intercept is of minor interest, only the large sample results for the parameter vector
β are considered here. The strong consistency of βˆ has been proven by Vaart and
Wellner, 2001. Breslow et al., 2003 showed for two-phase data arising from Bernoulli
sampling that
√
N(βˆ −β0) is asymptotically normal with mean 0 and variance I−1P ,
where β0 is the true parameter value. Moreover, the semiparametric MLE βˆ was
demonstrated to be fully eﬃcient because its variance achieves the asymptotic infor-
mation bound for the two-phase case-control sampling scheme. Lee, 2007 extended
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these results to more general sampling schemes allowing samples also to be drawn
from diﬀerent populations.
Remarks on the assumptions for two-phase methods: Two assumptions
are usually imposed in the literature concerning two-phase methods: the missing-
at-random (MAR) assumption and the conditional independence assumption. The
MAR assumption supposes that the selection of subjects into the phase 2 sample
only depends on known covariates. This is also postulated for the above described
scenario because subjects are selected randomly from each stratum for phase 2 and
therefore Pr(xk|dk, sk, RIIk = 1) = Pr(xk|dk, sk, RIIk = 0). The conditional indepen-
dence assumption, which is given by Pr(dk|sk,xk) = Pr(dk|xk), is always fulﬁlled
in the considered setting because it is assumed that the covariate vector xk fully
determines the stratum membership. This assumption is fulﬁlled if at least those
covariates which have been used to build the stratiﬁcation are included in the re-
gression model. The functional relation used for modelling xk in f does not have an
impact on the validity of the assumption, e.g., age may be included as continuous
variable in f although only age groups are considered in the stratiﬁcation.
3.3 Further estimation procedures
Several estimation procedures have been proposed for the parameter estimation in
two-phase studies, one of which, the proﬁle likelihood approach, has been described
in the previous section. Another semiparametric MLE was developed by Breslow
and Holubkov, 1997a who derived the score equation directly by solving a max-
imisation problem with several constraints. Since both semiparametric MLEs have
been shown to be equivalent (Scott et al., 2007), the Breslow-Holubkov estima-
tor is not described in detail here. A computational approach to obtain the MLE
from two-phase case-control data is based on the application of an Expectation-
Maximisation(EM)-algorithm to a Poisson likelihood which has been suggested by
Schill and Drescher, 1997. This approach will be brieﬂy outlined in this section.
Furthermore, the WL approach will be introduced which is less eﬃcient than the
MLE but will nevertheless be used for the derivation of design criteria in Chapter 4
due to the simplicity of its covariance formula.
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3.3.1 ML estimation via the EM-algorithm
The EM-algorithm is an iterative numerical approach that can be used to determine
maximum likelihood estimators from data which has not been completely observed.
Its application to the incomplete phase 1 data of a two-phase study as suggested by
Schill and Drescher, 1997 is described in the following.
Consider that the vector of covariates X assumes a ﬁnite number of values,
xj1, . . . ,xjMj , j = 1, . . . , J , in each stratum of the two-phase study. Then, phase
1 and phase 2 data can be classiﬁed into cells (i, j,m), i = 0, 1, j = 1, . . . , J ,
m = 1, . . . ,Mj, where i denotes the disease status, j denotes the stratum, and m
denotes the covariate value. The number Nijm of subjects in cell (i, j,m) of the
phase 1 data set is unobserved whereas the respective number nijm in the phase 2
data set as well as the stratum counts Nij in phase 1 are observed. We assume that
Nijm is Poisson distributed with expectation
μijm =
{
exp(ζjm + α + x
T
jmβ) if i = 1
exp(ζjm) if i = 0
. (3.19)
Then, the EM-algorithm can be applied to estimate the parameter vector θP =
(ζT , α,βT )T , ζ = (ζ11, . . . , ζJMJ )T . In the E-step of the algorithm, the unobserved
cell counts Nijm are replaced by their expected values given the observed data, i.e.,
by Nˆijm = E[Nijm|nijm, Nij]. The M-step then estimates θP by maximising the
likelihood of model (3.19) on the completed data.
Using that N˜ijm = Nijm−nijm given the stratum counts (Nij, nij) is multinomially
distributed, i.e., N˜ijm|(Nij, nij) ∼ Mult(Nij−nij, ( μij1μij+ , . . . ,
μijMj
μij+
)), the expected cell
counts can be written as
Nˆijm = nijm + (Nij − nij) μˆijm
μˆij+
,
where μˆijm is calculated by inserting θˆP in (3.19). Iteration of the E- and M-step
yields the MLE.
Scott and Wild, 1991 have shown that the MLE βˆ resulting from the Poisson
model (3.19) coincides with the MLE of a logistic model. Hence, the EM estimator
is equal to the MLE obtained from the proﬁle likelihood approach discussed in
Section 3.2.2.
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3.3.2 WL estimation
The weighted likelihood method has been proposed for the parameter estimation in
two-phase studies by Flanders and Greenland, 1991. An equivalent approach, the
mean-score method, has been derived a few years later by Reilly and Pepe, 1995.
Here, the description of the method is based on the results of Reilly and Pepe.
Since the intercept α is not of much interest, only the estimation procedure for
the parameter vector β is considered in this section. Reilly and Pepe suggested to
solve the following estimating equation to obtain estimates for β :
∑
q∈{k:rIIk =1}
∂
∂β
log f(dq|xq;β) +
∑
q′∈{k:rIIk =0}
Eˆ
(
∂
∂β
log f(dq′ |X)
∣∣∣ dq′ , sq′) , (3.20)
where rIIk is the indicator for selection into phase 2 as speciﬁed in Section 3.2.2 and
Eˆ
(
∂
∂β
log f(dq′ |X)
∣∣∣ dq′ , sq′) is calculated as
Eˆ
(
∂
∂β
log f(dq′ |X)
∣∣∣ dq′ , sq′) = ∑
r∈{k:rIIk =1,sk=sq′∈Sij}
1
nij
∂
∂β
log f(dq′ |xr;β).
Since complete covariate information is only available for subjects included in the
phase 2 sample, the estimation equation is divided into two parts. One part cor-
responds to the usual score contribution of subjects with complete covariate in-
formation and the other part corresponds to the contribution of subjects without
complete covariate information. For subjects without complete covariate informa-
tion, the score contribution is estimated from subjects in the same stratum who have
complete covariate information, i.e., the mean score contribution of phase 2 subjects
in the speciﬁc stratum is considered for these subjects. Equation (3.20) corresponds
to the respective estimating equation arising from the weighted likelihood
LW =
1∏
i=0
J∏
j=1
nij∏
k=1
f(dk|xk;β)
Nij
nij .
Reilly and Pepe have proven that the estimator βˆ solving (3.20) is strongly consistent
for the true parameter value β0 and that
√
N(βˆ −β0) is asymptotically normal with
mean 0 and variance
I−1R + I
−1
R ΩI
−1
R , (3.21)
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where
IR = E
( −∂2
∂β∂βT
log f(D|X;β)
)
and
Ω =
1∑
i=0
J∑
j=1
Qij(1− pIIij )
pIIij
Cov
(
∂
∂β
log f(D|X;β)
∣∣∣ (D,X) ∈ Sij, RII = 1) . (3.22)
The variance formula is further discussed in Section 4.
The WL estimator has been shown to be less eﬃcient than the MLE (see e.g.,
Schill and Drescher, 1997; Breslow and Holubkov, 1997b; Breslow and Chatterjee,
1999). The loss in eﬃciency is particularly high if the sampling fractions vary
substantially between the strata.
3.4 Implementation in R and SAS software
As mentioned in the introduction, applications of the two-phase design to case-
control data are rare. One reason for the reluctance to conduct logistic two-phase
studies might be that two-phase methods have not been implemented in standard
statistical software like R and SAS until recently. During the last years, however, the
following well-documented and easy-to-use R and SAS packages became available
for the analysis of two-phase studies.
The survey package: Lumley, 2004 released the R package survey which provides
functions for the analysis of complex survey samples. Among these, the function
twophase allows the handling of two-phase designs. The Horvitz-Thompson esti-
mator (Horvitz and Thompson, 1952) which is equivalent to the WL estimator is
implemented in this package. The covariance delivered by the survey package dif-
fers slightly from that of the WL method by a correction factor that accounts for
sampling from a ﬁnite population.
The osDesign package: More recently, Haneuse et al., 2011 published the R pack-
age osDesign that is designated to the analysis of two-phase case-control studies.
WL, PL, and ML methods are included in this package. The ML approach is
based on Breslow and Holubkov, 1997a who derived an estimation equation for a
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constrained ML problem, where the constraints are imposed for each phase of retro-
spective sampling, i.e. there are phase 1 and phase 2 constraints. Unfortunately, in
speciﬁc data constellations the implementation of the ML method reveals estimators
which do not fulﬁl all of the constraints. For instance, when analysing the example
data set "Ohio" used by Haneuse et al., 2011 with a model including only sex and
race as dependent variables a warning is produced instead of ML estimators. A fur-
ther disadvantage of osDesign is that only empirical but no model-based standard
errors are provided for the WL estimators. Nevertheless, in many data constellations
the package provides valid estimators in short computing time, hence being suitable
for simulation studies. The osDesign package was used for parameter estimation in
the two phase analyses described in Sections 2.3 and 4.1.
The sas-twophase-package: The sas-twophase-package by Schill et al., 2013
is a SAS-based software package for the analysis of two-phase studies that is avail-
able from the BIPS homepage (http://www.bips.uni-bremen.de/sastwophase).
It is a collection of SAS-macros providing WL, PL, and ML estimators and corre-
sponding model-based standard errors. ML estimators are calculated by using the
EM-algorithm of Section 3.3.1. The EM-algorithm is unfortunately associated with
a long computing time and may also fail due to lack of memory for large phase 2 data
sets (e.g., n=10,000). A detailed discussion on the performance of the EM-algorithm
is given in Schill et al., 2013. All two-phase analyses presented in Sections 4.2 and
4.5 were conducted with an earlier version of the sas-twophase-package which also
included a SAS-implementation of the Breslow-Holubkov estimator as programmed
in the osDesign package.
Although the currently available software is suﬃcient to analyse single two-phase
studies there is still a lack of software which is suitable for ML estimation in sim-
ulation studies. More recent methodological development concentrated on eﬃcient
computing of semiparametric estimators in two-phase studies based on the pro-
ﬁle likelihood approach introduced in Section 3.2 (see Scott and Wild, 2006; Hi-
rose and Lee, 2012). The R-based package missreg, in which Description of the
"missreg" library implemented these methods, is unfortunately not available at the
Comprehensive R Archive Network (CRAN, http://cran.r-project.org) and has
not the appropriate format for packages in current versions of R. Nevertheless, the
package and a detailed documentation can be downloaded from Wild’s homepage
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(http://www.stat.auckland.ac.nz/~wild/software.html). Since the missreg
package has been designed more generally for the analysis of data arising from selec-
tive sampling or data with partially missing information using arbitrary regression
models, this software requires comprehensive statistical knowledge of the underlying
methods.
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Chapter 4
Stratiﬁcation strategies for the
eﬃcient use of phase 1 information
Stratiﬁcation according to phase 1 variables is the key element of a two-phase de-
sign. This follows immediately from the estimation methods described in the previ-
ous chapter. In two-phase analyses, stratiﬁcation fulﬁls two purposes: First, strati-
ﬁcation incorporates information on the distribution of phase 1 covariates, estimated
in the large phase 1 data set, in the two-phase analysis. This leads to reduced stan-
dard errors of the corresponding parameter estimators. Second, stratiﬁcation is able
to account for the intended and unintended selection processes which then eliminates
the bias introduced by the selective sampling of the phase 2 sample. A selection
process is considered to be intended if it is controlled by the study investigator who
assigns selection probabilities for subjects with speciﬁc characteristics. In this thesis,
intended selection processes are equivalent to the concept of a priori stratiﬁcation
which has been introduced in Chapter 1. Unintended selection processes are not
under control of the study investigator but may occur in many applications. Exam-
ples for unintended selection processes are non-response in surveys or self-selection
regarding the participation in special programmes such as Disease Management Pro-
grammes (DMPs) oﬀered by the German statutory health insurances. An example
of an unintended selection process has been described for the empirical study in
Chapter 2.3. In this study, age and sex were identiﬁed from the set of phase 1 vari-
ables as predictors for the selection into phase 2. These predictors were included
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in a post stratiﬁcation in order to reduce the bias introduced by the selective sam-
pling. Using post stratiﬁcations (see Chapter 1 for an explanation of this concept)
is reasonable to account for unintended selection processes and can also be useful
to consider additional covariate information from phase 1 to improve eﬃciency of
the parameter estimation. The focus of this chapter is on the use of stratiﬁcations
in the sense of their ﬁrst purpose, namely for the reduction of standard errors in
two-phase database studies.
A special feature of two-phase database studies is that the phase 1 data set
comprises information on a multitude of covariates which could be included in the
stratiﬁcation. This is in contrast to traditional two-phase studies where the data
originates from ﬁeld studies and the ascertainment of each phase 1 variable is associ-
ated with additional costs. Hence, only few phase 1 covariates are available in these
studies and the stratiﬁcation is usually simply deﬁned by a cross-classiﬁcation of the
phase 1 covariates. Applying the same approach to two-phase database studies is im-
possible because cross-classiﬁcation of all available phase 1 covariates would lead to
a tremendously high number of strata. Since two-phase methods require non-empty
strata in phase 2, the number of strata is limited by the size and composition of the
phase 2 data set. As a consequence, the stratiﬁcation needs to be deﬁned in view of
the following dilemma: On the one hand, consideration of each additional covariate
in the cross-classiﬁcation increases the number of strata and therefore the risk of
empty cells. On the other hand, ignoring information on phase 1 covariates results
in unnecessarily large standard errors of the corresponding parameter estimators.
This chapter addresses potential solutions of this dilemma by illustrating it in the
empirical study where cross-classiﬁcation by additional covariates results in empty
cells but ignoring these covariates precludes the estimation of precise covariate ef-
fects. In the second section, an alternative stratiﬁcation strategy is proposed which
uses percentiles of a disease score. The alternative strategy is applied to the empirical
study and is further evaluated in a simulation study based on the empirical study.
The remainder of the chapter deals with the planning of an eﬃcient stratiﬁcation.
For this purpose, a criterion for the comparison of stratiﬁcations with respect to
their eﬃciency is derived from the covariance formula of the WL approach. This
criterion is then applied to the empirical study to identify candidates for eﬃcient
stratiﬁcations which are subsequently evaluated in a simulation study.
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4.1 Limitations of cross-classiﬁcation in the
empirical study
The two-phase study of Chapter 2.3 on the one hand revealed a precise estima-
tor for the parameter of main interest, i.e., for phenprocoumon exposure, but on
the other hand failed to provide meaningful risk estimators for the comorbidities
hypertension and diabetes mellitus. The post stratiﬁcation which was used in the
two-phase analysis, in the following denoted by stratiﬁcation A, did neither include
phase 1 information on hypertension nor on diabetes mellitus but was deﬁned by
cross-classiﬁcation of age, sex, and phenprocoumon exposure only (cf. Chapter 2.3).
Therefore, the two-phase analysis is now repeated with two alternative post stratiﬁ-
cations, one including additional information on hypertension (stratiﬁcation B) and
the other one including additional information on diabetes mellitus (stratiﬁcation C).
In this section, results of these additional two-phase analyses are presented to clarify
the aforementioned dilemma which exists for the application of cross-classiﬁcation if
many phase 1 covariates are available. Hence, the focus is on the problem of empty
strata and on the eﬃciency of parameter estimation for hypertension and diabetes.
Further results are given in Behr et al., 2012 (Appendix D).
Table 4 in Appendix D illustrates the problem of sparsely populated strata by
showing the number of subjects in each cell of the phase 1 and phase 2 data set
stratiﬁed by post stratiﬁcations A, B, and C. Overall, only few cases are exposed
to phenprocoumon. Thus, the six subgroups of exposed cases deﬁned by age and
sex in stratiﬁcation A have cell counts ranging from 2 to 7 in the phase 2 data set.
Further subclassiﬁcation of these sparsely populated cells would certainly result in
empty cells as can be seen for the example of hypertension in Figure 4.1. Four
cells in the youngest age group are empty in phase 2 and need to be collapsed with
other cells before two-phase methods can be applied. Stratiﬁcation B is therefore
constructed by combining the cells of exposed male subjects in the youngest age
group for cases and controls as well as the cells of exposed female subjects in the
same age group (see Table 4 in Appendix D). That means that information on
hypertension is ignored in these cells. Furthermore, the distinction in male and
female is neglected in the youngest age group of cases and controls with a diagnosis of
hypertension but without exposure to phenprocoumon. There are many alternative
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ways to collapse the four cells. The rationale for the chosen one is to combine the
smallest strata. A similar approach is used to deﬁne stratiﬁcation C, where six
strata have to be collapsed to avoid empty cells. Since hypertension and diabetes
mellitus are the most prevalent comorbidities (see Table 2 in Appendix D) even more
empty cells are expected when subdividing the cells in stratiﬁcation A by any other
covariate. Inclusion of two, three or more phase 1 covariates in the stratiﬁcation
would only add information to the most frequent cells, e.g., to controls who are not
exposed to phenprocoumon, because sparsely populated cells cannot be subclassiﬁed
any further.
Figure 4.1: Cross-classiﬁcation by age, sex, and hypertension (Hyp+/Hyp-) ac-
cording to post stratiﬁcation B.
For a more theoretical comparison of the stratiﬁcations, the eﬃciency of param-
eter estimation is measured by the square root of the asymptotic relative eﬃciency
(ARE) which is deﬁned for stratiﬁcation S and covariate k by
EFFS ,k =
√
ARE =
SE(βˆ1,k)
SE(βˆIIS ,k)
,
where SE(βˆ1,k) and SE(βˆIIS ,k) denote the standard errors of parameter estimates
based on the phase 1 analysis and the two-phase analysis, respectively. The esti-
mated eﬃciency for each estimated parameter is compared for post stratiﬁcations
A, B, and C in Table 4.1. The corresponding estimated ORs and 95% conﬁdence
intervals are given in Table 6 in Appendix D. There is no notable diﬀerence be-
tween the stratiﬁcations with respect to the eﬃciency of parameter estimates for
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phenprocoumon, age, sex, and the two-way interactions between phenprocoumon
exposure and age and sex. The eﬃciency of the parameter estimates for hyperten-
sion and diabetes is more than doubled if the respective covariate is considered in
the stratiﬁcation. The precision gained with post stratiﬁcation B for the estimation
of the bleeding risk associated with hypertension and with post stratiﬁcation C for
diabetes mellitus leads to statistically signiﬁcant results for these parameters.
Table 4.1: Eﬃciency of two-phase estimators for diﬀerent post stratiﬁcations
Multivariable modela Eﬃciency
Stratiﬁcation Ab Stratiﬁcation Bc Stratiﬁcation Cd
ŜE(β̂1,k)
ŜE(βˆIISA,k)
ŜE(βˆ1,k)
ŜE(βˆIISB,k)
ŜE(βˆ1,k)
ŜE(βˆIISC,k)
Phenprocoumon exposure 0.64 0.69 0.68
Age (centred at 55 years) 0.33 0.33 0.33
Interaction: phen. * age 0.81 0.81 0.81
Female sex 0.72 0.72 0.75
Interaction: phen. * sex 0.92 0.93 0.90
Comorbid conditions:
Diabetes mellitus 0.34 0.35 0.75
Hypertension 0.33 0.70 0.34
a The multivariable model includes also the variables smoking, BMI, and the interaction between
BMI and phenprocoumon for which no eﬃciency can be calculated since these have only been
collected in phase 2.
b Stratiﬁcation A includes information on age, sex, and phenprocoumon exposure.
c Stratiﬁcation B includes information on age, sex, phenprocoumon exposure, and hypertension.
d Stratiﬁcation C includes information on age, sex, phenprocoumon exposure, and diabetes mellitus.
These results demonstrate that the choice of variables of which phase 1 infor-
mation is considered in the two-phase analysis has a substantial impact on the
eﬃciency of parameter estimates. However, also the problem of empty strata, that
occurs with cross-classiﬁcation for covariate combinations of low prevalence in small
phase 2 samples, becomes obvious. Deﬁning stratiﬁcations by cross-classiﬁcation of
covariates only works well for a small number of covariates if the covariate distribu-
tion is balanced or if the phase 2 sample is large. Collapsing strata of low prevalence
is an option to avoid empty strata. A disadvantage of this option is that the process
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of choosing strata to be combined is laborious, data-driven, and somehow arbitrary.
The stated dilemma for cross-classiﬁcation is the motivation for the development
of alternative stratiﬁcation strategies which include the maximum amount of phase
1 information without increasing simultaneously the number of strata with each
additional covariate. Such an alternative strategy is proposed in the next section.
4.2 Alternative stratiﬁcation strategy:
Using a disease score for stratiﬁcation
A new stratiﬁcation strategy is proposed and evaluated in a paper which will be
submitted for publication to a methodological epidemiology journal (Behr and Schill,
2013; Appendix E). The concept of stratifying on disease scores is introduced and
results of the paper are brieﬂy summarised in this section.
4.2.1 Background
The requirement for the new stratiﬁcation approach is that information on all avail-
able phase 1 covariates can be included without inducing a large number of strata.
A similar problem exists for the estimation of adjusted risks for rare events if a
multivariable model including a large number of covariates has to be ﬁt to data
with only few events. Scores like the Charlson index (Charlson et al., 1987) or the
Chronic Disease Score (Korﬀ et al., 1992), which summarise information on several
covariates in one value, have been used for confounder adjustment in this situation.
The idea of using a score to adjust for imbalances of the covariate distribution be-
tween treatment groups has also been employed in the propensity score approach
(Rosenbaum and Rubin, 1983). Based on this rationale, the idea of constructing
a score as a summary measure of several covariates will be exploited to solve the
stratiﬁcation problem in two-phase studies.
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4.2.2 Deﬁnition of stratiﬁcations based on disease scores
Let Y = (Y1, . . . , Yp′)T denote the vector of all available phase 1 covariates and let
YI denote a regression vector consisting of components of Y as well as of product
terms between components of Y, which represent main eﬀects and interactions in a
regression model. A disease score is deﬁned as the probability of disease given the
covariate vector, i.e., Pr(D = 1|YI). The disease score (DSC) is calculated for each
subject h in the phase 1 sample by
DSCh =
exp(αˆI + βˆ
T
I yIh)
1 + exp(αˆI + βˆ
T
I yIh)
, (4.1)
where the parameters αI and β I are estimated in a logistic regression model based on
the full phase 1 sample. To deﬁne a stratiﬁcation, the range of disease scores is split
into subclasses. Choice of the number and placement of the cut-points inﬂuences
the size of the strata and the amount of information on phase 1 covariates which is
included in the stratiﬁcation. A stratiﬁcation with a small number of wide strata will
include less information than a stratiﬁcation with a large number of narrow strata.
Narrow strata, however, can lead to empty strata for cases or for controls because
cut-points are deﬁned by percentiles of the marginal distribution of disease scores but
the conditional distribution in cases (DSC|D = 1) may diﬀer from the conditional
distribution in controls (DSC|D = 0). As an example, consider the distribution of
disease scores estimated in the empirical study depicted in Figure E.1 in Appendix
E. The marginal distribution is dominated by the conditional distribution of controls
due to a case:control ratio of 1:20. It is thus possible that values below the 50th
percentile of the marginal distribution are less frequent in cases. Another reason for
empty strata in cases or controls might be a lack of overlap in disease scores. The
overlap in the empirical example is large. In studies where the phase 1 covariates
Y discriminate well between cases and controls the overlap may be very small.
Although the same problem arises with the propensity score approach, arguments
raised for instance by Myers and Louis, 2007 cannot be applied to stratiﬁcation in
two-phase designs because the aim for using the score is diﬀerent. Whereas the
propensity score is used as a balancing score to allow for an unbiased comparison of
two groups, the disease score is used as a stratiﬁcation variable which is correlated
with each relevant phase 1 variable. In this context, relevance is measured by the
estimated eﬀect in the disease model. Since determination of an optimal partition
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of the range of disease scores requires a performance criterion for stratiﬁcations in
two-phase studies, this discussion is postponed to Section 4.4.
4.2.3 Application to the empirical study
The proposed stratiﬁcation strategy is applied to the empirical two-phase study.
In contrast to the two-phase model considered in Sections 2.3 and 4.1 the model
in this application includes eight additional phase 1 variables listed in Table E.2
in Appendix E. The disease score is estimated by using the same set of phase 1
covariates as well as interactions between phenprocoumon exposure and age and
sex, respectively. Three post stratiﬁcations (D, E*, F) are deﬁned by percentiles
of the disease score based on ﬁve (D, F) or two (E*) cut-points. To account for
the stratiﬁed sampling by phenprocoumon exposure, post stratiﬁcations D, E*, and
F are additionally classiﬁed by phenprocoumon exposure and E* as well as F also
include information on age group and sex (see Table E.1 in Appendix E). These
post stratiﬁcations are compared with post stratiﬁcations A, B, and C of Section
4.1 regarding potential bias and standard errors of parameters estimates in the two-
phase model.
The comparison of the stratiﬁcations reveals that stratifying on percentiles of a
disease score leads to a reduction of standard errors of estimated parameters for the
phase 1 covariates. However, the reduction is negligible. In particular, the standard
errors of parameter estimates for hypertension and diabetes are much more reduced
by using stratiﬁcations B and C which include phase 1 information of these covariates
directly (see Table E.2 in Appendix E). Potential bias, assessed by the diﬀerence
between phase 1 and two-phase estimators, is observed for post stratiﬁcation D in
estimators related to phenprocoumon exposure and sex. This bias can be explained
by two arguments: First, the response analysis of Section 2.3 demonstrated that
the phase 2 sample is not random with respect to age which introduces bias in a
complete-case analysis. Second, stratiﬁcation D includes information on sex only
via the disease score. This is not suﬃcient to correct the aforementioned bias.
Furthermore, some two-phase estimators related to comorbidities and concomitant
medications diﬀer from the respective phase 1 estimators indicating bias. Estimators
obtained from a stratiﬁcation based on disease scores are closer to the phase 1
46
estimators which might be interpreted as bias reduction. Since the true parameter
values are not known in this study, it cannot be concluded which estimators are
biased. The performance of the stratiﬁcations regarding bias is therefore evaluated
in the simulation study where the true parameter values are speciﬁed in the design.
4.2.4 Performance in the simulation study
The simulation study investigating the performance of stratiﬁcations based on disease
scores is part of a more complex simulation study. The other parts as well as techni-
cal details of the set-up are described in Section 4.5. In this section, stratiﬁcations
A, B, C, D, and E* of the previous section as well as a simpler variant of E*, called
stratiﬁcation E, are evaluated regarding bias and eﬃciency of the two-phase estima-
tors. Bias is deﬁned by the diﬀerence between the two-phase estimator and the true
parameter value and eﬃciency is deﬁned as speciﬁed in Section 4.1. Furthermore,
failure proportions are considered, where an analysis is counted as a failure in case
of empty strata or convergence problems of the estimation procedure. The set-up
of this part of the simulation study is depicted in Figure E.2 in Appendix E.
The simulation study conﬁrms the results of Section 4.2.3: Direct inclusion of
information on hypertension and diabetes by cross-classiﬁcation is more eﬃcient
than including this information via a disease score (see Figure E.4 in Appendix E).
Furthermore, the bias that occurs with post stratiﬁcation D in the empirical study
due to insuﬃcient consideration of the sampling procedure is also apparent in the
simulated two-phase studies. Whereas in the empirical study parameters related to
sex are estimated with bias when using stratiﬁcation D, the same problem is observed
for age in the simulation study when analysing age-stratiﬁed phase 2 samples with
stratiﬁcation D. The reason for the bias is quite obvious because in this situation
the a priori stratiﬁcation is ﬁner than the post stratiﬁcation. Since age is correlated
with many covariates, ignoring the full age information in the post stratiﬁcation also
leads to biased estimates for other covariates (see Figure E.3 in Appendix E).
Another ﬁnding of the simulation study is related to the proportion of failures,
which are mostly caused by empty strata (> 95% of failures). Only a small number
of strata is feasible for the evaluation of small phase 2 samples because stratiﬁca-
tions with a larger number of strata are associated with high failure proportions.
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Stratiﬁcations based on percentiles of disease scores are more likely to result in
empty strata than stratiﬁcations with the same number of strata deﬁned by cross-
classiﬁcation. However, for a given number of strata, stratiﬁcations using a disease
score include information on much more covariates than stratiﬁcations deﬁned by
cross-classiﬁcation. This observation indicates that some of the strata deﬁned by
disease scores are sparsely populated in the phase 1 sample. This most probably
results from the diﬀerent conditional distributions of disease scores in cases and con-
trols. The problem of empty strata vanishes if the sampling stratiﬁcation and the
evaluation stratiﬁcation coincide.
Among all tested combinations of a priori and post stratiﬁcations, using strati-
ﬁcation E* for sampling and analysis delivers the best performance with respect to
low failure proportions, small bias and high eﬃciency. As can be seen from Table
E.3 in Appendix E, eﬃciencies are considerably improved for most phase 1 covari-
ates. Therefore, the same inferences on phase 1 covariates can be drawn from the
two-phase analysis using stratiﬁcation E* and the phase 1 analysis which is based
on a data set that is ten times larger. Further results of the simulation study are
described in Behr and Schill, 2013 and in Section 4.5.
4.2.5 Discussion
The ﬁrst applications of using disease scores for stratiﬁcation in two-phase analyses
yield promising results. Advantages of this stratiﬁcation approach are:
1. Phase 1 information on all relevant covariates can be included in the analysis
without increasing the number of strata with each additional covariate.
2. Standard errors of these covariates are notably reduced.
A considerable gain in eﬃciency is only achieved if the stratiﬁcation is also used for
sampling the phase 2 data. If the phase 2 data set is sampled with respect to a
cross-classiﬁcation of variables, the post stratiﬁcation has to include these variables
directly and cannot be solely deﬁned on percentiles of the disease score. In this case,
the post stratiﬁcation is deﬁned by cross-classiﬁcation of the a priori stratiﬁcation
and subclasses of the disease score, where the number and placement of the cut-
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points is restricted by the requirement of non-empty strata. Choice of number
and placement of the cut-points is also inﬂuenced by the diﬀerence between the
conditional distributions of disease scores in cases and controls. It remains unclear
how subclasses of the disease score should be deﬁned to yield eﬃcient a priori and
post stratiﬁcations.
4.3 Criteria for planning the a priori stratiﬁcation
As has been demonstrated in Sections 4.1 and 4.2 it is diﬃcult to deﬁne an eﬃcient
stratiﬁcation using information on a multitude of phase 1 covariates. There is no
general rule available stating that one stratiﬁcation strategy is better than the other.
Additionally, for each strategy many possibilities exist to build stratiﬁcations. In
particular, it is an open question how eﬃcient stratiﬁcations can be identiﬁed at
the planning stage of a two-phase study when only phase 1 information is available.
Thus, a criterion is desirable which allows for the comparison of a priori stratiﬁca-
tions with respect to eﬃciency based on phase 1 data alone. In this section, such
a design criterion is derived from the variance formula of the weighted likelihood
estimator (WLE).
4.3.1 Variance of the WLE
Before the design criterion is derived, the variance formula (3.21) of the WLE is
discussed in more detail based on results and arguments given in Reilly and Pepe,
1995. In the following, only the variance of the estimated parameter vector βˆ is con-
sidered whereas rows and columns of the covariance matrix referring to the estimated
intercept αˆ are ignored.
The covariance matrix of the WLE βˆ is given by
Cov(βˆ) =
1
N
I−1R +
1
N
I−1R ΩI
−1
R . (4.2)
Since N−1I−1R corresponds to the variance that would have been obtained if com-
plete data was available for everyone in phase 1, the second part of the formula,
N−1I−1R ΩI
−1
R , can be interpreted as penalty term which is a measure for the loss in
49
eﬃciency due to the partially missing covariate information. Reilly and Pepe have
shown that the information IR can be consistently estimated by
IˆR =
1
N
⎡⎣ ∑
q∈{k:rIIk =1}
(
− ∂
2
∂β∂βT
log f(dq|xq;β)
)
+
∑
q′∈{k:rIIk =0}
Eˆ
(
− ∂
2
∂β∂βT
log f(dq′ |X;β)
∣∣∣ dq′ , sq′)
⎤⎦
β=βˆ
, (4.3)
where
Eˆ
(
− ∂
2
∂β∂βT
log f(dq′ |X;β)
∣∣∣ dq′ , sq′) =∑
t
1
nij
(
− ∂
2
∂β∂βT
log f(dt|xt;β)
)
and
∑
t is the summation over phase 2 subjects in the respective stratum determined
by sq′ , i.e., t ∈ {k : rIIk = 1, sk = sq′ ∈ Sij}.
A consistent estimator of Ω (see (3.22)) is given by
Ωˆ =
1∑
i=0
J∑
j=1
Nij
N
Nij − nij
nij
Ĉov
(
SC(βˆ)
∣∣∣ (D,X) ∈ Sij, RII = 1) , (4.4)
where Ĉov denotes the empirical covariance matrix in stratum (i, j) of the phase 2
data set and SC(βˆ) denotes the score vector evaluated at βˆ , i.e.,
SC(βˆ) =
[
∂
∂β
log f(D|X;β)
]
β=βˆ
.
In (4.4), Nij
N
and nij
Nij
are used as consistent estimators of the marginal stratum
probabilities Qij and the selection probabilities pIIij .
Let Πˆk denote the estimated probability of contracting the disease for subject k
which is deﬁned by
Πˆk =
exp(αˆ + βˆ
T
xk)
1 + exp(αˆ + βˆ
T
xk)
with βˆ being the WLE. The subject-speciﬁc score vector (SCk) evaluated at βˆ is
then given by
SCk(βˆ) = (dk − Πˆk)xk.
Accordingly, the information Iˆk(βˆ) of subject k has the form
Iˆk(βˆ) = Πˆk(1− Πˆk)xkxTk .
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Using the above expressions, Ωˆ and IˆR can be written as
Ωˆ =
1∑
i=0
J∑
j=1
Nij
N
Nij − nij
nij
Ĉov
(
(D − Πˆ)X
∣∣∣ (D,X) ∈ Sij, RII = 1) (4.5)
and
IˆR =
1
N
1∑
i=0
J∑
j=1
[
nij∑
k=1
Πˆijk(1− Πˆijk)xijkxTijk +
Nij − nij
nij
nij∑
k=1
Πˆijk(1− Πˆijk)xijkxTijk
]
=
1
N
1∑
i=0
J∑
j=1
nij∑
k=1
Nij
nij
Πˆijk(1− Πˆijk)xijkxTijk. (4.6)
Only the second part of (4.2), i.e. the penalty term, depends on the stratiﬁcation
S through Ω. Therefore, a design criterion considering only the penalty term should
be suﬃcient for the identiﬁcation of eﬃcient stratiﬁcations. Since both estimators
IˆR and Ωˆ depend on S , this is only ‘asymptotically’ correct in the sense that the
estimators converge to IR and Ω, respectively, as the sample size tends to inﬁnity.
Nevertheless, the ﬁrst part of (4.2) is assumed to be neglectable for the deﬁnition of
a design criterion because
1. for large phase 1 and relatively small phase 2 samples the phase 1 sample
variance N−1I−1R is considered to be much smaller than the penalty term;
2. only the weights of phase 2 contributions change for diﬀerent stratiﬁcations in
a ﬁxed phase 2 sample which is expected to result in major diﬀerences only in
presence of extreme weights.
4.3.2 Constructing a design criterion based on phase 1 data
The aim is to deﬁne a design criterion which identiﬁes the most eﬃcient stratiﬁca-
tions from a set of stratiﬁcations by using only phase 1 data. The idea is to predict
for each stratiﬁcation the size of the penalty term and therefore the loss in eﬃciency
that would occur in a two-phase analysis using the respective stratiﬁcation. It is
assumed that phase 2 data is not available for the prediction, so that only the eﬃ-
ciency of parameter estimation for phase 1 covariates can be assessed. Furthermore,
the subject-speciﬁc score vector and information matrix cannot be obtained from a
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two-phase analysis but have to be taken from a usual logistic regression analysis of
the phase 1 data.
Recall from Chapter 3 that the vector of complete covariate information XT =
(YT ,ZT ) is partitioned into phase 1 information Y and phase 2 variables Z. Let βˆ I
denote the MLE of the phase 1 model f(D|Y;β I) and II the corresponding infor-
mation matrix obtained from usual logistic regression. For simplicity of notation, in
the following no distinction is made between Y and the regression vector YI based
on Y as well as between X and the respective regression vector.
The penalty term related to phase 1 covariates can be approximated based on
phase 1 data by
1. replacing NIˆR with the estimated phase 1 information IˆI ,
2. estimating the score variability in each phase 1 stratum by the empirical co-
variance
Ĉov
(
(D − ΠˆI)Y
∣∣∣ (D,X) ∈ Sij) ,
where ΠˆI is the estimated disease probability
ΠˆI =
exp(αˆI + βˆ
T
I y)
1 + exp(αˆI + βˆ
T
I y)
, (4.7)
and
3. setting the phase 2 stratum size nij to
nij = min
{ n
2J
,Nij
}
,
where n is the phase 2 sample size and J is the number of strata in order to
achieve a balanced phase 2 sample with an equal number of subjects in each
stratum.
Then, an approximation of the penalty term (PT) is obtained as
P̂ T I(S ) = NIˆ
−1
I
(
1∑
i=0
J∑
j=1
Nij
N
Nij − nij
nij
Ĉov
(
(D − ΠˆI)Y
∣∣∣ (D,X) ∈ Sij)) Iˆ−1I
(4.8)
=: NIˆ−1I ΩˆI Iˆ
−1
I .
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The rationale for using the estimated phase 1 covariance Iˆ−1I follows immediately
from the previous section because N−1I−1R corresponds to the covariance that would
have been obtained from the full phase 1 sample if complete covariate information
was available for everyone in phase 1. It has to be noted that Iˆ−1I is obtained
from a model including only phase 1 covariates whereas N−1Iˆ−1R is the estimated
covariance of parameter estimators from a model that includes also phase 2 variables.
Therefore, P̂ T I is a p′ × p′-matrix instead of a p × p-matrix, where p′ = dim(Y)
and p = dim(X). This means that no information on the penalties associated with
the estimation of phase 2 parameters is available. Also the variability of the score is
estimated by a model including only phase 1 variables instead of phase 1 and phase
2 variables. The consequences of ignoring phase 2 variables in the approximation of
the penalty term is discussed in the next section. A further diﬀerence is that the
score variability is estimated in the phase 1 strata instead of phase 2 strata as is
deﬁned in (4.4). However, if the MAR assumption is fulﬁlled for the phase 2 sample,
strata with a large variability in phase 1 will also have a large variability in phase
2. In particular, if stratiﬁcations are ranked with respect to the score variability,
ranks will be equal or at least similar in phase 1 and phase 2 strata. Setting nij
as in 3. is based on the assumption of a balanced design taking into account the
restriction imposed by the phase 1 stratum sizes Nij. This choice is arbitrary and
could be replaced depending on another design, e.g., by assuming random sampling
of the phase 2 data set.
Although the approximation diﬀers from the penalty term calculated for the
two-phase analysis, it may be used to predict the performance of stratiﬁcations with
respect to an eﬃcient estimation of parameters related to phase 1 covariates. For the
comparison of diﬀerent stratiﬁcations, the diagonal elements of P̂ T I , which represent
the variances of the respective parameter estimates, are plotted as shown in Section
4.4, Figure 4.2, where each column refers to a single stratiﬁcation. Stratiﬁcations
with small penalty terms for all or the most important phase 1 covariates are then
considered as the most eﬃcient stratiﬁcations. The choice of the most important
covariates is based on qualitative criteria which take into account for instance prior
knowledge and the speciﬁc study question. Thus, the design criterion is deﬁned as
follows:
Design Criterion. Consider a two-phase study based on data (D,X), where D is
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the disease indicator and XT = (YT ,ZT ) is the complete covariate vector available
in phase 2 with Y being the vector of covariates available in phase 1 and Z being
the additional information available in phase 2. Then, eﬃcient stratiﬁcations are
identiﬁed by the following steps:
1. Deﬁne a ranking of covariates X1, . . . , Xp according to their importance for
the study.
2. Deﬁne a set of candidate stratiﬁcations {S1, . . . ,SL}.
3. Estimate P̂ T I(Sl), l = 1, . . . , L, and select the stratiﬁcations with the smallest
diagonal elements of these matrices for all or the most important covariates.
The application of the proposed design criterion is exempliﬁed for the empirical
study in Section 4.4. Its properties and limitations are discussed in the next section.
4.3.3 Properties and limitations of the design criterion
The suggested design criterion relies on an approximation of the penalty term that
is based on the full phase 1 data and a model including only phase 1 covariates.
Since no information on the eﬃciency of parameter estimation for phase 2 variables
is provided by the criterion, stratiﬁcations are only selected with respect to eﬃcient
estimation of parameters for phase 1 variables. This is a clear limitation. However,
at the planning stage, when only phase 1 data is available, this limitation cannot
be avoided. If known proxies for phase 2 variables are available in phase 1, this
limitation can be at least partly compensated by including these variables in the
selected stratiﬁcation.
Approximation error Ignoring phase 2 variables in the model also leads to an
approximation error of the penalties related to the estimation of parameters for
phase 1 covariates because NIˆR = IˆI and Ωˆ = ΩˆI . To examine this error in more
detail, consider the penalty term P̂ T k of βˆk related to a phase 1 covariate Xk and
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its approximation P̂ T I,k:
P̂ T k =
1
N
p∑
u=1
p∑
v=1
(
i−1R
)
kv
(ω)vu
(
i−1R
)
uk
, (4.9)
P̂ T I,k = N
p′∑
u=1
p′∑
v=1
(
i−1I
)
kv
(ωI)vu
(
i−1I
)
uk
, (4.10)
where
(
i−1R
)
ab
, (ω)ab,
(
i−1I
)
ab
, and (ωI)ab are the elements of the ath row and bth
column of the matrices Iˆ−1R , Ωˆ, Iˆ
−1
I , and ΩˆI , respectively. Apart from the diﬀerences
between N−1
(
i−1R
)
ab
and
(
i−1I
)
ab
as well as between (ω)ab and (ωI)ab for 1 ≤ a, b ≤ p′,
the two terms diﬀer by the summands related to phase 2 variables, i.e., by
1
N
p∑
u=p′+1
p∑
v=p′+1
(
i−1R
)
kv
(ω)vu
(
i−1R
)
uk
.
The size of this sum depends on the covariance of Xk and the phase 2 variables
as well as on the empirical covariance of the score in each stratum for components
related to phase 2 variables. Whereas the ﬁrst dependency is not inﬂuenced by the
stratiﬁcation, the second dependency is. Stratiﬁcations including information on Xk
and on proxies for the phase 2 variables are likely to reduce the score variability of the
respective components, though it cannot be calculated based on phase 1 data. This
is another argument for including proxies for phase 2 variables in the stratiﬁcation.
The diﬀerence between N−1
(
i−1R
)
ab
and
(
i−1I
)
ab
for 1 ≤ a, b ≤ p′ is not neglectable
because it has been shown that at least the variance
(
i−1I
)
kk
is inﬂated by including
additional covariates in the model (see e.g., Whittemore, 1981; Hsieh et al., 1998).
However, since the size of the diﬀerence is independent of the stratiﬁcation, it does
not need to be considered in the design criterion.
The terms (ω)ab and (ωI)ab for 1 ≤ a, b ≤ p′ diﬀer with respect to the score
variability which is estimated for (ω)ab by the empirical covariance of the score
SC = (D− Πˆ)Y in each phase 2 stratum and for (ωI)ab by the empirical covariance
of the score SCI = (D − ΠˆI)Y in each phase 1 stratum. As has been discussed in
the previous section, the issue of using phase 1 strata instead of phase 2 strata is
not relevant for the design criterion. The diﬀerence between
Πˆh =
exp(αˆ + βˆ
T
xh)
1 + exp(αˆ + βˆ
T
xh)
and ΠˆI,h =
exp(αˆI + βˆ
T
I yh)
1 + exp(αˆI + βˆ
T
I yh)
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for each subject h might, however, lead to divergent conclusions on the performance
of the investigated stratiﬁcations. If the phase 1 data includes most of the informa-
tion on the disease such that Πˆ ≈ ΠˆI , the design criterion results in valid predictions
of the penalties. As two-phase database studies comprise a multitude of phase 1 co-
variates, this condition is assumed to be fulﬁlled. Even if Πˆ ≈ ΠˆI , the approximation
error will most likely only lead to an underestimation of the eﬃciency of stratiﬁ-
cations including proxy information on phase 2 covariates. This limitation of the
design criterion is already known.
Relation to the disease score As can be seen from (4.7), the estimated disease
probability ΠˆI which is used in the approximation of the penalty term coincides
with the disease score DSC deﬁned in (4.1). Since the empirical covariance of the
score in stratum Sij only depends on the variabilities of ΠˆI and Y in this stratum,
it is obviously reduced when the stratiﬁcation is based on ΠˆI . Thus, stratiﬁcations
deﬁned by percentiles of the disease score are likely to have small penalty terms.
Transferability to ML estimation The design criterion is based on the variance
of the WLE because the variance formula allows for a relatively easy approximation
of the variance by using only phase 1 data. For the variance of the MLE (cf. Section
3.2.2) no decomposition in the phase 1 variance and a penalty term exists. ML
is, however, the preferred estimation approach because it is more eﬃcient than the
WL approach (cf. Section 3.3.2). The design criterion might underestimate the
eﬃciency of ML estimators especially for stratiﬁcations with a high variability of
sampling fractions. If the variability of sampling fractions is similar for the compared
stratiﬁcations, it is assumed that eﬃcient stratiﬁcations according to the design
criterion are also eﬃcient when using ML estimation.
How the theoretical properties of the design criterion translate into practice is
investigated in Sections 4.4 and 4.5 where the criterion is used to identify eﬃcient
stratiﬁcations for the empirical study which are then evaluated in a simulation study.
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4.4 Planning an eﬃcient stratiﬁcation for the
empirical study
The design criterion is applied to the empirical two-phase study to identify eﬃcient
stratiﬁcations for the extended two-phase model considered in Section 4.2.3. Hence,
penalties are to be predicted for the parameter estimation of the phase 1 covariates
phenprocoumon exposure, age, sex, hypertension, diabetes mellitus, and eight bi-
nary covariates for comorbid diseases and concomitant medications. According to
Section 4.3.2, the search is conducted in three steps: First, the covariates are ranked
according to their importance for the study. Second, a set of candidate stratiﬁ-
cations is deﬁned taking into account the ranking of covariates. Third, penalties
are predicted for these stratiﬁcations and evaluated graphically to identify the best
stratiﬁcations with respect to small penalties. The three steps are detailed in the
following.
Step 1: Ranking of covariates
The ranking of covariates according to their importance for the study is based on the
study objective, subject matter knowledge, and prior knowledge on the covariates.
Since the study aims at assessing the risk of bleeding associated with phenprocoumon
use, the most important variable is phenprocoumon exposure. Age and sex are cho-
sen to be the second most important covariates because older age and male sex are
known risk factors for bleedings (see for instance Hernandez-Diaz and Rodriguez,
2002). The variable age is of particular importance because it is the only continuous
phase 1 variable. Moreover, age is associated with most of the considered comorbid
diseases and concomitant medications. All other covariates are deﬁned to be of sec-
ondary importance. As hypertension and diabetes are the most prevalent diseases,
they are considered to be more important than diseases with a lower prevalence.
Consequently, ranks are assigned to the phase 1 covariates as shown in Table 4.2.
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Table 4.2: Ranking of phase 1 covariates
Rank Covariate
1 Phenprocoumon exposure
2 Age
3 Sex
4 Hypertension, diabetes mellitus
5 Ischemic heart disease, liver disease, GI disease,
use of NSAIDs, ASA, diuretics, statins, gastroprotective drugs
ASA: acetylsalicylic acid, GI: gastrointestinal, NSAID: non-steroidal anti-inﬂammatory drug
Step 2: Deﬁnition of candidate stratiﬁcations
Taking into account the ranking of covariates, 31 stratiﬁcations are constructed by
cross-classiﬁcation of covariates. Starting with a stratiﬁcation based on the most
important covariate, this covariate is then combined with the second most important
covariate and so forth. Since cross-classiﬁcation of phenprocoumon exposure, age (in
three categories), sex and two further covariates results in up to 48 strata, no more
than two covariates are added to the variables of most and second most importance.
Moreover, to avoid empty cells, only combinations with the most prevalent covariates
hypertension and diabetes are considered.
In addition, ﬁve stratiﬁcations are deﬁned by percentiles of two diﬀerent disease
scores. While the ﬁrst disease score (DSC1) corresponds to the one used in Section
4.2.3, the second disease score (DSC2) is obtained from a logistic regression model
including all phase 1 covariates except phenprocoumon, age, and sex. For both
disease scores, stratiﬁcations are deﬁned by cross-classiﬁcation of phenprocoumon
exposure, age, sex, and either deciles or the 90th and 95th percentiles of the disease
score. The ﬁfth stratiﬁcation is based on deciles of DSC1 alone. Hence, the set of
candidate stratiﬁcations consists of the 36 stratiﬁcations listed in Table 4.3.
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Table 4.3: Deﬁnition of stratiﬁcations
ID No. Stratiﬁed by...
1 ...phenprocoumon exposure (phen.)
2a ... phen., agea
2b ... phen., sex
2ab ... phen., agea, sex
3a ... phen., agea, sex, hypertension
3b ... phen., agea, sex, diabetes mellitus
3ab ... phen., agea, sex, hypertension, diabetes mellitus
3ac ... phen., agea, sex, hypertension, liver disease
3ad ... phen., agea, sex, hypertension, ischemic heart disease
3ae ... phen., agea, sex, hypertension, GI disease
3af ... phen., agea, sex, hypertension, use of ASA
3ag ... phen., agea, sex, hypertension, use of NSAIDs
3ah ... phen., agea, sex, hypertension, use of statins
3ai ... phen., agea, sex, hypertension, use of diuretics
3aj ... phen., agea, sex, hypertension, use of gastroprotective drugs
3bc ... phen., agea, sex, diabetes mellitus, liver disease
3bd ... phen., agea, sex, diabetes mellitus, ischemic heart disease
3be ... phen., agea, sex, diabetes mellitus, GI disease
3bf ... phen., agea, sex, diabetes mellitus, use of ASA
3bg ... phen., agea, sex, diabetes mellitus, use of NSAIDs
3bh ... phen., agea, sex, diabetes mellitus, use of statins
3bi ... phen., agea, sex, diabetes mellitus, use of diuretics
3bj ... phen., agea, sex, diabetes mellitus, use of gastroprotective drugs
4_1a ... phen., agea, sex, deciles of DSC1
4_1b ... phen., agea, sex, 90th/95th %-ile of DSC1
4_1c ... deciles of DSC1
4_2a ... phen., agea, sex, deciles of DSC2
4_2b ... phen., agea, sex, 90th/95th %-ile of DSC2
a Age is considered in categories <50 years, 50-<65 years, and ≥65 years.
ASA: acetylsalicylic acid, DSC1: disease score 1, DSC2: disease score 2, GI: gastrointestinal,
NSAID: non-steroidal anti-inﬂammatory drug, phen.: phenprocoumon
59
Step 3: Prediction of penalties and choosing the best strati-
ﬁcation
The penalty terms P̂ T I(S ) are calculated for the 36 candidate stratiﬁcations and
each phase 1 covariate assuming balanced phase 2 samples of sizes 500, 1,000, 2,000,
and 10,000. The size of P̂ T I(S ) is assessed graphically as shown in Figure 4.2,
where all covariates except phenprocoumon exposure and age can be included in the
same graph because their penalties have the same order of magnitude. Since the
same picture arises for all phase 2 sample sizes, results are only presented for the
sample size 2,000.
Regarding phenprocoumon exposure, all stratiﬁcations have the same low val-
ues of P̂ T I(S ) except for the stratiﬁcation that does not include phenprocoumon
exposure explicitly (4_1c) (see Figure 4.3). For age, the smallest penalty occurs
for the stratiﬁcation deﬁned by phenprocoumon exposure, age, sex, and deciles of
DSC1 (4_1a) and the highest values are observed for those stratiﬁcations ignoring
age information (1, 2b) and for some of the stratiﬁcations including phenprocoumon
exposure, age, sex, diabetes mellitus, and one further covariate (see Figure 4.3). Con-
cerning the other covariates, the best results are obtained for stratiﬁcations based
on a disease score as can be seen in Figure 4.2. Interestingly, most stratiﬁcations
based on cross-classiﬁcation of phenprocoumon exposure, age, sex, and at least one
comorbid disease or concomitant medication are less eﬃcient for the estimation of
the age eﬀect compared to other stratiﬁcations including age information. This can
only be explained by diﬀerent sampling fractions in the age groups. They apparently
lead to sampling of less informative subjects with respect to age. The gap that can
be seen in Figure 4.2 between dots related to variables included in the stratiﬁcation
and those not included indicates that the loss of age information also results in less
eﬃcient estimation for variables not included in the stratiﬁcation. Thus, includ-
ing additional covariates in a stratiﬁcation deﬁned by cross-classiﬁcation does not
only lead to a gain in eﬃciency for the additional covariate but may also result in
eﬃciency loss for the other covariates.
Considering only the size of P̂ T I(S ), stratiﬁcations based on phenprocoumon
exposure, age, sex, and deciles of a disease score (4_1a, 4_2a) would be chosen as the
most promising stratiﬁcations for an eﬃcient study design. A disadvantage of both
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stratiﬁcations is that the strata referring to the lower percentiles are very sparsely
populated. The risk of empty strata is then increased for real phase 2 samples in
which phase 2 information presumably cannot be obtained for all selected persons.
Therefore, the coarser stratiﬁcations (4_1b, 4_2b) are to be preferred in practice.
To evaluate how these stratiﬁcations perform in a realistic two-phase analysis a
simulation study is conducted mimicking the empirical data situation.
Among the 36 stratiﬁcations compared in this section are also stratiﬁcations based
on two partitions of the disease score: one includes ten subclasses with equidistant
cut-points and the second one consists of three subclasses with cut-points that ensure
a suﬃcient number of cases in each subclass. The estimated penalties indicate that
the stratiﬁcation based on the ten narrow subclasses is more eﬃcient than that based
on the three broad subclasses. Although not further investigated here, the design
criterion seems to be useful for determining good partitions of the disease score.
Figure 4.2: Penalty terms estimated from phase 1 data for a phase 2 sample of
size 2,000
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(a) Phenprocoumon exposure
(b) Age
Figure 4.3: Penalty terms for phenprocoumon exposure and age
estimated from phase 1 data for a phase 2 sample of size 2,000
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4.5 Simulation study to assess the performance of
selected stratiﬁcations
Complementary to the empirical study, a simulation study is conducted to compare
diﬀerent stratiﬁcation strategies in two-phase analyses with a rich phase 1 data set.
The simulation study mimics the empirical study but allows the investigation of
larger phase 2 samples and the examination of bias in the parameter estimation.
The objectives are speciﬁcally
1. to assess the performance of stratiﬁcations deﬁned by percentiles of a disease
score in comparison to cross-classiﬁcation,
2. to assess the performance of the a priori stratiﬁcations selected by the design
criterion, and
3. to assess the interplay of a priori and post stratiﬁcations.
This section starts with a description of the set-up of the complete simulation study
whereas results are only reported for the second and third objectives. Results ac-
cording to the ﬁrst objective have already been described in Section 4.2.4.
4.5.1 Set-up of the simulation study
Simulation of phase 1 and phase 2 data sets At ﬁrst, 1,000 phase 1 data
sets are simulated which have the same size and the same covariate structure as
the empirical study. Technically, the covariates are simulated in three steps: The
ﬁrst step relates to the simulation of 12 binary covariates according to the estimated
covariate distribution of the empirical study for 26,208 subjects. Then, age is simu-
lated based on the conditional distribution of age given the binary covariates. In the
third step, the phase 2 variables BMI and smoking are generated for each subject
as categorical variables with four and three categories using the distribution esti-
mated from the phase 2 data set of the empirical study. The disease status is then
derived according to the estimated logistic disease model of the empirical study
(see Table E.3 in Appendix E). From each phase 1 data set, 44 phase 2 samples
of 500, 1,000, 2,000, and 10,000 subjects, respectively, are drawn with respect to
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11 sampling schemes including random sampling and stratiﬁed sampling by the a
priori stratiﬁcations listed in Table 4.4. Of the ten a priori stratiﬁcations, the sim-
plest stratiﬁcation includes only two strata deﬁned by phenprocoumon exposure, the
next six stratiﬁcations are derived by cross-classiﬁcation of phenprocoumon expo-
sure and several covariates, and the last three are based on the disease scores DSC1
and DSC2. In particular, stratiﬁcations IX and X are those selected in Section 4.4
by the design criterion. Moreover, stratiﬁcation IX corresponds to stratiﬁcation E*
used in Section 4.2. The number of strata ranges from two until 40 strata (see Table
4.4). To avoid empty cells for stratiﬁcations with more than 20 strata, those strata
occurring only in cases or only in controls are collapsed by ignoring information
on the least important covariate. Consider for example a stratiﬁcation deﬁned by
cross-classiﬁcation of phenprocoumon exposure, age, sex, and hypertension and sup-
pose that no male cases exposed to phenprocoumon in the youngest age group are
diagnosed with hypertension. Then, this stratum is combined with the respective
stratum of persons without hypertension. This approach ensures that information
on the more important covariates such as phenprocoumon and age is always included
in the stratiﬁcation.
The phase 1 data sets are simulated by using the SAS call routine rantbl for
generation of the covariates and ranbin for the disease status. Random selection
of the phase 2 samples is achieved by invoking the SAS call routine ranuni and
selecting subjects with the 500-10,000 smallest random numbers. Two seed streams
are deployed, one for simulation of the phase 1 data and one for drawing the phase
2 samples. Independence of the simulations is guaranteed because only 5% and 60%
of the period length of the random number generator is exhausted.
Analysis of the data sets Two-phase analysis of the 44,000 two-phase studies
are conducted employing ML and WL methods which utilise the respective a priori
stratiﬁcation. Phase 2 samples drawn according to four selected a priori stratiﬁca-
tions (0, I, II, VIII) are additionally analysed with respect to six post stratiﬁcations
(A-F, see Table 4.5). For each parameter estimator βˆki for variable k in simulation
i within-simulation standard errors SE(βˆki) are calculated as well as bias and ef-
ﬁciency as deﬁned in Section 4.2.4. Besides the within-simulation standard errors,
also the empirical standard error is determined representing the uncertainty of βˆk
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between the simulations. The empirical standard error is calculated as
SEemp =
√√√√ 1
nsim − 1
nsim∑
i=1
(βˆki − ¯ˆβk)2,
where ¯ˆβk is the average parameter estimate. The stratiﬁcations are compared regard-
ing failure proportions and the average bias as well as the average eﬃciency of the
two-phase estimators, where failures are deﬁned as in Section 4.2.4. For Objective
2, also the average within-simulation standard errors of the estimated coeﬃcients of
the phase 2 variables BMI and smoking are compared.
Table 4.4: Deﬁnition of a priori stratiﬁcations
ID in No of ID in
simulation Stratiﬁed by... stratab Section4.4
0 Random sample 0 –
I ...phenprocoumon exposure (phen.) 2 (1)
II ...phen., agea 6 (2a)
III ...phen., sex 4 (2b)
IV ...phen., agea, sex 12 (2ab)
V ...phen., agea, sex, hypertension 20 (3a)
VI ...phen., agea, sex, diabetes mellitus (DM) 20 (3b)
VII ...phen., agea, sex, hypertension, DM 40 (39-40) (3ab)
VIII ...deciles of DSC1 10 (4_1c)
IX (=E*) ...phen., agea, sex, 90th/95th %-ile of DSC1 21 (20-22) (4_1b)
X ...phen., agea, sex, 90th/95th %-ile of DSC2 30 (30-30) (4_2b)
a Age is considered in categories <50 years, 50-<65 years, and ≥65 years.
b If the number of strata varies, the median number of strata is presented with the quartiles Q1
and Q3 in parentheses.
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Table 4.5: Deﬁnition of post stratiﬁcations
No of
ID Stratiﬁed by... strata
A ...phenprocoumon exposure (phen.), age, sex 10
B ...phen., agea, sex, hypertension 20
C ...phen., agea, sex, diabetes mellitus 20
D ...phen., 50th/75th/90th/95th/99th %-ile of DSC1 12
E ...phen., agea, sex, 90th %-ile of DSC1 20
F ...phen., ageb, sex, hypertension 16
a Age is considered in categories <50 years, 50-<65 years, and ≥65 years.
b Age is considered in categories <65 years and ≥65 years.
4.5.2 Results
Performance of a priori stratiﬁcations
For the comparison of a priori stratiﬁcations, only two-phase analyses are considered
in which the a priori stratiﬁcation is used for sampling and analysis of the phase
2 data. Results with respect to other post stratiﬁcations are described in the next
section. The simulation study conﬁrms the good performance of stratiﬁcations IX
and X, which have been identiﬁed as most eﬃcient by the design criterion in Section
4.4. Regarding the estimated coeﬃcients for phenprocoumon exposure, age, and
sex, both are among the most eﬃcient stratiﬁcations. Concerning the parameter
estimation for hypertension and diabetes, eﬃciencies are lower compared to strati-
ﬁcations including these covariates directly but higher compared to other stratiﬁca-
tions. Both stratiﬁcations are more eﬃcient for the parameter estimation of all other
phase 1 covariates. Moreover, the parameter estimation is unbiased and no failures
are observed with these stratiﬁcations. The simulation study also demonstrates that
stratiﬁcation VIII is worse than other stratiﬁcations because it is associated with
high failure proportions and ineﬃcient parameter estimation for most phase 1 covari-
ates including the parameter of main interest (phenprocoumon). However, eﬀects
of the phase 2 covariates smoking and BMI are estimated with the smallest stan-
dard errors when using this stratiﬁcation. Furthermore, the study reveals a problem
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for cross-classiﬁcation when the WL approach is used: Since cross-classiﬁcation of
several covariates leads to a high variability of sampling fractions, the WL estima-
tors are biased and ineﬃcient. More detailed results of the simulation study are
described below.
Failure proportion The failure proportions are approximately zero for all a priori
stratiﬁcations except for stratiﬁcation VIII where proportions of up to 70% failures
are observed for small phase 2 samples (see Table 4.7).
Bias The stratiﬁed sampling of most phase 2 samples introduces bias in complete-
case analyses (i.e., in logistic regression analyses using only phase 2 data) for all
parameter estimates related to variables included in the a priori stratiﬁcation. In
two-phase analysis using the ML approach, the bias is removed for all parameter
estimates and all stratiﬁcations (results not shown). When applying the WL ap-
proach to phase 2 samples of sizes 500 and 1,000, residual bias occurs in parameter
estimates of hypertension and diabetes mellitus for stratiﬁcations including these
variables (i.e., V, VI, VII; see Table 4.6). This might be explained by the high
variability of sampling fractions for these stratiﬁcations which is particularly high
for small samples. Sampling fractions vary more for these stratiﬁcations because
the number of strata is large and strata of subjects with diabetes mellitus and hy-
pertension and/or phenprocoumon exposure are very sparsely populated whereas
strata with healthy subjects not taking phenprocoumon contain a large number of
subjects. For small phase 2 samples, the proportion of subjects selected from these
large strata is very small thereby leading to very high weights in the weighted ana-
lysis. For instance, the smallest average sampling fraction in samples of size 500 for
a priori stratiﬁcation VII is 0.0009 leading to a weight of 1111.11.
Eﬃciency With respect to eﬃciency, the performance of the a priori stratiﬁca-
tions diﬀers widely subject to the covariates. Regarding phenprocoumon exposure,
all stratiﬁcations have similar eﬃciencies except for stratiﬁcation VIII which is inef-
ﬁcient (see Figure 4.5(a)). The coeﬃcient for age can only be estimated eﬃciently if
age is included in the a priori stratiﬁcation either directly or indirectly via a disease
score (see Figure 4.5(b)). High eﬃciencies are also observed if the covariate infor-
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Table 4.6: Results of ML and WL estimation using a priori stratiﬁcation
VII based on phase 2 samples of size n = 500
Estimation approach ML WL
Number of simulations: nsim = 999 nsim = 1, 000
Multivariable model True βa βˆ
b
(SE) βˆ
b
(SE)
Phenprocoumon exposure 1.37 1.37 (0.25) 1.30 (0.33)
Age (centred at 55 years) 0.038 0.038 (0.005) 0.038 (0.009)
Interaction: phen. * age -0.034 -0.034 (0.019) -0.031 (0.022)
Female sex -0.12 -0.12 (0.11) -0.13 (0.17)
Interaction: phen. * sex 0.29 0.29 (0.27) 0.30 (0.34)
BMI ≥30kg/m2 0.45 0.47 (0.23) 0.49 (0.40)
Interaction: phen. * BMI -0.39 -0.40 (0.41) -0.41 (0.58)
Current smoker 0.83 0.87 (0.19) 0.97 (0.37)
Comorbid conditions:
Hypertension 0.12 0.11 (0.12) -0.02 (0.20)
Diabetes mellitus 0.24 0.23 (0.12) 0.08 (0.19)
Ischemic heart disease 0.05 0.05 (0.27) 0.06 (0.47)
Liver disease 0.27 0.27 (0.27) 0.36 (0.51)
GI disease 0.32 0.35 (0.35) 0.47 (0.65)
Use of NSAIDs 0.37 0.39 (0.31) 0.49 (0.57)
Use of ASA 0.56 0.58 (0.39) 0.67 (0.59)
Use of diuretics 0.21 0.22 (0.21) 0.27 (0.38)
Use of statins -0.11 -0.12 (0.27) -0.13 (0.48)
Use of gastroprotective drugs 0.57 0.59 (0.28) 0.69 (0.52)
a Parameter that has been used for the simulation of the disease status.
b Parameter estimate and standard error (SE) are averaged over all simulations.
ASA: acetylsalicylic acid, GI: gastrointestinal, NSAID: non-steroidal anti-inﬂammatory
drug, phen.: phenprocoumon
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(a) Smoking
(b) BMI
Figure 4.4: Standard errors of ML estimators for phase 2 variables
in samples of size 2,000
A priori stratiﬁcations used in the analysis are denoted by the num-
bers 0 - 10, post stratiﬁcations are denoted by the capitals A-F.
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mation is directly included in the stratiﬁcation as is exempliﬁed for the covariate
diabetes in Figure 4.5(c). A priori stratiﬁcations IX and X, which are based on a
disease score, are also eﬃcient for all other phase 1 covariates not included directly
in any a priori stratiﬁcation (e.g., for gastroprotective drugs see Figure 4.5(d)).
Standard error of phase 2 variables The standard errors (SE) for the main
eﬀects of smoking and BMI are depicted in Figure 4.4. The SE for the interaction
between phenprocoumon exposure and BMI is dominated by the SE for the eﬀect of
phenprocoumon. Hence, the performance of stratiﬁcations is similar to that shown
in Figure 4.5(a). Interestingly, stratiﬁcation VIII results in the smallest errors for
both parameter estimates. Stratiﬁcations IX and X, which are also based on a
disease score, reveal smaller errors than the other a priori stratiﬁcations. The eﬀect
of BMI, however, is estimated with a better precision in the random samples (0)
(see Figure 4.4(b)). These results indicate that there is no strong proxy for smoking
or BMI in the phase 1 data set. In particular, inclusion of sex information does not
reduce the SE of the estimated BMI parameter.
Interplay of a priori and post stratiﬁcations
The results described in the previous section are only relevant for two-phase studies
where the actually derived phase 2 sample coincides with the planned phase 2 sam-
ple. In practice, the samples may diﬀer due to unintended selection processes such
as non-response of subjects with speciﬁc characteristics. If the stratiﬁcation used
in the two-phase analysis does not account for all variables inﬂuencing the selection
probability, parameter estimates are biased. This is one reason for employing a post
stratiﬁcation that diﬀers from the a priori stratiﬁcation. The issue of bias occurring
when the post stratiﬁcation does not account for the selective sampling of phase 2
has already been addressed in Section 4.2.4. Potential non-response is also an argu-
ment for not deﬁning very ﬁne a priori stratiﬁcations because non-response can lead
to empty cells for sparsely populated strata. A possible solution would be to use a
relatively coarse a priori stratiﬁcation for sampling and a ﬁne post stratiﬁcation for
the evaluation. Whether this approach is feasible and leads to eﬃcient parameter
estimation can be seen from the results described in this section.
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The simulation study shows that random samples and samples in which subjects
with rare exposures of interest are not oversampled are associated with high failure
proportions and therefore with a high risk of empty strata. Regarding eﬃciency, the
impact of the sampling and the evaluation stratiﬁcation depends on the covariate.
Sampling according to rare exposures, e.g., phenprocoumon, is more eﬃcient than
including this exposure only in the post stratiﬁcation. For more prevalent covariates,
the impact of the a priori stratiﬁcation is less important. Thus, it is suﬃcient to
include covariates such as sex only in the post stratiﬁcation. For all other phase 1
covariates in between these extremes inclusion in the a priori stratiﬁcation, at least
via a disease score, results in small eﬃciency gains. More details on the results
are presented below. As results regarding failure proportions and eﬃciency are
similar for ML and WL estimation (except for the range of eﬃciency), they are only
presented for ML estimation but apply for WL estimation as well.
Failure proportion Table 4.7 shows the failure proportions observed for com-
binations of a priori and post stratiﬁcations. The worst failure proportions are
obtained for random samples and samples drawn according to deciles of a disease
score (VIII). These samples only have acceptable failure proportions if they com-
prise at least 2,000 subjects when analysed with stratiﬁcation A or if they comprise
at least 10,000 subjects when analysed with stratiﬁcations other than stratiﬁcation
A. The high failure proportions are caused by empty strata. They occur because
sparsely populated strata are not necessarily oversampled when the phase 2 samples
are not drawn according to the post stratiﬁcations. The ﬁnding that post stratiﬁca-
tions with few strata have much lower failure proportions than stratiﬁcations with
more strata has already been discussed in Section 4.2.4.
Eﬃciency Due to the high failure proportions observed for some stratiﬁcations in
samples of size 500 and 1,000, the comparison of eﬃciency is exempliﬁed for sam-
ples of size 2,000. The interplay of a priori and post stratiﬁcations with regard to
eﬃciency of parameter estimation is illustrated for phenprocoumon exposure, age,
diabetes mellitus, and use of gastroprotective drugs in Figure 4.5. The eﬃciency
of parameter estimates for phenprocoumon is mainly driven by the a priori strati-
ﬁcation. The ineﬃciency obtained for random samples (0) and samples stratiﬁed
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Table 4.7: Failure proportion of ML-estimation for diﬀerent a priori/post strati-
ﬁcation combinations
Sample A priori Post stratiﬁcation
size strat. A B C D E F a priori
500 0 94.50% 100% 100% 100.00% 100% 100% –
I 1.80% 73.60% 98.60% 46.80% 99.90% 28.30% 0.50%
II 0.10% 79.80% 99.00% 20.70% 99.60% 3.00% 0.10%
IV 0.40% 78.30% 96.50% 19.60% 99.90% 2.10% 0.40%
VIII 97.40% 100% 100% 100% 100% 100% 70.40%
1,000 0 67.50% 99.70% 99.80% 97.50% 100% 99.70% –
I 0.00% 17.80% 66.60% 16.70% 90.90% 3.50% 0.00%
II 0.00% 30.60% 76.30% 2.20% 93.70% 0.00% 0.00%
IV 0.30% 30.50% 75.30% 1.80% 94.10% 0.30% 0.30%
VIII 66.60% 99.90% 100% 98.80% 100% 99.90% 20.60%
2,000 0 24.30% 92.20% 97.40% 83.60% 98.60% 92.40% –
I 0.00% 0.20% 6.20% 1.80% 37.90% 0.00% 0.00%
II 0.00% 3.30% 21.10% 0.00% 64.50% 0.00% 0.00%
IV 0.30% 3.30% 20.10% 0.00% 63.60% 0.30% 0.30%
VIII 13.50% 88.90% 98.00% 78.90% 98.90% 88.50% 0.80%
10,000 0 0.00% 0.20% 5.00% 2.40% 6.50% 0.20% –
I 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
II 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
IV 0.30% 0.30% 0.30% 0.00% 0.30% 0.30% 0.30%
VIII 0.00% 0.20% 2.30% 0.80% 3.30% 0.20% 0.00%
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(a) Phenprocoumon (b) Age
(c) Diabetes mellitus (d) Gastroprotective drugs
Figure 4.5: Eﬃciency of ML estimators in phase 2 samples of size 2,000
A priori stratiﬁcations used in the analysis are denoted by the numbers 1* - 10*,
post stratiﬁcations are denoted by the capitals A-F.
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by the disease score (VIII) is not improved by any post stratiﬁcation (see Figure
4.5(a)). For an eﬃcient estimation of the age parameter, it is only important that
age is included in the post stratiﬁcation (see Figure 4.5(b)). To be more precise,
stratiﬁcations D, I, and III, which do not include age, have the worst eﬃciencies.
Moreover, including age in the sampling stratiﬁcation does not lead to a gain in
eﬃciency for the estimation of the age parameter as can be seen for stratiﬁcations II
and IV. However, sampling on age slightly improves the eﬃciency of parameter esti-
mates for covariates related to age (see Figure 4.5(c) and Figure 4.5(d). Regarding
all other phase 1 covariates, an eﬃcient parameter estimation depends on both, the
sampling and the evaluation stratiﬁcation. This is best illustrated by the example of
diabetes mellitus: It is apparent from Figure 4.5(c) that inclusion of diabetes melli-
tus in the post stratiﬁcation (C) improves the eﬃciency. An even higher eﬃciency is
achieved if the a priori stratiﬁcation includes diabetes mellitus (VI, VII). Although
the direct inclusion of a covariate is more eﬃcient than the inclusion via a disease
score, considerable gains in eﬃciency are observed for most phase 1 covariates when
the sampling and evaluation stratiﬁcation include percentiles of a disease score (see
stratiﬁcations IX and X in Figure 4.5(d)). In particular, these stratiﬁcations are
more eﬃcient for the parameter estimation for most phase 1 covariates then a priori
stratiﬁcations including age information (II, IV).
4.5.3 Discussion
A summary of the simulation results regarding all three objectives of the study is at
the same time also a summary of the whole chapter. Using a disease score for the
deﬁnition of the stratiﬁcation permits the inclusion of phase 1 information on many
covariates thereby improving the eﬃciency of parameter estimation. Since covariate
information is considered only indirectly, stratiﬁcations based on disease scores are
coarser with respect to the speciﬁc covariate than stratiﬁcations deﬁned by cross-
classiﬁcation. Therefore, a combination of both strategies, i.e. cross-classiﬁcation by
important variables and percentiles of a disease score, results in the best performance
with respect to bias and eﬃciency. To avoid bias, important variables mean at least
all variables used for sampling.
In the light of these results it is reassuring that these stratiﬁcations are chosen
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by the design criterion. The simulation study conﬁrms the choice suggested by the
criterion also for ML estimation, although the criterion is derived from the WL
approach. In the investigated data scenario, the selected stratiﬁcations are also
eﬃcient for the estimation of parameters related to phase 2 variables. This result
probably cannot be transferred to two-phase studies which include proxy information
for phase 2 variables in the phase 1 data set.
The simulation study has also demonstrated that cross-classiﬁcation of several
phase 1 covariates is not only associated with the problem of empty strata. When
using the WL approach for parameter estimation, this stratiﬁcation strategy may
also lead to unstable results caused by the high variability of sampling weights.
In conclusion, the following recommendation can be derived from the simulation
study for the deﬁnition of a priori and post stratiﬁcations for two-phase studies with
a rich phase 1 data set. At the planning stage of the study, when only phase 1 data
is available, the a priori stratiﬁcation should be deﬁned based on prior knowledge
and the design criterion described in Section 4.4. For step 2 of the planning process,
i.e., for the deﬁnition of candidate stratiﬁcations, it should be taken into account
that variables like sex, which are very common, do not need to be considered in
the a priori stratiﬁcation. Instead of including information on age in the a priori
stratiﬁcation the inclusion of percentiles of a disease score yields more eﬃcient es-
timates. Very rare exposures of interest should be included in any case. For the
analysis of the phase 2 sample, it is crucial that the post stratiﬁcation is ﬁner than
the a priori stratiﬁcation and includes all variables inﬂuencing the selection proba-
bility of the phase 2 sample. Therefore, a response analysis should be conducted to
identify all relevant phase 1 variables. Furthermore, age should be included in the
post stratiﬁcation for two reasons: (1) age itself is a risk factor for the disease; (2)
age is related to most comorbidities and use of comedications. It has to be noted
that this recommendation may only be valid for similar two-phase studies investigat-
ing other pharmacoepidemiological research questions or for studies with a similar
data structure. This data structure is characterised by a rare exposure of interest
and mostly binary covariates. The impact of age is likely to be the same in other
pharmacoepidemiological studies.
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Chapter 5
Beyond two-phase methods:
Approaches for using the full phase 1
information
Two-phase methodology is not the only approach to incorporate phase 1 information
into the analysis of the phase 2 data set. Calibration and estimation of weights
in a weighted analysis as well as multiple imputation are survey methodological
approaches which can be used in the setting of a two-phase study.
Calibration of weights was proposed by Deville et al., 1993 for the inclusion of
information on auxiliary variables that are available for the whole study popula-
tion. In context of a two-phase study, the phase 1 variables can be understood as
auxiliary variables. The weights, deﬁned by the inverse sampling fractions for the
WL approach (see Section 3.3.2), are adjusted according to the condition that the
weighted phase 2 totals of the phase 1 variables equal the known phase 1 totals, i.e.
n∑
i=1
wiyi =
N∑
i=1
yi,
where wi, i = 1, . . . , n, are the adjusted weights and yi is the vector of phase 1
covariates for subject i.
Robins et al., 1994 suggested to estimate the weights by a model that predicts
the sampling probability based on phase 1 variables. To achieve unbiased estimates
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in a stratiﬁed two-phase study, the prediction model should also include the a priori
stratiﬁcation, i.e., the model should be deﬁned by Pr(RII = 1|Y,S ). This has
been noted by Breslow et al., 2013 who compared calibration and estimation of
weights with WL, PL and ML estimation in a two-phase stratiﬁed case-control
study. Compared to WL estimation, they found reduced standard errors of the
estimated coeﬃcients for the phase 1 variables but also diﬀerences in the parameter
estimates for phase 1 as well as phase 2 variables. Standard errors obtained with
adjusted weights were not smaller than those obtained with ML estimation. A
detailed discussion of using calibrated and estimated weights for the analysis of the
particular two-phase studies considered in this thesis is beyond the scope of this
chapter.
Multiple imputation was introduced by Rubin, 1978 to handle non-response in
sample surveys. It is a "ﬁlling-in" method, because the missing values are replaced
by plausible estimates. Instead of imputing only one value for each missing obser-
vation, the imputation is repeated several times to reﬂect the uncertainty related
to the imputation process. Details of the method are described in the next section.
Marti and Chavance, 2011 compared multiple imputation to weighted methods using
inverse probability, calibrated, and estimated weights in a case-cohort study which
can also be interpreted as a two-phase study. They found that the multiple imputa-
tion estimator was slightly more eﬃcient than the weighted estimators for the phase
1 variables but it was also biased in some situations.
A simple multiple imputation method called "hot-deck multiple imputation" has
been shown to be equivalent to WL estimation (Reilly and Pepe, 1997). For this
approach, missing values are replaced by randomly taking values from subjects with
the same observed variables instead of estimating these values. Since WL estimation
is less eﬃcient than ML estimation, hot-deck imputation is not further considered.
Rubin, 1987 proved that the variance estimator developed for multiple imputation
is not appropriate for estimating the variance of the hot-deck multiple imputation
estimator because it is biased. Hence, the variance of the multiple imputation esti-
mator diﬀers from the WLE variance and might especially be more eﬃcient. How
multiple imputation performs in two-phase studies is investigated in this chapter.
After a brief introduction of the theory, the approach is applied to the empirical
two-phase study. Furthermore, a simulation study similar to the study described in
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Section 4.5 is conducted to assess bias in multiple imputation estimates.
5.1 Introduction to multiple imputation
Multiple imputation has been widely used for the handling of missing data in various
ﬁelds of application including epidemiology (see e.g. Rubin, 1996, for a selection
of examples). A detailed description of the technique, its requirements and its
properties is given for instance in Rubin, 1987, Schafer, 1999, and Little and Rubin,
2002. The concept is brieﬂy summarised in the following.
Multiple imputation is conducted in three steps: First, M ≥ 2 complete data
sets are generated by replacing each missing value by a M -dimensional vector of
plausible values. These values are simulated with respect to an imputation model
estimating the predictive distribution of the missing data. Second, the M complete
data sets are analysed with any adequate method for the analysis of complete data
sets to obtain the desired estimate θˆm, m = 1, . . . ,M . Third, the M estimates
θˆm are combined to constitute the multiple imputation estimate and the respective
variance for statistical inference. The multiple imputation estimate is the mean of
the M estimates
θˆIM =
1
M
M∑
m=1
θˆm.
The total variance Var(θˆIM) is composed of the estimated between-imputation vari-
ance Bˆ and the average within-imputation variance estimate Wˆ
V̂ar(θˆIM) =
M + 1
M
Bˆ + Wˆ
=
M + 1
M
1
M − 1
M∑
m=1
(
θˆm − θˆIM
)(
θˆm − θˆIM
)T
+
1
M
M∑
m=1
V̂ar(θˆm).
Two requirements have to be fulﬁlled to achieve unbiased estimates θˆIM : (1) the
missing-at-random (MAR) assumption has to be fulﬁlled; (2) the imputation model
has to give reasonable predictions for the missing observations. Particularly, the
imputation model and the analysis model applied in the second step have to coincide
with respect to the underlying assumptions. If the imputation model for instance
ignores interaction terms, these interactions are estimated with bias in the analysis
model (see Schafer, 1999, for a discussion of this issue).
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Although multiple imputation has been developed for missing data that arises
from mechanisms like non-response or loss to follow-up, two-phase database studies
can be perceived as a missing-data situation in which multiple imputation can be
applied. The ﬁrst requirement, the MAR assumption, also needs to be fulﬁlled for
the application of two-phase methods. Hence, no additional assumption is imposed.
The second requirement depends on the availability of information about the missing
observations. In two-phase database studies, a multitude of phase 1 covariates is
available to deﬁne the imputation model. Thus, for suﬃciently large phase 2 samples
the second requirement is most probably satisﬁed unless the imputation model is
misspeciﬁed.
Besides the imputation model, the method used for imputation is important for
the validity of results. Several imputation methods have been implemented in SAS
software (see SAS/STAT 9.2 User’s Guide). The most commonly applied method is
Markov chain Monte Carlo (MCMC) which can be used for continuous, categorical
and mixed multivariate data. If the data has a monotone missing pattern, the
logistic regression method (Rubin, 1987) and the propensity score method (Lavori et
al., 1995) can be applied to impute ordinal and continuous covariates, respectively.
Variables Z1, . . . , Zp have a monotone missing pattern if a missing value for Zj
implies that values for Zk, k > j, are also missing. Since values of phase 2 covariates
are missing for all subjects outside of the phase 2 sample and are observed for all
subjects in the phase 2 sample, two-phase studies have a monotone missing pattern.
Both methods are easier to apply than MCMC because convergence of MCMC is
often diﬃcult to verify. These methods are therefore employed in the application to
the empirical study as well as in the simulation study. A sketch of the methods is
given below.
Logistic regression method To impute values of an ordinal variable Z a logis-
tic regression model is ﬁt to the observed values of Z and explanatory variables
Y1, . . . , Yk:
logit(Pr(Z ≤ i|y;θi)) = αi + βTy, i = 1, . . . , I.
The resulting parameter estimates θˆ
T
i = (αˆi, βˆ1, . . . , βˆk), i = 1, . . . , I, and the
corresponding covariance matrix are used to deﬁne the posterior predictive distri-
bution of θi given by θi|Z,Y ∼ N (θˆi, Ĉov(θˆi)). For the mth imputation of Z,
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new parameters θmi are drawn from the posterior distribution and the probabilities
pmi = Pr(Z ≤ i|y;θmi ) are calculated for a subject with missing Z and covariate val-
ues y. These probabilities are compared to a random number um generated from a
uniform distribution over the interval [0, 1]. Values of Z are then imputed according
to the following rule: If um ≤ pm1 , Z is set to 1; if pm1 < um ≤ pm2 , Z is set to 2; and
so forth.
The performance of the logistic regression method for the imputation of categori-
cal variables has been investigated by Allison, 2005 who concludes that this method
is preferable to linear imputation methods such as MCMC.
Propensity score method To impute values of a continuous variable Z, an ap-
proximate Bayesian bootstrap imputation is conducted that draws observations from
groups deﬁned by quintiles of the propensity score representing the probability of
a missing value in Z given the covariates Y. To be more precise, the imputation
consists of the following steps: Let R denote the indicator for missing observations
in Z with R = 0 if Z is missing and R = 1 if Z is observed. The ﬁrst step is then
to estimate the propensity score p = Pr(R = 0|y) for each observation by logis-
tic regression. In the second step, the n0 observations with missing values for Z,
Zmis, and the n1 observations with observed values for Z, Zobs, are divided into ﬁve
groups according to their propensity score resulting in groups of sizes n0k and n1k,
k = 1, . . . , 5. In the third step, n1k observations are randomly drawn with replace-
ment from the kth group of Zobs to generate a new set Z∗obs,k. Finally, to impute
values for Zmis,k, n0k observations are drawn randomly with replacement from Z∗obs,k.
It has been mentioned by Schafer, 1999 that the propensity score method may
not be appropriate for estimating the relationship between Z and a covariate which
is unrelated to the indicator of missing information R.
In contrast to most applications of multiple imputation, the proportion of miss-
ing information is usually much higher in two-phase studies. For example in the
empirical two-phase study more than 98% of the information on BMI and smoking
is missing. A further diﬀerence between two-phase studies and common missing-
data situations is that missing data in two-phase studies results from the design
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instead of from an unintended (by the investigator) or random process. In the next
section, multiple imputation is applied to the empirical two-phase study to assess if
the technique is also reasonable for relatively small phase 2 data sets obtained by
stratiﬁed sampling and if it is superior to two-phase methodology concerning bias
and standard errors of the parameter estimates.
5.2 Multiple imputation in the empirical study
In the empirical study on phenprocoumon exposure and serious bleedings, the vari-
ables BMI and smoking have to be imputed based on the phase 2 data set to obtain
a complete data set. Both variables have been included as binary covariates in all
previous analyses, although smoking information is available in three categories and
BMI is observed as continuous covariate. Five imputation models are used to im-
pute values for smoking and BMI. While smoking information is always imputed in
three categories, BMI is considered as binary, categorical (four categories) or con-
tinuous variable. The main focus is on the imputation of categorical values for BMI
to be consistent with the simulation study described in Section 4.5. To evaluate the
performance of multiple imputation utilising the maximum and minimum amount
of information on BMI, respectively, additional imputation models are applied to
impute continuous and binary values for BMI. Two further models are employed
that account for the stratiﬁed sampling of the phase 2 data set. Details on each
model are speciﬁed in the following:
IM1 Imputation Model 1 employs the propensity score method to generate con-
tinuous values for BMI and the logistic regression method to derive categorical
values of smoking. For both methods, disease status and all phase 1 variables
are included as explanatory variables in the model.
IM2 Imputation Model 2 imputes categorical values for BMI and smoking by
using the logistic regression method with the same set of explanatory variables
as in IM1.
IM3 Imputation Model 3 generates binary values for BMI and smoking by using
the logistic regression method with the same set of explanatory variables as in
IM1.
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IM4 Imputation Model 4 includes separate imputations in the four strata deﬁned
by disease and phenprocoumon exposure. In each stratum, categorical values
of BMI and smoking are imputed by a logistic regression model including all
phase 1 variables except phenprocoumon exposure.
IM5 Imputation Model 5 also uses the logistic regression method to generate
categorical values for BMI and smoking. Stratum indicators for disease status
and phenprocoumon exposure are explicitly included as covariates in the model
in addition to all phase 1 variables except phenprocoumon exposure.
All imputations are conducted using the SAS procedure PROC MI.
Twentyﬁve complete data sets are imputed with each imputation model. Usually,
only ﬁve to ten imputations are recommended (see e.g. Schafer, 1999) because the
relative eﬃciency of an estimate based on M imputations compared to an inﬁnite
number of imputations is (1+ λ
M
)−1, where λ is the proportion of missing information.
The rationale for choosing M = 25 is the high proportion of missing information
in this two-phase study. Each complete data set is analysed with two logistic re-
gression models. The ﬁrst analysis model includes all phase 1 variables, two binary
covariates for BMI ≥ 30 kg/m2 and current smoking as well as interaction terms for
phenprocoumon exposure and age and sex, respectively. The second analysis model
additionally includes an interaction term for BMI and phenprocoumon exposure.
The SAS procedure PROC MIANALYZE is used to combine the results according
to the rules described in the previous section.
Estimates obtained from the four multiple imputation models are compared to
phase 1 and two-phase estimates for both analysis models in Table 5.1 and Table
5.2. The estimated coeﬃcients diﬀer between the imputation models especially for
phenprocoumon exposure, smoking and the interaction between phenprocoumon and
BMI. In particular, the parameter estimate for phenprocoumon based on data sets
generated according to IM5 is much smaller than those based on other data sets.
Except for the standard error of the phenprocoumon coeﬃcient for IM5, the standard
errors for multiple imputation estimates of phase 1 variables are comparable to those
obtained from the phase 1 analysis. When comparing imputation models IM1, IM2,
and IM3 with respect to the estimation of coeﬃcients for the phase 1 variables, it
can be seen that IM1 is more eﬃcient than IM2 and IM2 is more eﬃcient than
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IM3. This indicates that categorising as well as dichotomising BMI information
is associated with a loss in eﬃciency. The stratiﬁed imputation implemented for
IM4 is also associated with a slight loss in eﬃciency for these variables. Regarding
estimation of the phase 2 variables in the model without BMI interaction, IM1 and
IM4 are more eﬃcient than IM2, IM3 and IM5. The largest standard errors in both
analysis models are observed for IM5.
The results suggest that multiple imputation is much more eﬃcient for the esti-
mation of the phase 1 variables than two-phase methods whereas phase 2 variables
can be estimated with a comparable precision. However, the estimated coeﬃcients
diﬀer between the models especially for the variable of main interest. As the true
parameter value is not known, it cannot be concluded which estimate is biased. To
investigate the potential for bias in the four imputation models, a simulation study
is conducted and described in the next section.
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5.3 Simulation study to assess bias in multiple im-
putation analyses
To reduce complexity of the simulation study, only imputation models IM2 and IM4
are investigated. Four scenarios are simulated with 500 repetitions each, of which
three address bias occurring with IM2 and one evaluates bias occurring with IM4.
For Scenarios 1, 2 and 4, phase 1 data sets are simulated as described in Chapter
4.5. For simulation of Scenario 3, the phase 1 data set is generated according to a
disease model omitting the interaction between phenprocoumon exposure and BMI.
Phase 2 samples of 500, 1,000, and 2,000 subjects are drawn from each phase 1
data set by simple random sampling (Scenarios 1 and 3) or by stratiﬁed sampling
according to a priori stratiﬁcation IV, i.e. with respect to phenprocoumon expo-
sure, age, and sex (Scenarios 2 and 4). Further a priori stratiﬁcations and phase 2
sample sizes considered in the simulation study of Section 4.5 are not implemented,
again to reduce complexity of this study. Values of the phase 2 variables BMI and
smoking are ﬁrst deleted for all subjects not included in the phase 2 subsamples and
afterwards imputed according to IM2 or IM4. The characteristics of the scenarios
are summarised in Table 5.3.
Table 5.3: Simulation scenarios for investigation of bias
Scenario
Characteristic 1 2 3 4
Disease model includes interaction with BMI × × ×
Random sample in phase 2 × ×
Stratiﬁed sample in phase 2 × ×
Imputation Model 2 × × ×
Imputation Model 4 ×
The bias observed in each of the scenarios is depicted for phase 2 samples of
500 subjects in Figure 5.1. Coeﬃcients for BMI and smoking are estimated with
bias in scenarios 1, 2 and 3. Scenarios 1 and 2, which are based on a phase 1 data
set simulated according to a disease model including BMI interaction, also the pa-
rameter estimate for the interaction between phenprocoumon exposure and BMI as
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(a) Scenario 1 (b) Scenario 2
(c) Scenario 3 (d) Scenario 4
Figure 5.1: Bias in multiple imputation analysis in phase 2 samples of size 500
dis: disease, DM: diabetes mellitus, hypert: hypertension, IA: interaction,
Phenpro: phenprocoumon
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well as the parameter estimate for phenprocoumon exposure are biased. The bias
is slightly larger in Scenario 2 which diﬀers from Scenario 1 only by the selection of
the phase 2 sample. Whereas Scenario 1 involves random phase 2 samples, stratiﬁed
sampling has been conducted to sample the phase 2 data sets in Scenario 2. When
comparing Scenario 1 with Scenario 3 it becomes apparent, that the bias in Scenario
1 is not only caused by the interaction between phenprocoumon exposure and BMI
because the bias of parameter estimates of BMI and smoking is similar in both sce-
narios. Additional bias can be seen in Scenario 3 for sex and the interaction between
phenprocoumon exposure and sex. Biased sampling of the phase 2 samples can be
excluded as reason for the bias because both scenarios are based on random phase 2
samples. The only plausible explanation for the bias is that the simulation of BMI
and smoking for the phase 1 data set is based on the empirical distribution of these
variables in the phase 2 sample of the empirical study which is a stratiﬁed sample.
If the stratiﬁed sampling is accounted for by imputing the missing values separately
in the four strata deﬁned by phenprocoumon exposure and disease status, as has
been done in Scenario 4, the parameter estimation is unbiased thereby conﬁrming
the explanation. These results are based on phase 2 samples of size 500 meaning
that 98% of the information on BMI and smoking has been imputed. Slightly less
bias is observed for phase 2 samples of 1,000 and 2,000 subjects for which 96% and
92% of the data has been imputed.
The average parameter estimates and standard errors are summarised in Table
5.4 for IM4 based on phase 2 samples of 500 and 2,000 subjects. For comparison,
the table also shows the true parameter vector and results of the phase 1 analysis as
well as for IM2 based on phase 2 samples of size 2,000. As has been seen before, the
parameter estimates obtained with IM4 are unbiased. Furthermore, for samples of
size 2,000 the standard error for coeﬃcients of phase 1 covariates is nearly as small
as the respective error in the phase 1 analysis. Standard errors for coeﬃcients of the
phase 2 variables are of the same magnitude than those obtained from two-phase
analyses (see Table E.3 in Appendix E). Compared to standard errors obtained from
IM2, the loss in eﬃciency for IM4 is very small when using phase 2 samples of 2,000
subjects.
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5.4 Discussion
The results of multiple imputation in the empirical study as well as the simulation
study have shown that coeﬃcients of phase 1 covariates can be estimated more pre-
cisely compared to two-phase methods. Regarding phase 2 variables and related
interactions, eﬃciency is comparable for multiple imputation and two-phase meth-
ods. The problem of using multiple imputation for the analysis of two-phase studies
is the potential for bias. Especially if the phase 2 data set is not a random sample
and is relatively small, e.g. more than 90% of the information has to be imputed,
parameter estimates may be biased. With the implemented imputation models, the
only way to avoid biased estimates is the imputation in strata deﬁned by variables
used for sampling of the empirical phase 2 data set. If it is assumed that the stratiﬁed
imputation in IM4 also leads to unbiased estimates in the empirical study, diﬀer-
ences in the parameter estimates obtained with other imputation models as well as
from the phase 1 and the two-phase analysis can be interpreted as bias. However,
due to the large standard errors in the empirical study, the observed diﬀerences are
not relevant.
Compared to the study conducted by Marti and Chavance, 2011, the simulation
study described here reveals substantially higher bias for some imputation models.
Marti and Chavance observed only about 2% bias in a simulated case-cohort study
when using a misspeciﬁed imputation model. In the simulation using IM2 49% bias
occurs for the parameter estimate of BMI. Furthermore, with a standard error of
0.1 the biased estimate (β¯ = 0.23) is signiﬁcantly diﬀerent from the true parameter
value (β = 0.45). The simulated case-cohort study is only comparable with respect
to the size of the phase 1 (N=25,000) and the phase 2 (n=1,000) data sets. Oth-
erwise it is based on completely simulated data consisting of two Gaussian and one
binary variable, whereas this simulation study is based on the covariate distribution
observed in the empirical study including 15 variables. Another important diﬀerence
might be that the subcohort in the simulated case-cohort study is a random sample
of controls and not a stratiﬁed sample.
In conclusion, multiple imputation in two-phase studies with a rich phase 1 data
set leads on the one hand to eﬃcient parameter estimates of phase 1 as well as
phase 2 variables by utilising the complete phase 1 data set. On the other hand
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the risk of bias is large, particularly if the phase 2 data set is not a random sample.
For the described data constellation, the study design has been accounted for in
the imputation model by imputing the data separately in strata. This approach
will only be feasible if each stratum includes a suﬃcient number of subjects. The
analyses described in this chapter should only be viewed as a ﬁrst impression of ap-
plying multiple imputation to two-phase studies, because the plurality of techniques
available for multiple imputation has not been entirely investigated.
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Chapter 6
Conclusion
Aim of this thesis was to explore two-phase designs for case-control studies based
on administrative databases that make use of all available phase 1 data to estimate
adjusted exposure eﬀects eﬃciently. Phase 1 information is utilised in the two-phase
analysis by stratiﬁcation which leads to a reduction of standard errors compared to
an analysis including only phase 2 data. This approach also allows for an unbiased
estimation of regression coeﬃcients if all variables inﬂuencing the composition of the
phase 2 data set are included in the stratiﬁcation. A speciﬁc feature of two-phase
database studies is the availability of a rich phase 1 data set providing information
on most variables of interest for the whole study population. Hence, information on
many phase 1 variables can potentially be included in the analysis. This also estab-
lishes the possibility to identify variables inﬂuencing the selection into the phase 2
subsample by modelling the probability of selection in a non-response analysis (Behr
et al., 2012; Appendix D; Behr and Schill, 2013). As an example of a two-phase
database study, a study investigating the risk of bleeding associated with phenpro-
coumon exposure was conducted in which phase 1 data was extracted from claims
data of one statutory health insurance and additional information on body mass
index and smoking in phase 2 was ascertained in a health survey. This empirical
study was exploited as a vehicle to (1) illustrate the dilemma occurring with strati-
ﬁcation on multiple variables, (2) propose a new stratiﬁcation strategy resolving the
dilemma and (3) develop a design criterion for the selection of the most eﬃcient
stratiﬁcations. The dilemma was identiﬁed for cross-classiﬁcation of phase 1 covari-
ates which is the stratiﬁcation strategy used in traditional two-phase ﬁeld studies (cf.
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Section 4.1): On the one hand, inclusion of each additional covariate in the strati-
ﬁcation increases the number of strata and therefore the risk of empty cells. On the
other hand, ignoring information on phase 1 covariates results in unnecessarily large
standard errors of the respective parameter estimates. Deﬁning the stratiﬁcation by
percentiles of a disease score (DSC), which is a summary measure of several phase
1 covariates, solves the problem (cf. Section 4.2). With this stratiﬁcation strategy,
the number of strata does not depend on the number of phase 1 variables but on
the number of cut-points chosen to deﬁne the stratiﬁcation. In the empirical study
as well as in simulations based on this study, this stratiﬁcation strategy led to a
reduction of the standard errors of parameter estimates for most phase 1 covariates.
A limitation of the stratiﬁcation based on disease scores is that it does not fully
account for the bias introduced by stratiﬁed sampling of the phase 2 sample. This
limitation can be compensated by deﬁning the stratiﬁcation by cross-classiﬁcation
of variables used for sampling and subclasses of the disease score (Behr and Schill,
2013). However, if several variables have been used for sampling, the choice of sub-
classes of the disease score is restricted by the requirement of non-empty strata. The
choice of the number and placement of cut-points is essential for the eﬃciency of the
stratiﬁcation. It should consider the overlap of the conditional score distributions
in cases (DSC|D = 1) and controls (DSC|D = 0) to avoid empty cells. In this the-
sis, stratiﬁcations based on one to ﬁve cut-points showed a good performance with
respect to the design criterion proposed in Section 4.3 and in the empirical study as
well as the simulation study. The optimal choice of number and placement of the
cut-points has not been investigated yet in a systematic way. The design criterion
might be used in future research to determine rules for good stratiﬁcations based on
disease scores.
The motivation behind the development of the design criterion was the lack of
guidance for choosing an eﬃcient stratiﬁcation from the variety of possible stratiﬁca-
tions. The criterion combines qualitative and quantitative aspects. The qualitative
part involves the ranking of covariates by their importance based on prior knowledge
and the formation of a set of candidate stratiﬁcations. The quantitative part was
derived from the variance of the weighted likelihood estimator (WLE) which can
be expressed as the sum of the phase 1 variance and a penalty term. The penalty
term is approximated for each stratiﬁcation and each variable on the basis of phase
1 data. The resulting penalty terms are then compared graphically. The design
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criterion was tested in the empirical study and successfully validated for the spe-
ciﬁc data constellation in a simulation study. The qualitative aspect of the design
criterion can be interpreted as both a strength and a weakness at the same time.
Its strength lies in the inclusion of prior and expert knowledge and its weakness in
the subjectivity. A clear limitation of the criterion is that it is unable to determine
eﬃcient stratiﬁcations for the parameter estimation of phase 2 variables. If known
proxies of the phase 2 variables are available in the phase 1 data, inclusion of these
variables in the stratiﬁcation may compensate this limitation. Schill and Wild, 2006
were confronted with a similar problem, when they tried to ﬁnd optimal sampling
fractions for a given stratiﬁcation based on phase 1 data to eﬃciently estimate a
parameter vector. They suggested to deﬁne scenarios in which the stratumwise co-
variate distributions among controls are speciﬁed by the conditional probabilities
Pr(X|S , D = 0) and the parameter vector of the logistic disease model is assigned.
In contrast to the situation considered by Schill and Wild, in the present situation
separate scenarios would have to be speciﬁed for each stratiﬁcation out of the set of
candidate stratiﬁcations which would increase the complexity of the comparison.
The simulation study conducted to evaluate the performance of the new strati-
ﬁcation strategy and the design criterion also provided guidance for the planning of
future two-phase studies. At the planning stage of a two-phase study, when only
phase 1 data is available, it has to be decided which variables will be used for sam-
pling the phase 2 data, i.e. which variables compose the a priori stratiﬁcation. When
employing an a priori stratiﬁcation for sampling and a diﬀerent post stratiﬁcation
for the analysis, the post stratiﬁcation always has to be ﬁner than the a priori strati-
ﬁcation. To improve eﬃciency it is not worthwhile to include covariates like sex in
the a priori stratiﬁcation which solely have frequently occurring categories. Large
gains in eﬃciency can be achieved when covariates related to rare exposures such as
phenprocoumon exposure are included in the a priori stratiﬁcation. Furthermore,
the speciﬁc role of age became obvious in the study. Although all age categories are
frequent and therefore do not need to be considered in the a priori stratiﬁcation to
increase eﬃciency of the estimation of the age eﬀect, inclusion of age in the a pri-
ori stratiﬁcation is recommendable because this leads to smaller standard errors of
parameter estimates for rare diseases and exposures which are related to age. Even
more eﬃcient for the estimation of these eﬀects is the inclusion of disease scores in
the a priori stratiﬁcation.
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For the empirical study, a stratiﬁcation deﬁned by cross-classiﬁcation of phen-
procoumon exposure, age, sex and three subclasses of a disease score was identiﬁed
as the most eﬃcient stratiﬁcation to estimate the eﬀects of most phase 1 covariates.
The results of the two-phase analysis using this stratiﬁcation were compared to the
results of multiple imputation analyses (cf. Section 5). Multiple imputation, which
is a survey methodological approach for the analysis of incomplete data sets, has
been tested in this thesis for its applicability to two-phase data sets. In comparison
to the two-phase analysis in the empirical study, multiple imputation was more ef-
ﬁcient for the parameter estimation of most phase 1 covariates and at least equally
eﬃcient for the parameter estimation of the other variables. In the simulation study
it became apparent that multiple imputation leads to biased parameter estimates if
the imputation model does not suﬃciently account for the sampling design of the
phase 2 data set. To be more precise, the inclusion of stratum indicators in the
imputation model was not suﬃcient to correct for the bias introduced by strati-
ﬁed sampling. Applying stratiﬁed imputation, i.e. separate imputation in the four
strata used for sampling, revealed unbiased parameter estimates. In conclusion, the
ﬁrst application of multiple imputation in a two-phase database study was on the
one hand promising with respect to small standard errors of parameter estimates
for phase 1 covariates. On the other hand, using an incorrect imputation model
led to biased estimates of coeﬃcients for phase 2 variables as well as for variables
associated with the phase 2 variables. In that regard, two-phase methods were more
robust against bias. It has to be noted that the adequacy of multiple imputation
for two-phase studies comprising a rich phase 1 data set has only been investigated
for this speciﬁc study situation and might not be transferable to studies with for
instance a smaller phase 2 data set or a more complex sampling strategy.
This aspect has also to be taken into account in the assessment of the results
achieved in this thesis since they all rely on the empirical study and simulations
based on it. The data constellation in the empirical study is characterised by the
following facts:
1. The study investigates the association between a rare disease and a rare ex-
posure.
2. The phase 2 data set comprises the most informative subjects with respect to
disease and exposure.
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3. Most variables which are relevant for the disease model are available in phase
1.
4. Lack of adjustment for phase 2 variables does not confound the estimated
eﬀect of any phase 1 covariate.
5. Except for age, all variables are included as binary covariates in the logistic
model.
While the ﬁrst and the ﬁfth characteristic are typical for pharmacoepidemiological
database studies, the second, third and fourth characteristic depend on the study de-
sign and the speciﬁc study situation. Both the performance of the new stratiﬁcation
strategy and the design criterion may be diﬀerent in other data constellations. The
performance of stratiﬁcations based on a disease score is likely to depend on the spe-
ciﬁc disease model and on the overlap of the conditional distributions of the score
for cases and controls. Furthermore, it will be related to the number of variables
inﬂuencing the composition of the phase 2 sample. The performance of the design
criterion is most probably connected to the accuracy of the approximation of the
penalty term. The approximation error depends for instance on the diﬀerence be-
tween the disease probability estimated by using phase 1 data only and the disease
probability estimated by using the complete covariate information in phase 2. It
has been assumed that these probabilities do not diﬀer strongly because of the rich
phase 1 data set. In studies for which an important risk factor for the disease is only
available in phase 2 this assumption will most likely be violated. Therefore, both
novel approaches should be evaluated in further data constellations.
It is envisaged to use the design criterion for the planning of a two-phase study
investigating the risk of diabetic complications in patients treated with diﬀerent an-
tidiabetic drugs. In this study, phase 1 data will comprise claims data of one German
statutory health insurance and phase 2 data will be derived from the documentation
of the Disease Management Programme (DMP) for type 2 diabetes which provides
information on body mass index, blood pressure as well as duration, intensity and
control of diabetes. A challenge will be to model the selectivity of participation in
the DMP, which may be inﬂuenced by several variables. Also the new stratiﬁcation
strategy will be tested in this study. This study will diﬀer from the present empirical
study in that the phase 2 data set will not include the most informative subjects
for answering the study question because subjects are not selected into the phase 2
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sample by the investigator but are self-selected. Furthermore, phase 2 data in this
study may comprise important confounders.
Methods for the combined analysis of several data sources will certainly be rel-
evant in context of the National Cohort which is a long-term German population
study with the objective to investigate the causes, risk factors and prevention of
widespread diseases (http:\www.nationale-kohorte.de). To achieve this objec-
tive it is planned to link secondary data, e.g. health insurance data, to the data
collected in the study for all participants who agreed to the linkage of the data.
Although this data constellation will diﬀer from the two-phase database studies
considered in this thesis, there are important parallels: (1) the data from the Na-
tional Cohort can be viewed as phase 1 data comprising a multitude of variables; (2)
the linked secondary data will only provide information for a subsample of partici-
pants because secondary data will not be available for each participant and not all
participants will agree to the linkage. Therefore, the secondary data can be inter-
preted as the phase 2 data set comprising additional information, whereas the most
important information is included in the phase 1 data. If the proportion of missing
information is high, application of the two-phase methods considered in this thesis
may be reasonable. Otherwise, it is a typical missing-data situation where multiple
imputation is likely to be the better approach. Moreover, these two-phase methods
are restricted to logistic regression whereas multiple imputation can be applied more
general. Further research is needed to improve the methods for the analysis of such
data and to better understand their strengths and limitations. Besides multiple
imputation and the two-phase methods described in this thesis, weighted analy-
ses using calibrated or estimated weights may be a promising approach. Recently,
pseudo likelihood methods have been extended to include estimated weights (Scott
and Wild, 2011). A ﬁrst application of this approach showed good results in com-
parison to the ordinary two-phase analysis (Breslow et al., 2013). A comparison of
these approaches for diverse data constellations is still missing.
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Appendix A
Mathematical details for Chapter 3
A.1 Proof of (3.6)
To prove (3.6) the following constrained maximisation problem has to be solved:
Maximise l(θ, δ) subject to
M∑
m=1
δm − 1 = 0,
where l(θ, δ) is deﬁned according to (3.5). If δˆ solves the maximisation problem,
then there exists a Lagrange multiplier λ ∈ R such that[
∂
∂δ
l(θ, δ) + λ
∂
∂δ
(
M∑
m=1
δm − 1
)]
δ=δˆ
= 0.
For ﬁxed m it follows that[
∂l(θ, δ)
∂δm
+ λ
]
δ=δˆ
= 0 (A.1)
⇔
[
n+m
1
δm
−
1∑
i=0
Ni
f(D = i|x˜m;θ)∑M
l=1 f(D = i|x˜l;θ)δl
+ λ
]
δ=δˆ
= 0.
Multiplication with δm and summation over m leads to:[
M∑
m=1
n+m −
1∑
i=0
Ni
∑M
m=1 f(D = i|x˜m;θ)δm∑M
l=1 f(D = i|x˜l;θ)δl
+ λ
M∑
m=1
δm
]
δ=δˆ
= 0
⇔
[
N −N + λ
M∑
m=1
δm
]
δ=δˆ
= 0.
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Since
∑M
m=1 δm = 1 it follows that λ = 0 and from (A.1) and (3.4) it follows
immediately that δˆ fulﬁls the system of equations
δm = τm(θ) =
n+m∑1
i=0
Nif(D=i|x˜m;θ)
πi
, m = 1, . . . ,M.

A.2 Proof of (3.7) and (3.8)
The proﬁle likelihood as given in (3.7) can be derived from (3.5) and (3.6) as follows:
lP (θ) = l(θ, τ(θ))
=
1∑
i=0
M∑
m=1
nim log f(D = i|x˜m;θ) +
M∑
m=1
n+m log
(
n+m∑
h
Nhf(D=h|x˜m;θ)
πh
)
−N1 log π1 −N0 log π0
=
1∑
i=0
M∑
m=1
nim log f(D = i|x˜m;θ)−
M∑
m=1
n+m log
∑
h
Nhf(D = h|x˜m;θ)
πh
+
M∑
m=1
n+m log(n+m)
−N1 log π1 −N0 log π0
=
1∑
i=0
M∑
m=1
nim log
(
f(D = i|x˜m;θ)∑
h f(D = h|x˜m;θ)Nhπh
)
+
M∑
m=1
n+m log(n+m)−N1 log π1 −N0 log π0
=
1∑
i=0
M∑
m=1
nim log
(
f(D = i|x˜m;θ) NiπiN∑
h f(D = h|x˜m;θ) NhπhN
)
−
1∑
i=0
Ni log
(
Ni
πi
)
+
M∑
m=1
n+m log(n+m)−N1 log π1 −N0 log π0
=
1∑
i=0
M∑
m=1
nim log
(
f(D = i|x˜m;θ)μi∑
h f(D = h|x˜m;θ)μh
)
+
M∑
m=1
n+m log(n+m)−N1 logN1 −N0 logN0.
Since the last three terms are independent of θ, (3.7) holds.

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Using (3.7) it follows immediately that
log
(
f ∗(D = 1|x˜m;θ)
f ∗(D = 0|x˜m;θ)
)
= log(f ∗(D = 1|x˜m;θ))− log(f ∗(D = 0|x˜m;θ))
= log(f(D = 1|x˜m;θ)N1
π1
)− log(f(D = 0|x˜m;θ)N0
π0
)
= log
(
f(D = 1|x˜m;θ)
f(D = 0|x˜m;θ)
)
+ log
(
N1
π1
N0
π0
)
and therefore (3.8).

A.3 Proof of ∂l
∗(Φ)
∂κ = 0
Using (3.2) and (3.8) the pseudo log-likelihood l∗ is given in terms of (θ, κ) by
l∗(θ, κ) =
N∑
k=1
log f ∗(dk|xk;θ, κ)
=
N∑
k=1
log
((
exp(θTxk + log(κ))
1 + exp(θTxk + log(κ))
)dk ( 1
1 + exp(θTxk + log(κ))
)1−dk)
=
N∑
k=1
dk log
(
exp(θTxk + log(κ))
1 + exp(θTxk + log(κ))
)
+
N∑
k=1
(1− dk) log
(
1
1 + exp(θTxk + log(κ))
)
=
N∑
k=1
dk(θ
Txk + log(κ))−
N∑
k=1
dk log(1 + exp(θ
Txk + log(κ))
−
N∑
k=1
(1− dk) log(1 + exp(θTxk + log(κ)))
=
N∑
k=1
dk(θ
Txk + log(κ))−
N∑
k=1
log(1 + exp(θTxk + log(κ))).
Then it follows on the one hand for κ that
∂l∗(θ, κ)
∂κ
=
N∑
k=1
dk
κ
−
N∑
k=1
exp(θTxk + log(κ))
1
κ
1 + exp(θTxk + log(κ))
=
1
κ
(
N1 −
M∑
m=1
n+mf
∗(D = 1|x˜m;θ)
)
.
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On the other hand it can be deduced from (3.6) and (3.7) that
μ1 =
N1
π1
=
N1∑M
m=1 f(D = 1|x˜m;θ)δm
=
N1∑M
m=1 f(D = 1|x˜m;θ) n+m∑
i μif(D=i|x˜m;θ)
⇔
M∑
m=1
μ1f(D = 1|x˜m;θ)n+m∑
i μif(D = i|x˜m;θ)
= N1
⇔
M∑
m=1
f ∗(D = 1|x˜m;θ)n+m = N1.
Combining both arguments completes the proof.

A.4 Proof of λ = N and of (3.12)
If δˆ solves the maximisation problem (3.11) then there exists a Lagrange multiplier
λ such that [
∂l(θ, δ)
∂δ
+ λ
]
δ=δˆ
= 0.
It follows that λ = −N because[
∂l(θ, δ)
∂δm
+ λ
]
δ=δˆ
= 0
⇔
[
1∑
i=0
(Ni −Ni) f(D = i|x˜m;θ)∑
l f(D = i|x˜l;θ)δl
+
1∑
i=0
J∑
j=1
(Nij − nij)
Q∗ij(x˜m)∑
lQ
∗
ij(x˜l)δl
+
n++m
δm
+ λ
]
δ=δˆ
= 0
⇔
[
1∑
i=0
(Ni −Ni) f(D = i|x˜m;θ)δm∑
l f(D = i|x˜l;θ)δl
+
1∑
i=0
J∑
j=1
(Nij − nij)
Q∗ij(x˜m)δm∑
lQ
∗
ij(x˜l)δl
+ n++m + λδm
]
δ=δˆ
= 0 (A.2)
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and with summation over m:[
1∑
i=0
(Ni −Ni)
∑
m f(D = i|x˜m;θ)δm∑
l f(D = i|x˜l;θ)δl
+
1∑
i=0
J∑
j=1
(Nij − nij)
∑
mQ
∗
ij(x˜m)δm∑
lQ
∗
ij(x˜l)δl
+
M∑
m=1
n++m + λ
M∑
m=1
δm
]
δ=δˆ
= 0
⇔
1∑
i=0
(Ni −Ni) +
1∑
i=0
J∑
j=1
(Nij − nij) + n+ λ = 0
⇔−N = λ.
(A.2) yields that δ fulﬁls the system of equations
δm = τm(θ) =
n++m
N −∑i Ni−Niπi f(D = i|x˜m;θ)−∑i∑j(Nij − nij)Q∗ij(x˜m)Qij .

A.5 Parametrisation of Qij
With
Qij =
exp(ρij)∑
i
∑
j exp(ρij)
it follows immediately that 0 < Qij < 1 and
∑
i
∑
j Qij = 1. This is also true if ρ1J
is set to 0. Then it follows from
log(Qij) = log
(
exp(ρij)∑
i
∑
j exp(ρij)
)
= ρij − log
(∑
i
∑
j
exp(ρij)
)
and
log(Q1J) = log
(
exp(ρ1J)∑
i
∑
j exp(ρij)
)
= ρ1J − log
(∑
i
∑
j
exp(ρij)
)
that
log(Qij)− log(Q1J) = ρij − ρ1J = ρij
and thus
log
(
Qij
Q1J
)
= ρij, for ij = 1J.
Hence, both parameterisations are equivalent.

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A.6 Proof of (3.18)
Omitting the ﬁrst term from (3.11) leads to the proﬁle log-likelihood for the pseudo
model:
l˜P (θ) =
1∑
i=0
J∑
j=1
(Nij − nij) log
(
M∑
m=1
Q∗ij(x˜m)δm
)
+
1∑
i=0
J∑
j=1
M∑
m=1
nijm log f(D = i|x˜m;θ) +
M∑
m=1
n++m log δm.
With (3.14) and substituting Q∗ij by f(D = i|x˜;θ) it follows
l˜P (θ) =
1∑
i=0
J∑
j=1
(Nij − nij) log
(
M∑
m=1
Q∗ij(x˜m)
n++m
N
∑
i
∑
j μijQ
∗
ij(x˜m)
)
+
1∑
i=0
J∑
j=1
M∑
m=1
nijm log f(D = i|x˜m;θ) +
M∑
m=1
n++m log
(
n++m
N
∑
i
∑
j μijQ
∗
ij(x˜m)
)
=
1∑
i=0
J∑
j=1
(Nij − nij) log
⎛⎝ ∑
l:x˜l∈Sij
f(D = i|x˜l;θ) n++l
N
∑
i
∑
j μijf(D = i|x˜l;θ)
⎞⎠
+
1∑
i=0
J∑
j=1
M∑
m=1
nijm log f(D = i|x˜m;θ)
+
M∑
m=1
n++m log
(
n++m
N
∑
i
∑
j μijf(D = i|x˜m;θ)
)
.
The constant N can be omitted from the denominator of the ﬁrst and third term
because it can be written as a single summand in the proﬁle log-likelihood. Inserting
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(3.15) in the following equation yields
l˜P (θ) =
1∑
i=0
J∑
j=1
(Nij − nij) log
⎛⎝ ∑
l:x˜l∈Sij
n++lf
∗(D = i|x˜l;θ)
μij
⎞⎠
+
1∑
i=0
J∑
j=1
M∑
m=1
nijm log f(D = i|x˜m;θ)
+
M∑
m=1
n++m log(n++m)−
M∑
m=1
1∑
i=0
J∑
j=1
nijm log
(∑
i
∑
j
μijf(D = i|x˜m;θ)
)
=
1∑
i=0
J∑
j=1
(Nij − nij) log
⎛⎝ ∑
l:x˜l∈Sij
n++lf
∗(D = i|x˜l;θ)
⎞⎠− 1∑
i=0
J∑
j=1
(Nij − nij) log(μij)
+
1∑
i=0
J∑
j=1
M∑
m=1
nijm log
(
f(D = i|x˜m;θ)∑
i
∑
j μijf(D = i|x˜m;θ
)
+
M∑
m=1
n++m log(n++m).
This equation is simpliﬁed as follows by inserting γij according to (3.17) and by
ignoring the last term:
l˜P (θ) =
1∑
i=0
J∑
j=1
(Nij − nij) log(nij − γij)−
1∑
i=0
J∑
j=1
(Nij − nij) log
(
nij − γij
Nij − γij
)
+
1∑
i=0
J∑
j=1
M∑
m=1
nijm log (f
∗(D = i|x˜m;θ))−
1∑
i=0
J∑
j=1
M∑
m=1
nijm log(μij)
=
1∑
i=0
J∑
j=1
(Nij − nij) log(Nij − γij) +
1∑
i=0
J∑
j=1
M∑
m=1
nijm log (f
∗(D = i|x˜m;θ))
−
1∑
i=0
J∑
j=1
nij log(nij − γij) +
1∑
i=0
J∑
j=1
nij log(Nij − γij)
=
1∑
i=0
J∑
j=1
M∑
m=1
nijm log (f
∗(D = i|x˜m;θ))−
1∑
i=0
J∑
j=1
nij log(nij − γij)
+
1∑
i=0
J∑
j=1
Nij log(Nij − γij).

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Paper 1: Phenprocoumon and risk of
intracerebral haemorrhage
Contribution to the manuscript I herewith certify that I contributed to the
design of the study, performed all statistical analyses, interpreted the results, and
drafted the manuscript.
107
ORIGINAL REPORT
Risk of intracerebral hemorrhage associated with phenprocoumon
exposure: a nested case–control study in a large population-based
German databasey
Sigrid Behr1*, Frank Andersohn2 and Edeltraut Garbe1
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SUMMARY
Purpose Intracerebral hemorrhage (ICH) is the most serious complication of oral anticoagulation. This study investigated the risk of ICH
for phenprocoumon which is the most widely used oral anticoagulant in Germany.
Methods We conducted a nested case–control study in a cohort of 13.4 million insurants of 4 German statutory health insurances (SHIs)
who were continuously enrolled for 6 months prior to cohort entry. Cases were patients hospitalized for ICH. Ten controls were matched to
each case by SHI, birth year, and sex using incidence density sampling. Rate ratios (RR) of ICH for current phenprocoumon use as compared
to non-use were estimated from odds ratios calculated by conditional logistic regression analyses considering multiple risk factors.
Results Analysis of the full cohort revealed a strong increase in incidence of ICH with increasing age. In the nested case–control study
including 8138 cases of ICH and 81 373 matched controls, we observed an increased risk of ICH for current phenprocoumon exposure that
varied with age. The phenprocoumon-associated risk of ICH was lower in older age groups with RRs from 4.20 (95% conﬁdence interval (CI)
2.44–7.21) for phenprocoumon users less than 55 years of age to 2.43 (95%CI, 1.81–3.27) for those older than 85 years. Our study conﬁrmed
known risk factors of ICH.
Discussion Phenprocoumon exposure was associated with an increased risk of ICH. The interaction of risk for phenprocoumon with age
was unexpected and needs further study. Copyright # 2010 John Wiley & Sons, Ltd.
key words—intracerebral bleeding; oral anticoagulant; pharmacoepidemiological research database; nested case–control study
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INTRODUCTION
Oral anticoagulation plays an important role in the
primary and secondary prevention and treatment of
thromboembolic diseases. The most widely used oral
anticoagulants are coumarines such as warfarin or
phenprocoumon. Coumarines have a narrow thera-
peutic index and are quite frequently a cause of
bleeding. Intracerebral hemorrhage (ICH) is a very
severe complication of coumarine therapy which may
lead to irreparable impairment or death. The risk of
ICH associated with coumarine therapy has been
studied for warfarin1–3 and also for the combined group
of warfarin and phenprocoumon.4,5 However, there are
no published results for phenprocoumon, which is the
most widely used substance for oral anticoagulation in
Germany. Phenprocoumon accounts for more than
99% of coumarine use in Germany.6
Each coumarine has a single chiral center that gives
rise to two different enantiomeric forms of which the
S-form is more potent than the R-form.7 There are
substantial differences in pharmacokinetic properties
between phenprocoumon and warfarin or acenocou-
marol. Overall, cytochrom P450 (CYP) 2C9 appears to
be most important for the clearance of warfarin and
acenocoumarol, whereas it is less important for
phenprocoumon due to the involvement of CYP3A4
in its metabolism and signiﬁcant excretion of
unchanged drug in bile and urine.7 The elimination
half lives also differ substantially: acenocoumarol has
the shortest half life ranging between 1.8 and 6.6 hours
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for both enantiomeric forms, followed by warfarin
(24–58 hours) and phenprocoumon (110–130 hours).7
The longer half life of phenprocoumon could be
associated with a higher risk of bleeding, since it
leads to impaired control of drug treatment. Lesser
metabolism of phenprocoumon by CYP2C9 may on
the other hand result in a lower impact of genetic
polymorphisms of CYP2C9 which could reduce the
risk of bleeding in case of genetic polymorphisms of
CYP2C9.7
To study the risk of ICH associated with phenpro-
coumon, we conducted a nested case–control study in a
large insurance population in Germany.
METHODS
Data source
We used information from the German Pharmacoepi-
demiological Research Database (GePaRD) consisting
of claims data from four German statutory health
insurances (SHI). This database includes more than 14
million insurants covering all regions in Germany. The
study was conducted with data from the years 2004 to
2006. The database contains demographic information
for each insurant as well as information on hospital
admissions, ambulatory physician visits, and ambulat-
ory prescriptions. The hospital data comprises infor-
mation about the admission and discharge dates, the
reasons for admission and discharge, and diagnostic
and therapeutic procedures with their respective
dates. Claims of ambulatory physician visits include
ambulatory treatments, procedures, and diagnoses.
Since ambulatory physician visits are reimbursed on a
quarterly basis, ambulatory diagnoses can only be
allocated to a quarter of the year and not to an exact
day. All diagnoses, ambulatory as well as inpatient
diagnoses, are coded according to the German
modiﬁcation of the International Classiﬁcation of
Diseases (ICD-10 GM). Prescription data are available
for all ambulatory prescriptions which are reimbursed
by the SHIs. It includes the date of prescription, the date
when the prescription was redeemed at the pharmacy,
the amount of substance prescribed, and information on
the prescribing physician. Prescription data are linked
via the pharmaceutical reference number to a pharma-
ceutical reference database which contains information
on the anatomical-therapeutic-chemical (ATC) code, the
Deﬁned Daily Dose (DDD), packaging size, strength,
formulation, generic and trade name. Preliminary
analyses regarding age and sex distribution, the number
of hospital admissions and drug use have shown the
database to be representative for Germany.8,9
In Germany, the utilization of health insurance
data for scientiﬁc research is regulated by the Code of
Social Law (SGB X). This study was conducted with
permission from the Federal Ministry of Health.
Informed consent was not required by law, since the
study was based on pseudonymous data.
Study design
We conducted a case–control study nested in a cohort
of insurants who were required to be continuously
insured for 6 months before cohort entry. Cohort entry
was deﬁned as the ﬁrst day after 6 months of
continuous insurance. Cohort exit was the ﬁrst of the
following dates: end of the insurance period, hospi-
talization for ICH, death or end of study period (30
November 2006). The study period ended in November
2006 to avoid incomplete data for hospitalizations
spanning the turn of the year. Cases were deﬁned as
insurants who were hospitalized for ICH (main
discharge diagnosis with ICD-10 GM code I61 which
codes for intracerebral bleeding). The admission day is
referred to as the index day.
Ten controls were matched to each case with respect
to sex, year of birth, and SHI using incidence density
sampling. We assigned an index day to each control
that resulted in the same time of follow-up as for
the corresponding case. Cohort members who were
hospitalized at the index day of the case were excluded
from the set of potential controls because they were not
at risk of being admitted to hospital due to ICH at that
point in time. Cases were eligible to be selected as
controls until their hospitalization for ICH.
Exposure assessment
We considered current phenprocoumon exposure (ATC
code B01AA04) at the index day which was deﬁned as
a prescription overlapping the index day. Because we
had no information on the prescribed daily dose, we
estimated the average daily dose for each patient by
dividing the cumulative dose until the last phenpro-
coumon prescription before the index day by the
number of days corresponding to this time interval.
The average daily dose was then used to estimate the
duration of exposure for the last phenprocoumon
prescription preceding the index day. The cumulative
dose was obtained from the number of prescribed
tablets and their strength which is 3mg for most
phenprocoumon drugs on the German market. If there
was only one phenprocoumon prescription before the
index day, the DDD was used instead.
Among patients with current exposure, we distin-
guished between recent initiators of phenprocoumon
Copyright # 2010 John Wiley & Sons, Ltd. Pharmacoepidemiology and Drug Safety, 2010; 19: 722–730
DOI: 10.1002/pds
phenprocoumon and risk of ich 723
therapy and those with no recent initiation of therapy.
We deﬁned patients as recent initiators of phenpro-
coumon therapy if they had their ﬁrst prescription of
phenprocoumon recorded within the 90-day period
before the index day.
Risk factor and confounder assessment
Potential confounders were assessed in the 6-month
period before cohort entry. We considered the
following potential confounders in our analyses:
diabetes mellitus, systemic hypertension, ischemic
heart disease, ischemic cerebral infarction, cerebral
amyloid angiopathy, cerebral aneurysm, brain tumor,
epilepsy, liver diseases, renal failure, alcohol depen-
dence, epistaxis, previous hospitalization for ICH or
for other bleeding events. Concomitant medications
were assessed in the 90-day period preceding the
index day. We considered current use of the following
substances: platelet aggregation inhibitors, heparins,
non-steroidal anti-inﬂammatory drugs (NSAIDs) includ-
ing acetylsalicylic acid (ASA), selective serotonin
reuptake inhibitors (SSRIs), diuretics, corticosteroids,
and statins. The exact deﬁnition in terms of ICD-10
GM codes and ATC codes is provided in the Appendix.
Statistical analysis
We calculated incidence rates of ICH stratiﬁed by sex
for different age groups making use of the full cohort
data. Conﬁdence intervals for the incidence rates were
estimated by the substitution method assuming a
Poisson distribution for the number of bleedings.10
Based on the case–control data, crude odds ratios
(OR) were calculated by using the Mantel–Haenszel
estimator to account for the matching. We conducted
conditional logistic regression analyses to estimate
adjusted ORs and two-sided 95% conﬁdence intervals
(CI) for ICH and current use of phenprocoumon. Since
control selection was done by incidence density
sampling, ORs correspond to incidence rate ratios
(RR). The primary model for the multivariate analysis
was based on prior knowledge on risk factors and
included all variables. We kept two-way interaction
terms with phenprocoumon exposure in this model, if
the RR for phenprocoumon exposure changed by more
than 10% after adding the respective interaction term.
Following this approach, only phenprocoumon
interaction with age (centered at 68 years) remained
in the model. In addition, we used a backward selection
procedure to select relevant covariates. While
phenprocoumon exposure was forced to stay in
the model, covariates were removed from the
model step by step in case the Wald test was not
signiﬁcant (p> 0.05). We also performed a multivariate
analysis in several age strata: <55 years, 55–<65 years,
65–<75 years, 75–<85 years, >85 years.
In a further analysis, we estimated adjusted RRs for
ICH associated with current use of phenprocoumon
distinguishing between recent and non-recent initiators.
We conducted several sensitivity analyses regarding
our deﬁnition of current use at the index day. In these
sensitivity analyses, a person was deﬁned as exposed at
the index day, if phenprocoumonwas prescribed within
90 days, 180 days, or 270 days preceding the index day.
For all these analyses, the reference category was the
absence of current exposure to phenprocoumon.
All statistical analyses were done using SAS 8.2
(SAS Institute Inc., Cary, NC).
RESULTS
In total, 13.4 million insurants were included in the
cohortwith amean follow-up timeof 798days (standard
deviation (STD) 208 days). The average age in the
cohort was 39.9 (STD: 22.2) years and 45% of cohort
members were male. The incidence of ICH was higher
in males than in females and rose with increasing age
from 6.82 bleedings per 100 000 person years in males
younger than 55 to 236.29 bleedings per 100 000 person
years inmales older than 85 and from4.67 bleedings per
100 000 person years in females younger than 55 to
189.69 bleedings per 100 000 person years in females
older than 85 years (Figure 1).
Within this cohort we identiﬁed 8138 cases of ICH to
whom we matched 81 373 controls. Only three controls
could be matched to one case who was 102 years old at
cohort entry. In the case–control sample, the mean age
was 68.1 (STD: 14.3) years and proportions of males
(51%) and females (49%) were similar. Cases and
controls differed with respect to most risk factors
(Table 1). The greatest differences were observed for
history of ICH, cerebral amyloid angiopathy, cerebral
aneurysm, epilepsy, ischemic cerebral infarction, alco-
hol dependence, and heparin use. Table 2 displays crude
and adjusted RRs for phenprocoumon and other risk
factors for development of ICH. Among the other risk
factors, high risks were observed for cerebral aneurysm,
epilepsy, alcohol dependence, cerebral amyloid angio-
pathy and history of ICH, however, with broad
conﬁdence intervals for the latter two factors.
Current phenprocoumon use was associated with a
3.4 fold risk of ICH referring to a 68-year old person
(Table 2). A signiﬁcant interaction between phenpro-
coumon exposure and age was observed resulting in
lower phenprocoumon risk for ICH in persons older
than 68 years and in higher risk for those younger than
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68 years. The stratiﬁed analysis revealed adjusted RRs
of 4.20 (95%CI 2.44–7.21), 3.16 (95%CI 2.41–4.15),
3.51 (95%CI 3.00–4.10), 2.52 (95%CI 2.20–2.88), and
2.43 (95%CI 1.81–3.27) for phenprocoumon users in
the age groups <55 years, 55–<65 years, 65–<75
years, 75–<85 years, and >85 years, respectively.
The backward selection procedure eliminated brain
tumor and ischemic heart disease since both variables
were not signiﬁcant at the 5% level. However, the
adjusted RRs in the reduced model did not change for
phenprocoumon exposure or the other risk factors.
The distinction between recent and non-recent
initiators of therapy among current phenprocoumon
users revealed a higher RR for those patients who
started their therapy recently (Table 3).
Table 4 shows the results of the sensitivity analyses
concerning assessment of current phenprocoumon
exposure. Similar risks of ICH for phenprocoumon
were found for the different exposure measures. The
adjusted RRs varied from 3.26 for phenprocoumon
exposure identiﬁed by prescriptions within 90 days
before the index day to 3.68 for prescriptions issued
within 270 days before the index day. The correspond-
ing 95%CIs overlapped widely.
DISCUSSION
We found a more than three-fold risk of ICH in
phenprocoumon users as compared to non-users, which
was in the same range as the ORs reported for a
combined group of warfarin or phenprocoumon by
Johnsen et al. and Grønbaek et al.4,5 Johnsen et al.
conducted a case–control study in North Jutland
(Denmark) in a population of ca. 490 000 inhabitants
and observed an adjusted OR for ICH of 2.15 (95%CI
1.38–3.35) for users of oral anticoagulants compared to
non-users. Grønbaek et al. reported an adjusted OR for
ICH of 2.9 (95%CI 2.5–3.5) for patients treated with
oral anticoagulants from a case–control study includ-
ing about 1.4 million inhabitants of Denmark. Most
other epidemiological studies investigating the risk of
ICH for warfarin were not designed to compare use of
warfarin with non-use of warfarin. These studies
usually only included warfarin users and investigated
risk factors for ICH in this subgroup of patients.1,2,11,12
The role of age as an independent risk factor for ICH is
well known. Several previous studies have shown that
the risk of ICH increases with age.1,4,13 Sturgeon et al.
pooled two cohort studies (ARIC and CHS) and
Figure 1. Incidence rates of intracerebral hemorrhage by age group stratiﬁed by sex
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observed a doubling of risk for ICH with every 10 year
increase inage.14Ariesenetal. 15 conducteda systematic
review of cohort and case–control studies investigating
risk factors for ICH. For each risk factor, they
summarized the crude relative risk or odds ratio from
those studies in which the respective information was
available. For each10-year increase in age, they reported
a crude relative risk of 1.97 based on 5 cohort studies.
Since our case–control study was matched by age, we
could not estimate the effect of age as independent risk
factor. We, therefore, estimated the incidence of ICH in
theunderlyingcohort andobserveda signiﬁcant increase
in ICH incidence with rising age. These results were
comparable to the age-related incidence rates published
by Bamford et al., which were based on a population of
approximately 105 000 persons underlying the Oxford-
shire Community Stroke Project.13
Interestingly, in our study we also observed a
signiﬁcant interaction of phenprocoumon with age that
resulted in a lower phenprocoumon-associated risk of
ICH at older ages. This issue has not been addressed in
other studies investigating the risk of ICH associated
with oral anticoagulants. However, a similar age effect
can be seen for intracranial hemorrhage in a study by
Fang et al. which investigated warfarin-associated
hemorrhage in a cohort of more than 13 000 patients
with atrial ﬁbrillation (ATRIA study).16 Although the
phenprocoumon-associated risk of ICH is lower for
older patients we have shown in our full cohort analysis
that the incidence of ICH is much higher in older age
groups as it is expected based on the results of other
studies.17
Regarding the time of phenprocoumon initiation we
observed a higher risk of ICH associated with recent
initiation of phenprocoumon therapy. To our knowl-
edge the effect of the time of phenprocoumon initiation
has only been studied for major bleedings but not
speciﬁcally for ICH. However, several studies on major
bleedings also showed an increased risk for recent
initiation of therapy.17–20 Because we did not exclude
patients using phenprocoumon before cohort entry, the
risk we observed for no recent initiation of therapy is
likely to be underestimated as a consequence of
depletion of susceptible bias.21
Our study conﬁrmed several other well-known risk
factors for ICH. For alcohol dependence, an increased
Table 1. Characteristics of cases and matched controls
Cases N¼ 8138 n (%) Controls N¼ 81 373 n (%)
Age Mean (Std)
68.08 (14.33)
Male sex 4178 (51.34%) 41 773 (51.34%)
Comorbid conditions$
Diabetes mellitus 1717 (21.10%) 13 949 (17.14%)
Hypertension 4340 (53.33%) 37 747 (46.39%)
Ischemic heart disease 1806 (22.19%) 16 633 (20.44%)
Ischemic cerebral infarction 811 (9.97%) 3049 (3.75%)
Cerebral amyloid angiopathy 55 (0.68%) 2 (<0.01%)
Cerebral aneurysm 20 (0.25%) 37 (0.05%)
Brain tumor 115 (1.41%) 859 (1.06%)
Epilepsy 241 (2.96%) 726 (0.89%)
Liver diseases 938 (11.53%) 7755 (9.53%)
Renal failure 460 (5.65%) 3517 (4.32%)
Alcohol dependence 234 (2.88%) 804 (0.99%)
Epistaxis 103 (1.27%) 554 (0.68%)
Previous ICH 127 (1.56%) 20 (0.02%)
Other hemorrhage 207 (2.54%) 419 (0.51%)
Concomitant medicationx
Current use of . . .
Platelet aggregation inhibitors 701 (8.61%) 5049 (6.20%)
Heparin 223 (2.74%) 871 (1.07%)
NSAIDs 1192 (14.65%) 10 268 (12.62%)
ASA 80 (0.98%) 471 (0.58%)
SSRIs 198 (2.43%) 1084 (1.33%)
Diuretics 1832 (22.51%) 18 493 (22.73%)
Corticosteroids 310 (3.81%) 2611 (3.21%)
Statins 774 (9.51%) 7561 (9.29%)
NSAID: Non-steroidal anti-inﬂammatory drug; ASA: Acetylsalicylic acid; SSRI: Selective serotonin reuptake inhibitor; ICH: Intracerebral hemorrhage.
Birth year and sex are matching variables.
$Assessed in the 6 months baseline period preceding cohort entry.
xAmbulatory prescriptions assessed in the 90 days prior to the index day.
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risk of similar magnitudewas reported by Ariesen et al.
15 who calculated a crude OR of 3.36 for high alcohol
intake combining the results of eight case–control
studies. The increased risks we observed for previous
ischemic stroke, epistaxis, or epilepsy are in line with
results from a Finish case–control study conducted by
Saloheimo et al.,22 although the observed risks were
somewhat higher in their study.
Cerebral amyloid angiopathy has been discussed
as an important risk factor for ICH by Pezzini et al.
and Schutz et al. 23,24 and was speciﬁcally studied for
warfarin-associated ICH by Rosand et al. 25 who
conducted a genetic and pathologic study in 107
patients taking warfarin. In this study, cerebral amyloid
angiopathy was diagnosed in 7 out of 11 patients with
available tissue samples. Since cerebral amyloid
angiopathy is a rare disease most other studies could
not investigate the risk of ICH for this risk factor.
Strengths and limitations
To our knowledge this is the largest study analyzing the
risk of ICH for phenprocoumon exposure and other risk
factors. Previous studies have not speciﬁcally analyzed
Table 2. Crude and adjusted incidence rate ratios and 95% conﬁdence intervals for intracerebral bleeding
Multivariate model Crude incidence rate ratio Adjusted incidence rate ratio 95% conﬁdence interval
Phenprocoumon exposurey 3.00 3.42z 3.08–3.79
Comorbid conditions
Diabetes mellitus 1.31 1.16 1.09–1.23
Hypertension 1.36 1.28 1.21–1.35
Ischemic heart disease 1.12 0.95 0.89–1.01
Ischemic cerebral infarction 2.88 2.18 1.99–2.38
Cerebral amyloid angiopathy 275 279 67.4–1156
Cerebral aneurysm 5.41 3.65 2.03–6.55
Brain tumor 1.35 1.11 0.90–1.37
Epilepsy 3.38 2.43 2.07–2.85
Liver diseases 1.24 1.09 1.01–1.17
Renal failure 1.33 1.12 1.00–1.24
Alcohol dependence 3.00 2.57 2.20–3.01
Epistaxis 1.87 1.44 1.15–1.80
Previous ICH 66.8 50.8 30.7–84.0
Other hemorrhage 2.04 1.57 1.22–2.02
Current use of . . .
Platelet aggregation inhibitors 1.43 1.33 1.21–1.45
Heparin 2.60 1.77 1.51–2.08
NSAIDs 1.19 1.16 1.08–1.24
ASAx 1.71 1.53 1.20–1.97
SSRIs 1.85 1.53 1.30–1.80
Diuretics 0.99 0.77 0.72–0.82
Corticosteroids 1.20 1.16 1.02–1.31
Statins 1.03 0.82 0.75–0.89
NSAID: Non-steroidal anti-inﬂammatory drug; ASA: Acetylsalicylic acid; SSRI: Selective serotonin reuptake inhibitor; ICH: Intracerebral hemorrhage.
Adjusted for age, interaction between phenprocoumon exposure and age, sex and all other covariates included in the table.
yPhenprocoumon exposure is estimated by using the average daily dose and the number of prescribed tablets.
zAdjusted incidence rate ratio for phenprocoumon exposure refers to a 68 years old patient. The two-way interaction incidence rate ratio is 0.97 (95% conﬁdence
interval 0.97–0.98).
xThe effect of ASA is adjusted for all other covariates included in the table except for NSAIDs.
Table 3. Time of initiation of phenprocoumon therapy and risk of ICH
Initiation of phenprocoumon
exposure (before index day)
Cases N¼ 8138 n (%) Controls N¼ 81 373 n (%) Adjusted
incidence
rate ratio
95% conﬁdence
interval
No current exposurey 7323 (89.99%) 78 392 (96.34%) 1.00 —
Recent initiation (90 days) 116 (1.43%) 329 (0.40%) 4.28 3.27–5.59
No recent initiation (>90 days) 699 (8.59%) 2652 (3.26%) 3.30 2.95–3.69
Adjusted incidence rate ratios and corresponding conﬁdence intervals are adjusted for age, sex and all covariates included in Table 2. The adjusted incidence
rate ratios for phenprocoumon exposure refer to a 68 years old patient. The two-way interaction incidence rate ratios for recent initiation and non-recent
initiation are 0.97 (95%CI 0.94–0.99) and 0.98 (95%CI 0.97–0.99), respectively.
yReference category.
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the risk for phenprocoumon, but could only investigate
the risk for the combined group of phenprocoumon or
warfarin due to limited numbers of patients.4,5,20 Due
to the size of our study we could also investigate the
risk of ICH for rare diseases such as cerebral amyloid
angiopathy or cerebral aneurysm. Selection bias in the
choice of controls is unlikely because this study was
designed as a nested case–control study in a deﬁned
cohort providing both cases and controls. All
information was recorded prospectively so that recall
bias was avoided.
Cases were deﬁned by a hospitalization for
intracerebral bleeding based on the ICD-coded
discharge diagnosis of intracerebral bleeding. Due to
the great number of cases and restrictions by German
data protection laws, case validation based on medical
charts was not feasible. However, imaging procedures
as e.g. computed tomography (CT) or magnetic
resonance imaging (MRI) of the brain were identiﬁed
in close temporal relation in 88.1% of cases with
phenprocoumon use and 88.4% of cases without
phenprocoumon use. CTs do not necessarily need
to be coded when the patient is in a stroke unit. We
cannot rule out detection bias, i.e. that patients with
phenprocoumon use undergo imaging procedures more
frequently, even if they have only light symptoms and
are therefore diagnosed with ICH more frequently.
However, since ICH usually has a very severe course,
we think that the potential for detection bias is low.
We did not have information on the prescribed daily
dose in our database. We calculated the average daily
dose (ADD) of phenprocoumon instead and used it for
estimating the duration of phenprocoumon use in our
study. Sensitivity analyses using different methods of
exposure assessment showed that our main study
results were robust.
Our study included information on a great number of
risk factors such as diabetes mellitus, hypertension,
ischemic heart disease, brain tumor, epilepsy, liver
diseases, renal failure, alcohol dependence, or NSAID
use. However, we did not have information on other risk
factors such as smoking, intensity of anticoagulation, or
over-the-counter (OTC) use of ASA. Whereas smoking
can be considered as a weak risk factor,14,15 intensity of
anticoagulation was an important risk factor in several
studies.1,2,26 Increases in the bleeding risk were reported
for International Normalized Ratio (INR) values of more
than 3.0 with a dramatic increase in bleeding risk for INR
values of greater than 4.0.2,27 However, since the target
INR is between 2.0 and 3.0 for all indications except for
mechanical heart valve replacement where the target INR
is between 2.0 and 3.5, the risk estimated for
phenprocoumon exposure in our study may not suffer
from major bias.28 In Germany, ASA is available as
prescription drug in low doses for the secondary
prevention of cardiovascular disease, whereas it is used
in higher doses as OTC drug. We could, therefore, only
consider the risk for ASA in low dose and it is possible
that we did not identify all patients with low dose ASA,
since some of themmay have bought low dose ASAOTC
instead of getting a prescription from their physician.
Concomitant heparin use with phenprocoumon may
be related to the initiation phase of phenprocoumon
when overlapping heparin is required to bridge the time
until phenprocoumon develops its full anticoagulant
effect. Heparin use could only be identiﬁed from
outpatient prescriptions because our database does not
include information on inpatient medication. Since
phenprocoumon with overlapping heparin therapy is
often initiated in the hospital and heparin then is a
short-term therapy we most likely underestimated
concomitant heparin use.
In summary, we identiﬁed in our study a risk of ICH
associated with phenprocoumon that was similar to
risks reported for the combined group of warfarin and
phenprocoumon in Denmark where warfarin use is
much more prevalent than phenprocoumon use.4,5,20,29
Our results indicate that the risk of ICH associated with
phenprocoumon or warfarin may be in a similar range
despite their different pharmacokinetic and pharma-
cogenetic properties. Further studies are needed which
provide risk estimates for the sole use of warfarin
Table 4. Sensitivity analyses for current phenprocoumon exposure using different deﬁnitions for current phenprocoumon exposure
Phenprocoumon exposure Main exposure
assessment
Prescription within
90 days
Prescription within
180 days
Prescription within
270 days
Exposed cases 815 (10.01%) 599 (7.36%) 944 (11.60%) 1074 (13.20%)
Exposed controls 2981 (3.66%) 2143 (2.63%) 3366 (4.14%) 3872 (4.76%)
Crude incidence rate ratio 3.00 2.96 3.11 3.12
Adjusted incidence rate ratioy 3.42 3.26 3.57 3.68
95% conﬁdence interval (3.08–3.79) (2.90–3.66) (3.24–3.94) (3.36–4.04)
With last phenprocoumon prescription overlapping the index date.
yAdjusted incidence rate ratios and corresponding conﬁdence intervals are adjusted for age, sex and all covariates included in Table 2. The adjusted incidence
rate ratios for phenprocoumon exposure refer to a 68 years old patient.
Copyright # 2010 John Wiley & Sons, Ltd. Pharmacoepidemiology and Drug Safety, 2010; 19: 722–730
DOI: 10.1002/pds
728 s. behr ET AL.
against non-use for further comparison or which permit
to compare both substances head-to-head.
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KEY POINTS
 Intracerebral hemorrhage (ICH) is a severe
complication of oral anticoagulation.
 Phenprocoumon, the most widely used oral
anticoagulant in Germany, is associated with an
increased risk of ICH.
 The risk of ICH for phenprocoumon use is higher
(4-fold) for younger patients (<55 years) as
compared to older patients (2-fold for>85 years).
 Despite different pharmacokinetic properties the
risk of ICH is similar for phenprocoumon and
warfarin.
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APPENDIX
DEFINITION OF POTENTIAL CONFOUNDING
FACTORS
Potential confounding factors were identiﬁed via ICD-10
codes (German Modiﬁcation) or ATC codes: diabetes
mellitus (ICD-10 codes E10–E14 and prescriptions of
antidiabetic treatment: ATC codes A10A and A10B),
alcohol dependence (ICD-10 code F10 and prescriptions
of disulﬁram or acamprosate: ATC code N07BB), hyper-
tension (ICD-10 codes I10–I15), ischemic heart disease
(ICD-10 codes I20–I25), liver diseases (ICD-10 codes K70–
K77, B15–B19), renal failure (ICD-10 codes N17–N19,
P96.0), brain tumor (ICD-10 code C71), epilepsy (ICD-10
code G40), ischemic cerebral infarction (ICD-10 codes I63,
I64), cerebral amyloid angiopathy (ICD-10 code I68.0),
cerebral aneurysm (ICD-10 code I67.1), epistaxis (ICD-10
code R04.0), intracerebral hemorrhage (ICD code I61),
other hemorrhage (ICD-10 codes K92.0, K92.2, K25.0,
K25.2, K25.4, K25.6, K26.0, K26.2, K26.4, K26.6, K27.0,
K27.2, K27.4, K27.6, K28.0, K28.2, K28.4, K28.6, K29.0,
I85.0, K22.6, K31.82, K55.22, K57.01, K57.03, K57.11,
K57.13, K57.21, K57.23, K57.31, K57.33, K57.41, K57.43,
K57.51, K57.53, K57.81, K57.83, K57.91, K57.93, K62.5,
I60, I62, R04, H92.2, N02.-, N42.1, N83.6, N85.7, N89.7,
N93.-, N95.0, R31, H11.3, H21.0, H31.3, H35.6, H43.1,
I31.2, J94.2, K66.1, D68.3, D69.8, D69.9, M25.0, R23.3,
R58), platelet aggregation inhibitors (ATC code B01AC),
heparin (ATC code B01AB), non-steroidal anti-inﬂamma-
tory drugs (NSAIDs) including acetylsalicylic acid (ASA)
(ATC codes M01A, M01BA, N02BA01, N02BA51,
N02BA71), selective serotonin reuptake inhibitors (SSRIs)
(ATC code N06AB), diuretics (ATC code C03), corticoster-
oids (ATC code H02), and statins (ATC codes C10AA,
C10BA).
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Appendix C
Paper 2: Risk of subarachnoid
hemorrhage associated with
antithrombotic drug use
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1Subarachnoid hemorrhage (SAH) causes only 5% to 7%1,2 of all incident strokes; however, treatment-related costs 
and loss in productivity are high.3,4 One in 2 affected persons 
is <55 years and dies rapidly or experiences severe disability.4 
In 2000–2008, the risk of death within 30 days after onset 
was ≈25%5,6 and 10% to 15% before reaching the hospital.5,6 
Survivors often remain impaired with persistent SAH-related 
symptoms and experience a greatly reduced quality of life.7
A ruptured intracranial aneurysm accounts for 85% of SAH4 
and is more frequent in patients with autosomal-dominant 
polycystic kidney disease.4,8,9 Despite genetic predisposition, 
intracranial aneurysm is usually not congenital, but develops 
throughout the course of life.4,9 Thus, modiﬁable risk factors, 
such as hypertension, smoking, and alcohol abuse, remain 
most important in the prevention of SAH.1,2,8,10
The inﬂuence of antithrombotic drugs on the risk of SAH 
has not been systematically studied, although these are widely 
used in the secondary prevention of thromboembolic diseases. 
In Germany, the warfarin analog phenprocoumon was the only 
vitamin K antagonist in use during the study period.11 It has 
the longest plasma half-life of the coumarins and is associated 
with high-dose variability.12 In previous studies, we showed 
an increased risk of serious bleeding from all causes in phen-
procoumon users13,14 and also for intracerebral hemorrhage.15
The present study was conducted to assess the inﬂuence of 
antithrombotic drugs on the risk of SAH and on early case 
fatality within 30 days.
Methods
Study Design and Setting
We conducted a nested case–control study in a cohort of 13.4 million 
insurance members included in the German Pharmacoepidemiological 
Research Database who fulﬁlled the inclusion criteria deﬁned below. 
This database contains data from 4 German statutory health insurances 
(SHIs) covering all regions in Germany and representing ≈20% of 
the German population. The study was based on data from the years 
2004–2006 because more recent data were not available to us at the 
time of the analysis. The database included insurance members’ demo-
graphic characteristics, information on all hospitalizations, outpatient 
physician visits, and all refundable outpatient prescriptions. Death of 
insurance members can be identiﬁed (1) as reason for exit from the 
SHI or (2) as reason for discharge from the hospital for hospitalized 
patients. The hospital data contain information about the periods of 
and reasons for admission and discharge with diagnoses, as well as 
Background and Purpose—Subarachnoid hemorrhage (SAH) accounts for <7% of all strokes, but is an enormous individual 
and societal burden. We investigated the risk of SAH associated with prior use of antithrombotic drugs and their inﬂuence 
on 30-day case fatality.
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diagnostic and therapeutic procedures. Claims of outpatient physi-
cian visits include outpatient treatments, procedures, and diagnoses. 
All diagnoses are coded according to the German modiﬁcation of the 
International Classiﬁcation of Diseases, Tenth Revision (ICD-10 GM). 
Prescription data include the date of prescription and drug dispensation 
at the pharmacy, the amount of substance prescribed, and information 
on the prescribing physician. Prescription data are linked via the central 
pharmaceutical reference number to a pharmaceutical reference data-
base, which contains information on the anatomic-therapeutic-chemi-
cal code, the deﬁned daily dose, packaging size, strength, formulation, 
generic and trade name. Preliminary analyses on age and sex distribu-
tion, the number of hospital admissions, and drug use have shown the 
database to be representative for Germany.16
In Germany, the use of health insurance data for scientiﬁc research 
is regulated by the Code of Social Law. All involved SHIs, the Federal 
Ministry of Health (for federal SHI data), and the provincial health 
authority (for regional SHI data) approved the use of the data for this 
study. Informed consent was not required by law because the study 
was based on pseudonymous data.
Study Population and Outcome Assessment
All insurants with ≥6 months of continuous insurance and no history 
of hospitalization for SAH during this period were included in the 
cohort. Cohort entry was deﬁned as July 1, 2004, or the ﬁrst day after 
6 months of continuous enrollment in the SHI. Thereafter, data were 
collected from cohort entry onward until hospitalization for SAH, 
death, end of the insurance, or November 30, 2006. The latter was 
chosen to avoid incomplete data for hospitalizations spanning the end 
of the year.
Cases of SAH were identiﬁed from the main hospital discharge di-
agnosis (ICD-10 GM code of I60). To ensure that SAH was an acute 
event, a procedure code indicating imaging by computed tomogra-
phy, MRI, or arteriography or documentation of other intracranial 
procedures was also required (codes available on request). The day 
of hospital admission was deﬁned as the index date for the respec-
tive case. In a sensitivity analysis we also excluded all cases with 
head injuries (ICD-10 GM codes S00-S09) and those without MRI or 
computed tomography.
Ten controls were matched to each case by sex, year of birth, SHI, 
and time in cohort using risk set sampling.17 Thereby, the index date 
in each control was chosen with the same time of follow-up as for the 
corresponding case. Cohort members who were hospitalized on the 
index date of the case were excluded from the set of potential controls 
because they were not at risk of being admitted to hospital because 
of SAH at that time.
Early case fatality was deﬁned as the proportion of all patients with 
SAH who died in the 30-day period after the index date. Information on 
death was obtained from the hospital discharge and insurance records. 
In addition, cases without any medical treatment or physician contacts 
beyond 30 days after the index date were presumed to have died.
Exposure Assessment
Exposure to the following anticoagulants was assessed: phenprocou-
mon, unfractionated or low molecular weight heparins, clopidogrel/
ticlopidine, and low-dose acetylsalicylic acid (ASA). Exposure was 
deﬁned as current if the last prescription overlapped with the 7-day 
period preceding the index date. The duration of a prescription was 
estimated by the amount of deﬁned daily doses for all anticoagulants 
except for phenprocoumon where the deﬁned daily dose could not 
be applied because of high interindividual dose variability. For phen-
procoumon, the average daily dose was estimated for each patient by 
dividing the cumulative phenprocoumon dose until the last outpatient 
phenprocoumon prescription before the index date by the number of 
days corresponding to this period. The average daily dose was then 
used to estimate the duration of exposure for the last prescription pre-
ceding the index date. If there was only 1 prescription before the in-
dex date, the deﬁned daily dose was used instead. Sensitivity analyses 
were conducted using ﬁxed exposure assessment periods of 90, 180, 
and 270 days before the index date.
Confounder Assessment
The following comorbid conditions were assessed from hospital 
and outpatient diagnoses in the time period 6 months before cohort 
entry: diabetes mellitus, systemic hypertension, ischemic heart dis-
ease, ischemic cerebral infarction, cerebral aneurysm, brain tumor, 
epilepsy, liver and renal failure, polycystic kidney disease, alco-
hol dependence, history of bleeding events, and connective tissue 
disorders (Ehlers–Danlos syndrome, Marfan syndrome, neuroﬁ-
bromatosis, and ﬁbromuscular dysplasia). Diabetes mellitus and al-
cohol dependency were identiﬁed from diagnoses and prescriptions 
of antidiabetic substances and disulﬁram or acamprosate, respec-
tively. Selective serotonin reuptake inhibitors were also considered 
in the analyses.
Statistical Methods
Incidence rates of SAH were calculated in the full cohort for different 
age groups stratiﬁed by sex. Corresponding 95% conﬁdence intervals 
(CIs) were estimated by the substitution method assuming a Poisson 
distribution for the number of bleedings.18 In addition, incidence rates 
were standardized by age and sex to the 2006 European population19 
using the direct method.20
On the basis of case–control data, crude odds ratios (ORs) were 
calculated using the Mantel–Haenszel estimator to account for 
matching. Multivariable conditional logistic regression analyses were 
conducted to estimate adjusted ORs and 2-sided 95% CI for SAH in 
subjects currently using phenprocoumon, heparin, or platelet aggre-
gation inhibitors (ie, drugs of interest).
The preliminary multivariable model included known risk fac-
tors of SAH without interaction terms. Relevant covariates were 
selected by backward elimination using the Wald test (P<0.05) 
and forcing of all drugs of interest to stay in the model. Two-way 
interactions between sex or age, and other risk factors were only 
added to the model if they were signiﬁcant at the 5% level. In ad-
dition, 2-way interactions between all considered antithrombotics 
were explored.
Predictors for 30-day case fatality were analyzed in subjects with 
SAH by logistic regression analysis including all considered risk 
factors. Backward selection was performed at a signiﬁcance level of 
P<0.1 because of the small sample size.
Statistical analyses were performed using SAS/STAT software, 
version 9.2 of the SAS system for Windows (SAS Institute, Inc, Cary, 
NC).
Results
The cohort included 13.4 million insurants with a median 
follow-up time of 883 days. The average age was 39.9 years 
with a SD of 22.2 years, and 55% of cohort members were 
women. The overall crude incidence of SAH in this cohort 
was 7.1 (95% CI, 6.8–7.4) hemorrhages per 100 000 person-
years. It was higher in women (8.39; 95% CI, 7.95–8.85 SAH 
per 100 000 person-years) than in men (5.42; 95% CI, 5.02–
5.83 per 100 000 person-years) and rose with increasing age 
(Figure). The overall direct standardized incidence rate to the 
2006 European population was 6.38 (95% CI, 6.10–6.65) per 
100 000 person-years.
Within this cohort, we identiﬁed 2065 cases of SAH and 
20 649 matched controls. Characteristics of the case–control 
sample are presented in Table 1. The ﬁnal multivariable model 
included the drugs of interest and the covariables diabetes 
mellitus, arterial hypertension, cerebral aneurysm, epilepsy, 
polycystic kidney disease, alcohol dependence, and selec-
tive serotonin reuptake inhibitors. No interaction terms were 
added to the ﬁnal multivariable model because either the main 
effect or the interaction term was not signiﬁcant in the respec-
tive analysis.
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Table 2 shows the crude and adjusted ORs based on the 
multivariable analysis model. The crude ORs were similar to 
those obtained from the multivariable model. Use of ASA, 
clopidogrel/ticlopidine, and phenprocoumon was associated 
with a small, but signiﬁcantly increased risk of SAH. The risk 
was also increased for heparin; however, this increase was 
not signiﬁcant. Among the other risk factors, high risks were 
observed for cerebral aneurysm and polycystic kidney disease. 
The adjusted ORs resulting from the full model, including 
all covariables and those of the sensitivity analysis exclud-
ing cases with head injuries, were similar to those obtained 
from the ﬁnal model (results not shown). Similar results were 
also observed for the sensitivity analyses using ﬁxed exposure 
assessment periods of 90, 180, and 270 days before the index 
date (results not shown).
A total of 470 subjects with SAH (22.8%) died within 
30 days after hospitalization. Seventy percent of these were 
women and the average age was 60.5 (SD 15.8) years. A sig-
niﬁcantly increased risk was observed for ages >70 years (OR, 
2.3; 95% CI, 1.8–3.1) and arterial hypertension (OR, 1.3; 95% 
CI, 1.0–1.6). Antithrombotic drug use was not found to be 
associated with increased 30-day case fatality.
Discussion
In our population-based nested case–control study, use of anti-
thrombotics was associated with an increased risk of SAH, but 
not with early case fatality.
Our ﬁndings on phenprocoumon are in line with the results 
of a case–control study by Risselada et al,21 which investi-
gated the risk of SAH for phenprocoumon, acenocouma-
rol, and platelet aggregation inhibitors with the Institute for 
Drug Outcomes Research database in the Netherlands. Only 
1 study has investigated the risk of SAH in patients receiv-
ing warfarin.22 This was a population-based case–control 
study in Northern Denmark using data from the Danish 
National Registry of Patients. In contrary to our results, this 
study did not report an increased risk of SAH for vitamin K 
antagonist use (90% of patients used warfarin, only 10% had 
phenprocoumon prescribed). Overall vitamin K antagonist 
use in the Danish controls was with 1.3% similar to that in 
the controls of our study (1.6%); however, only 0.8% of the 
Figure. Incidence of subarachnoid hemorrhage by age group and stratiﬁed by sex. The solid line connects incidence rates per 100 000 
person-years per age stratum in men, the dashed line in women. 95% conﬁdence interval (CI) are shown. The numbers next to the CI 
bars are absolute numbers of cases per given age stratum.
Table 1. Characteristics of Cases and Controls
Variable
Cases 
(n=2065)
n (%)
Controls 
(n=20 649)
n (%)
Patient characteristics
  Age, y, mean (SD) 56.3 (14.6)
  Women 1354 (65.6) 13 539 (65.6)
Antithrombotic and anticoagulant 
medications
  Acetylsalicylic acid 72 (3.5) 488 (2.4)
  Clopidogrel/ticlopidine 31 (1.5) 177 (0.9)
  Heparin 8 (0.4) 50 (0.2)
  Phenprocoumon 55 (2.7) 326 (1.6)
Comorbid conditions before cohort entry
  Diabetes mellitus 172 (8.3) 2083 (10.1)
  Arterial hypertension 710 (34.4) 6308 (30.6)
  Ischemic heart disease 219 (10.6) 2059 (10.0)
  Ischemic cerebral infarction 47 (2.3) 371 (1.8)
  Cerebral aneurysm 20 (1.0) 9 (<0.1)
  Brain tumor 14 (0.7) 68 (0.3)
  Epilepsy 31 (1.5) 152 (0.7)
  Liver failure 158 (7.7) 1475 (7.1)
  Renal failure 57 (2.8) 428 (2.1)
  Polycystic kidney disease 3 (0.1) 6 (<0.1)
  Alcohol dependence 45 (2.2) 212 (1.0)
  History of bleeding 12 (0.6) 81 (0.4)
  Connective tissue disorders* 2 (0.1) 6 (<0.1)
Concomitant medication
  Selective serotonin reuptake inhibitors 42 (2.0) 243 (1.2)
*Connective tissue disorders: Ehlers–Danlos syndrome, Marfan syndrome, 
neuroﬁbromatosis, and ﬁbromuscular dysplasia.
 by guest on July 11, 2013http://stroke.ahajournals.org/Downloaded from 
4  Stroke  September 2013
Danish cases had used vitamin K antagonists compared with 
2.7% of the cases in our study. The age and sex distribution 
was nearly the same in both studies. Comorbidity of the study 
populations could not be well compared because the Danish 
study lacked outpatient diagnoses.
The increased risk observed for low-dose ASA is in line with 
the results of another Danish population–based nested case–
control study, which reported a 2.5-fold risk of SAH associ-
ated with new use of low-dose ASA, whereas this study did 
not ﬁnd an increased risk for long-term ASA use.23 Because 
of low numbers of clopidogrel users, this Danish study was 
inconclusive with respect to the risk of clopidogrel. In the study 
by Risselada et al,21 the use of platelet aggregation inhibitors 
was not associated with an increased risk of SAH. This study 
did, however, not differentiate between new or long-term use of 
platelet aggregation inhibitors or between ASA and clopidogrel.
In our study, heparin use resulted in a slight, but nonsigniﬁ-
cant increase in the risk of SAH. Because only outpatient drug 
use was available to us for analysis, and this was rather low, our 
study had limited power to detect any increased risk. There are 
no other studies which have reported on the risk of heparin use.
We did not observe an increased risk for 30-day case fatal-
ity with any of the antithrombotic drugs used; however, power 
was limited for some of the antithrombotic exposures because 
of the small sample size for this analysis. Mortality was, 
however, signiﬁcantly increased in patients >70 years and 
with arterial hypertension. Age has previously been shown 
to be a strong predictor for 60-day case fatality in a prog-
nostic model presented by Risselada et al.24 This prognostic 
model was based on data from the randomized International 
Subarachnoid Aneurysm Trial which provided considerably 
more clinical detail for risk prediction than the health insur-
ance data we had available for our study. Antithrombotic drug 
use and arterial hypertension were not considered as prognos-
tic factors in the model reported by Risselada et al.24
Early case fatality (ie, within 30 days of the event) was 
22.8% and is at the lower end of the estimates reported in a 
recent systematic review for high income countries (cover-
ing the period between 2000 and 2008, excluding Germany).5 
Because of the advancement of diagnostic and treatment strat-
egies for SAH, a constant decline of case fatality has been 
observed over time,5,6 which is in line with the rather low 
observed 30-day case fatality in our study.
Our results were consistent with previous research in terms 
of the crude incidence of SAH1 and the median age of patients 
with SAH.23 The standardized incidence rate was slightly lower 
than that provided in another study.25 Our study also conﬁrmed 
several well-known risk factors for SAH, such as arterial 
hypertension,2,8 alcohol dependence,2,8,10 and autosomal-dom-
inant polycystic kidney disease.10 Our ﬁndings also conﬁrmed 
the reduced risk for diabetes mellitus reported for case–control 
studies.2 The reason for this association is not well understood, 
but it was suggested that patients with diabetes mellitus might 
have a higher risk of mortality because of other causes, reduc-
ing the chances of developing SAH compared with controls.2
Strengths and Limitations
The study was conducted in a large database representative 
for Germany26,27 including >17 million subjects. It provides 
data on the practice of antithrombotic prescribing and the 
occurrence of SAH in a real-life setting on a population level. 
The large size of German Pharmacoepidemiological Research 
Database enabled us to also investigate single drugs and not 
only, for example, combined drug classes and rare diseases 
as risk factors for SAH. Because prescription data are avail-
able with the exact date of dispensal, there is low potential for 
misclassiﬁcation of drug exposure when compared with ﬁeld 
studies on the basis of interview data. Selection bias in the 
choice of controls is unlikely because this study was designed 
as a nested case–control study in a deﬁned cohort provid-
ing both cases and controls. In addition, all information was 
recorded prospectively, thereby avoiding recall bias.
Cases of SAH were identiﬁed by the main hospital dis-
charge diagnosis which provides the reason for the hospital-
ization. We did not consider secondary discharge diagnoses to 
avoid misclassifying prevalent as incident cases. Cases also 
had to have speciﬁc imaging and surgical procedures for SAH 
or one of the two to ensure an acute event. Because of the 
large amount of cases, but foremost because of restrictions of 
German data protection laws, we could not validate the cases 
on the basis of medical charts. However, with the case deﬁ-
nition chosen, the incidence of SAH we observed was com-
parable with that of other studies.1,4,23 A sensitivity analysis 
excluding SAH cases with head injuries and cases without 
MRI or computed tomography corroborated the ﬁndings.
Because the database does not contain information on the 
prescribed dose and duration of use, the duration of exposure 
for phenprocoumon was estimated on the basis of average daily 
dose. Sensitivity analyses using ﬁxed exposure assessment 
periods of 90, 180, and 270 days before the index date showed 
that our results were robust. Although we included informa-
tion on many potential risk factors of SAH, we could not con-
trol for other potential confounders, such as smoking or over 
the-counter use of high-dose ASA because this information is 
Table 2. Crude and Adjusted Odds Ratios of Subarachnoid 
Hemorrhage for Antithrombotics and Risk Factors
Variable Crude OR Adjusted* OR 95% CI** P Value**
Antithrombotic medications
  Acetylsalicylic acid 1.5 1.5 1.2–2.0 0.001
  Clopidogrel/ticlopidine 1.8 1.6 1.1–2.4 0.016
  Heparin 1.6 1.2 0.6–2.8 0.604
  Phenprocoumon 1.7 1.7 1.3–2.3 <0.001
Comorbid conditions
  Diabetes mellitus 0.8 0.7 0.6–0.9 <0.001
  Arterial hypertension 1.2 1.2 1.1–1.4 <0.001
  Cerebral aneurysm 22.2 19.5 8.8–43.3 <0.001
  Epilepsy 2.1 1.7 1.1–2.5 0.014
  Polycystic kidney disease 5.0 4.8 1.2–19.4 0.026
  Alcohol dependence 2.2 2.0 1.4–2.8 <0.001
Concomitant medication
  Selective serotonin reuptake 
inhibitors
1.8 1.7 1.2–2.3 0.003
CI indicates conﬁdence interval; and OR, odds ratio
*Adjusted for all other covariables.
**95% conﬁdence intervals and P values refer to the adjusted odds ratios.
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not available in the database. However, whether a risk factor is 
truly a confounder depends on whether it is also associated with 
the exposure under study. Besides, the potential for confound-
ing also depends on the magnitude of the risk of the potential 
risk factor. Smoking has been shown to be an important risk 
factor for SAH; however, the magnitude of the risk has varied 
between 1.227 and 2.2 in a systematic review of longitudinal 
studies.2 The association of smoking with oral anticoagulant 
exposure is probably weak, given that oral anticoagulation is 
prescribed for many conditions which seem rather unrelated to 
smoking. We, therefore, do not expect major confounding by 
lack of adjustment for smoking in our analyses. This is in line 
with the results of one of our previous studies on phenprocou-
mon use and serious bleeding where additional information on 
smoking obtained for a subsample of patients in a 2-phase anal-
ysis did not result in a relevant change of the risk estimate for 
phenprocoumon.13 Information on anticoagulation intensity is 
also lacking in the database. However, as it is a prerequisite that 
a confounder does not lie on the causal pathway between expo-
sure and outcome, we are not concerned by this lack of infor-
mation because we believe that high international normalized 
ratio values are on the causal pathway between phenprocou-
mon use and bleeding. Therefore, adjustment for anticoagula-
tion intensity as a confounder in the statistical analysis is not 
appropriate. We could not provide information on the new gen-
eration of anticoagulants, such as rivaroxaban or dabigatran, as 
they had not yet been marketed during the study period.
Conclusions
We found that outpatient use of antithrombotic drugs 
increased the risk of SAH. We did not observe an increase in 
30-day case fatality for the antithrombotic drugs under study; 
however, the power for this analysis was limited because of 
the small sample size for this analysis. Early case fatality was 
associated with an age >70 years and arterial hypertension.
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Does additional confounder information alter the estimated risk of
bleeding associated with phenprocoumon use—results of a
two-phase study
Sigrid Behr*, Walter Schill and Iris Pigeot
Bremen Institute for Prevention Research and Social Medicine, Bremen University, Bremen, Germany
ABSTRACT
Purpose Claims databases are an important source for pharmacoepidemiological studies although they often lack information on some
confounders. Two-phase methodology was used to estimate the bleeding risk in patients treated with phenprocoumon from claims data
combined with additional information on body mass index (BMI) and smoking.
Methods We conducted a nested case–control study using claims data from 2004 to 2007 (phase 1). Additional information was obtained
from interviews in a subset of 505 insurants (phase 2). Adjusted bleeding OR were calculated using logistic regression using data from the
complete case–control dataset. Furthermore, a two-phase analysis was conducted, taking into consideration phase 2 data on BMI and
smoking.
Results The phase 1 sample included 1248 cases and 24 960 controls. In phase 1, we observed an adjusted bleeding ORs of 3.93 (95%CI:
2.75–5.61) for male subjects aged 55 years taking phenprocoumon. The bleeding risk associated with phenprocoumon use decreased with
increasing age. The two-phase analysis revealed smoking and a high BMI as risk factors for bleeding. The OR for phenprocoumon obtained
from the two-phase analysis was of similar size as the phase 1 estimate.
Discussion Phase 2 data added valuable information on smoking and BMI. However, phase 1 results did not change dramatically after
accounting for phase 2 information, which is reassuring for the validity of database studies. Copyright © 2012 John Wiley & Sons, Ltd.
key words—two-phase design; validation sample; missing confounder information; database study
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BACKGROUND
Claims databases are an important source for pharma-
coepidemiological studies, although they often lack
information on potentially relevant confounders. The
German Pharmacoepidemiological Research Database
(GePaRD) consists of claims data from several German
statutory health insurances. A large number of risk
factors can be identiﬁed from diagnosis codes and
medications included in this database. However, the
database does not contain information on body mass
index (BMI) and smoking status, which are important
risk factors for many diseases. In previous research,
we conducted a study investigating the risk of intra-
cerebral hemorrhage associated with phenprocoumon
exposure using the GePaRD.1 A limitation of this study
was that BMI, smoking status, intensity of anticoagula-
tion and over-the-counter (OTC) use of acetylsalicylic
acid (ASA) could not be considered in the analysis
because this information was not available in the claims
database. One idea to overcome this limitation is to
collect additional data from patient interviews in a
subset of patients and to include this information into
the database study by using two-phase methodology.
Two-phase designs were introduced into epidemiology
in the 1980s by Walker and White to reduce costs of
covariate collection in ﬁeld studies.2,3 The basic idea
of a two-phase case–control study is that disease status
and at least crude information on exposure and covari-
ates are available for all cases and controls in phase 1,
whereas precise or additional information on exposure
and covariates is collected for a subsample of cases
and controls in phase 2. The statistical analysis is then
conducted on the complete phase 2 data taking into
*Correspondence to: S. Behr, Achterstr. 30, 28359 Bremen, Germany. E-mail:
behr@bips.uni-bremen.de
Copyright © 2012 John Wiley & Sons, Ltd.
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account the phase 1 information, which is available for
the full case–control sample. Although the two-phase
design has been recognized as efﬁcient design for large
database studies,4 until now, there are only very few
studies adopting this methodology.5 The present study
uses a two-phase design to investigate whether additional
confounder information on BMI and smoking status
obtained from patient interviews alters the results of a
database study on the risk of serious bleedings associated
with phenprocoumon use. The focus of the paper is to
describe the methods and results of this two-phase study
to provide an example of how two-phase methodology
can be exploited to better cope with missing confounder
information.
METHODS
Study design
We conducted a two-phase case–control study in a
population of inhabitants of the State of Bremen who
were insured at the regional healthcare provider AOK
Bremen/Bremerhaven between 2004 and 2007. Phase
1 data were obtained from insurance claims comprising
information on demographic characteristics, hospital
admissions, ambulatory physician visits, and ambula-
tory prescriptions. Hospital diagnoses as well as ambu-
latory diagnoses were coded according to the German
modiﬁcation of the International Classiﬁcation of
Diseases (ICD-10 GM). Ambulatory prescribed drugs
were characterized by the central pharmaceutical num-
ber, which was linked to the corresponding anatomical–
therapeutic–chemical (ATC) code and the Deﬁned
Daily Dose (DDD). In phase 1, cases and controls were
sampled from a cohort of insurants whowere required to
be continuously insured for 6months before cohort
entry. Cohort entry was deﬁned as the ﬁrst day after
6months of continuous insurance. Cohort exit was
deﬁned as the ﬁrst of the following dates: end of the
insurance period, hospitalization for serious bleedings
as deﬁned below, death or end of study period (31
December 2007). To ensure that all cohort members
were able to participate in the telephone interviews,
which were conducted for phase 2, we excluded
insurants with a diagnosis of dementia during the study
period and insurants younger than 18 years or older than
75 years at the time of the interview. Cases were deﬁned
as cohort members hospitalized for serious bleeding
including gastrointestinal bleedings, intracerebral
bleedings, urogenital bleedings and other bleedings.
The ICD-10 GM codes used for identiﬁcation of serious
bleedings are speciﬁed in the appendix. The respective
hospital admission date is referred to as the index date
for cases. Cohort members who did not become a case
during the study constitute the set of potential controls.
Controls were randomly selected from this set with a
case : control ratio of 1:20. A random index date was
chosen from the period between cohort entry and cohort
exit for each control. This control selection strategy was
chosen instead of the usual risk-set sampling because
two-phase methodology cannot be applied for matched
case–control pairs. Because the set of potential controls,
which were under risk at each time point during the
study, was very large, both selection strategies would
lead to similar control groups.
We identiﬁed current phenprocoumon exposure on
the index date by ambulatory prescriptions with ATC
code B01AA04 overlapping the index date. The dura-
tion of exposure associated with the last prescription
before the index date was calculated using the estimated
average daily dose as described in Behr et al.1
The following risk factors for serious bleedings and
potential confounders were extracted from the claims
data in phase 1 of the study: sex, age at cohort entry,
comorbid conditions (assessed in the 6months before
cohort entry), and concomitant medications (assessed
by prescriptions overlapping the index date). Comorbid
conditions included diabetes mellitus, systemic hyper-
tension, ischemic heart disease, ischemic cerebral
infarction, epilepsy, cancer, liver disease, renal failure,
chronic obstructive pulmonary disease (COPD), alcohol
dependency, diverticular disease, gastrointestinal dis-
ease (e.g., ulcers), and history of serious bleedings. We
considered current use of the following substances as
concomitant medications: platelet aggregation inhibitors
(i.e., clopidogrel, ticlopidine), heparins, non-steroidal
anti-inﬂammatory drugs (NSAIDs), prescribed ASA,
selective serotonin reuptake inhibitors (SSRIs), diuret-
ics, corticosteroids, statins, and gastroprotective drugs
(i.e., H2-receptor antagonists, proton pump inhibitors,
sucralfat, misoprostol, gastrozepin). Details on the
speciﬁcation of diseases and substances are given in
the appendix.
Phase 2 data
Additional information for phase 2 was gained from
computer-assisted telephone interviews, which were per-
formed in a subsample of persons included in phase 1.
The selection process for the subsample aimed at
achieving a balanced design regarding case–control
status and phenprocoumon exposure on the index date.
According to Breslow and Cain, the balanced design is
almost always the most efﬁcient design for sampling
phase 2.6,7 For this purpose, the phase 1 sample was
stratiﬁed according to case–control and exposure status,
and two batches of 2000 persons were selected by
s. behr et al.536
Copyright © 2012 John Wiley & Sons, Ltd. Pharmacoepidemiology and Drug Safety, 2012; 21: 535–545
DOI: 10.1002/pds
oversampling cases and exposed persons. For adopting
a two-phase approach, overall representativeness of the
phase 2 sample is not required. The representativeness
in each stratum was achieved by selecting persons
randomly from each stratum. We collected information
on BMI, current and past smoking behavior, general
health status, medication use for pain treatment (includ-
ing OTC drugs), hospital admissions, and on gastroin-
testinal disorders for 505 insurants who completed the
full interview.
The study was conducted with permission from the
ethical committee. Furthermore, we obtained individual
informed consent from each participant of the phase
2 sample.
Statistical analysis
The statistical analysis was accomplished in two steps.
The ﬁrst step included a full analysis of the phase 1
case–control sample considering all information avail-
able in phase 1. In the second step, a two-phase analysis
was conducted that made use of the combined data from
phase 1 and phase 2.
For the analysis of the phase 1 case–control sample,
the adjusted OR of serious bleedings comparing phen-
procoumon users with non-users and the corresponding
95%CI were calculated by means of multivariable
logistic regression. The regression model included all
risk factors and potential confounders speciﬁed above,
age (centered at 55 years), sex and interactions between
age and phenprocoumon use as well as between sex and
phenprocoumon use. Further interaction terms for
phenprocoumon use and comorbid conditions or con-
comitant medications were added to the model if they
were signiﬁcant (Wald test, p-value< 0.05). A sensitiv-
ity analysis was conducted to assess the relevance of the
covariate selection by adopting a backward selection
process that excluded non-signiﬁcant (p≥ 0.05) covari-
ates stepwise. Age, sex, phenprocoumon use, and the
interactions with phenprocoumon use were forced to
stay in the model. All phase 1 analyses were done using
SAS 8.2 and SAS 9.2 (SAS Institute Inc., Cary, NC).
The two-phase analysis was conducted as an explor-
atory analysis investigating the effect of BMI and
smoking behavior on the OR of serious bleedings
associated with phenprocoumon use. Several two-phase
logistic regression models were ﬁtted including current
phenprocoumon use, age (centered at 55 years), sex,
smoking status at cohort entry, BMI (< 30 versus
≥ 30 kg/m²), and two-way interaction terms with phen-
procoumon use as explanatory variables.
One simple approach to analyze a two-phase study is
as follows: ﬁrst, the full case–control sample is stratiﬁed
according to information available for each person in
phase 1 of the study. Second, sampling probabilities
for participation in phase 2 are calculated for each
stratum. Then, a weighted logistic regression analysis
is conducted based on cases and controls with complete
information in the phase 2 sample using the inverse
sampling probabilities as weights. More details on the
weighted logistic regression are given in Flanders and
Greenland.8 Alternatives to the weighted likelihood
approach are pseudo-likelihood and maximum likeli-
hood approaches.9 Because all three approaches involve
complex formulas for the variance estimation, standard
logistic regression procedures cannot be used for esti-
mation. However, the three approaches have now been
implemented in the R package osDesign.10 In this study,
the maximum likelihood estimator as described in
Breslow and Holubkov was used to estimate ORs and
corresponding SEs.11 Ninety-ﬁve percent CIs were
calculated based on the asymptotic normality of the
maximum likelihood estimates.
Because the two-phase methodology requires non-
empty strata among cases and controls in the phase 2
sample, stratiﬁcations had to be constructed that avoided
empty cells. In a ﬁrst step, phase 1 data were stratiﬁed in
12 strata by cross-classifying age at cohort entry (<50
years, 50–< 65years, and≥65 years), sex, and phenpro-
coumon exposure on the index day. Inclusion of further
covariate information in additional stratiﬁcations was
only considered for common diseases as arterial hyper-
tension and diabetes mellitus. ORs and corresponding
SEs were estimated by adopting the R package
osDesign.10 Results were validated with the SAS-based
program package by Schill et al.12
RESULTS
The study cohort consisted of 186 438 insurants of
the AOK Bremen/Bremerhaven, which had a mean
follow-up time of 2.83 years (SD 1.10 years). Within
this cohort, 1248 cases of serious bleedings were identi-
ﬁed, and 24 960 controls were sampled for inclusion in
the phase 1 case–control sample. Of the 4000 persons
who were initially selected to participate in the phase 2
survey, 3280 were contacted by mail. The remaining
persons could not be contacted because they were no
longer insured with the AOK Bremen/Bremerhaven,
died, or lived in nursing homes at the time of the survey.
A total of 505 interviews could be completed, resulting
in a response proportion of 15.35%. Two patients had to
be excluded from phase 2 because they were not entitled
to receive beneﬁts during the study period. In addition,
one patient was excluded because of lack of data
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quality.1 Thus, the phase 2 sample consisted of 156
cases and 346 controls. Because information on BMI
was missing for one control and information on
smoking was not observed for one case and two further
controls, regression analyses including BMI and
smoking status were based on 498 patients.
Characteristics of the phase 1 and phase 2 case–control
sample are summarized in Table 1. Compared with
phase 1, patients in the phase 2 sample were older and
had more claims for comorbidities and comedications.
The differences were more pronounced among controls
than among cases. A logistic regression analysis model-
ing the probability of participation in phase 2 revealed
age as an important predictor with a higher probability
of participation for older age. No association with prob-
ability of participation was observed for most comor-
bidities and most comedications; weak associations
were found for sex, diverticular disease, and use of
statins. The two-phase analysis accounted for the ob-
served differences between the phase 1 and the phase
2 sample by including information on age and sex in
all stratiﬁcations.
Analysis of the additional information from the patient
interviews disclosed that most of the participants in phase
2 were overweight (70% with BMI ≥25kg/m²), and
66% were past or current smokers (Table 2). Cases and
controls in the phase 2 sample differed from each other
with respect to their smoking behavior with more smok-
ers and also more packyears of smoking among cases.
The multivariable analysis of the phase 1 data revealed
that current phenprocoumon use was associated with a
3.9-fold risk of serious bleeding with 55-year-old male
subjects as a reference group. The most important risk
factors were increasing age, a history of serious bleed-
ings, alcohol dependency, and use of antithrombotic
medications (heparin, platelet aggregation inhibitors). A
signiﬁcant interaction between phenprocoumon use and
age was observed, indicating that increased age resulted
in a decreased risk of serious bleedings associated with
phenprocoumon use. No further interactions with phen-
procoumon met the criteria for inclusion in the model.
The results of the ﬁnal model are summarized in Table 3.
Similar risk estimates were obtained from the backward
selection model from which the covariates ischemic
heart disease, COPD, statin use, ischemic stroke, diver-
ticular disease, hypertension, and cancer were elimi-
nated. Neither the main effect for sex nor the interaction
between sex and phenprocoumon use were signiﬁcant in
the fully adjusted model. However, when adjusting only
for arterial hypertension, diabetes mellitus, and age
(model used for comparison with the two-phase analy-
sis), male sex turned out as a signiﬁcant risk factor for
bleeding, and the interaction between sex and phenpro-
coumon use also was signiﬁcant with a higher risk for
female phenprocoumon users (Table 5).
Three different stratiﬁcations as depicted in Table 4
were used for the two-phase analysis. Stratiﬁcation
A comprised phase 1 information on age, sex, and
phenprocoumon exposure cross-classiﬁed into 12 strata
for cases and controls. These strata were further classi-
ﬁed by underlying hypertensive disease in stratiﬁcation
B and by diabetes mellitus in stratiﬁcation C. To avoid
empty cells in stratiﬁcations B and C, some strata
needed to be combined. All two-phase logistic regres-
sion models included the phase 1 covariates age, sex,
phenprocoumon exposure, hypertension, and diabetes
mellitus. However, the effects of hypertension and
diabetes mellitus on serious bleedings could only be
estimated with sufﬁcient precision in the two-phase
analysis if the stratiﬁcation considered phase 1 informa-
tion on hypertension (stratiﬁcation B) or diabetes
mellitus (stratiﬁcation C), respectively. Table 6 also
shows estimates for the effects of hypertension and
diabetes mellitus using the three stratiﬁcations. Results
of two different two-phase models based on stratiﬁcation
A (one model with interaction between phenprocoumon
and smoking and the other model without this interac-
tion) and results of the respective phase 1 analysis are
compared in Table 5. In both two-phase models, current
smoking was a signiﬁcant risk factor for serious bleed-
ings. The interaction between phenprocoumon use and
smoking was not signiﬁcant. However, the risk of bleed-
ing associated with phenprocoumon use regardless of
smoking status (i.e., estimated from the two-phase model
without the interaction between phenprocoumon and
smoking) was 4.96 (95%CI: 2.91–8.45), which was
different from the risk estimated for phenprocoumon
use among non-smokers in a model with interaction
term (OR: 7.40, 95%CI: 3.31–16.54). Considering
the estimate for the interaction term (OR: 0.37, 95%
CI: 0.10–1.36), the corresponding risk of bleeding
among phenprocoumon users who smoke was 2.75.
Using stratiﬁcation B, the OR for the interaction be-
tween current smoking and phenprocoumon use was
0.33 (95%CI: 0.09–1.17). The two-phase models
omitting the smoking interaction revealed similar risk
estimates for phenprocoumon use compared with the
phase 1 analysis as can be seen from Figure 1.
An increased BMI (≥30 kg/m²) was associated with a
1.6-fold increased risk of bleeding. No interaction
between BMI and phenprocoumon use was observed
in the two-phase analysis, indicating that the risk of
1Most survey items for this patient were missing. In particular, the patient
could not remember any dates.
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bleeding associated with phenprocoumon use was the
same for high and low BMI (Tables 5 and 6). Models
including BMI information as continuous covariate or
as dichotomous variable with more than two categories
provided consistent results for the effect of BMI on
bleeding (results not shown).
The different stratiﬁcations had little effect on the
OR estimates for phenprocoumon use (Figure 1).
However, the precision with which ORs were esti-
mated varied between the stratiﬁcations, leading to
signiﬁcant results for BMI and hypertension when
employing stratiﬁcation B and signiﬁcant results for
diabetes mellitus when employing stratiﬁcation C
(Table 6).
The effect of smoked packyears on the bleeding risk
was investigated in a sensitivity analysis. A higher risk
was observed for patients with more than 10 packyears
of smoking, but no interaction between the number of
packyears and phenprocoumon use was detected
(results not shown).
Table 1. Characteristics of cases and controls in phase 1 and phase 2 sample
Phase 1 sample Phase 2 sample*
Cases Controls Cases Controls
N= 1248 N= 24960 N = 156 N= 346
n (%) n (%) n (%) n (%)
Age: mean (SD) 54.6 (13.4) 42.8 (16.2) 59.2 (9.9) 56.1 (12.9)
Age categories
<30 years 88 (7.1%) 6301 (25.2%) 2 (1.3%) 20 (5.8%)
30–<50 years 279 (22.4%) 9423 (37.8%) 24 (15.4%) 61 (17.6%)
50–<65 years 525 (42.1%) 6364 (25.5%) 69 (44.2%) 160 (46.2%)
≥ 65 years 356 (28.5%) 2872 (11.5%) 61 (39.1%) 105 (30.3%)
Male sex 686 (55.0%) 12 792 (51.3%) 71 (45.5%) 169 (48.8%)
Phenprocoumon exposure 117 (9.4%) 313 (1.3%) 26 (16.7%) 74 (21.4%)
Bleeding type
Gastrointestinal bleeding 639 (51.2%) — 79 (50.6%) —
Urogenital bleeding 216 (17.3%) — 33 (21.2%) —
Cerebral bleeding 189 (15.1%) — 21 (13.5%) —
Other bleeding 204 (16.3%) — 23 (14.7%) —
Comorbid conditions$
Diabetes mellitus 224 (17.9%) 1526 (6.1%) 35 (22.4%) 54 (15.6%)
Hypertension 397 (31.8%) 3298 (13.2%) 64 (41.0%) 108 (31.2%)
Ischemic heart disease 137 (11.0%) 839 (3.4%) 23 (14.7%) 42 (12.1%)
Ischemic cerebral infarction 25 (2.0%) 94 (0.4%) 4 (2.6%) 8 (2.3%)
Epilepsy 31 (2.5%) 218 (0.9%) 2 (1.3%) 0 (0.0%)
Cancer 76 (6.1%) 542 (2.2%) 12 (7.7%) 19 (5.5%)
Liver diseases 164 (13.1%) 1136 (4.6%) 18 (11.5%) 27 (7.8%)
Renal failure 43 (3.4%) 140 (0.6%) 3 (1.9%) 7 (2.0%)
COPD 80 (6.4%) 678 (2.7%) 12 (7.7%) 20 (5.8%)
Alcohol dependence 118 (9.5%) 492 (2.0%) 9 (5.8%) 9 (2.6%)
Diverticular disease 31 (2.5%) 151 (0.6%) 7 (4.5%) 8 ( 2.3%)
Gastrointestinal diseases 107 (8.6%) 930 (3.7%) 14 (9.0%) 21 (6.1%)
History of serious bleeding 22 (1.8%) 22 (0.1%) 2 (1.3%) 0 (0.0%)
Concomitant medication}
Current use of the following:
Platelet aggregation inhibitors 23 (1.8%) 57 (0.2%) 4 (2.6%) 1 (0.3%)
Heparin 27 (2.2%) 35 (0.1%) 4 ( 2.6%) 2 (0.6%)
NSAIDs 126 (10.1%) 1014 (4.1%) 17 (10.9%) 23 (6.6%)
ASA 90 (7.2%) 422 (1.7%) 10 (6.4%) 17 (4.9%)
SSRIs 19 (1.5%) 124 (0.5%) 2 (1.3%) 0 (0.0%)
Diuretics 286 (22.9%) 1970 (7.9%) 37 (23.7%) 89 (25.7%)
Corticosteroids 54 (4.3%) 306 (1.2%) 5 (3.2%) 6 (1.7%)
Statins 118 (9.5%) 825 (3.3%) 21 (13.5%) 45 (13.0%)
Gastroprotective drugs# 188 (15.1%) 1005 (4.0%) 24 (15.4%) 33 (9.5%)
*Information shown for phase 2 sample was obtained from the claims data.
$Assessed in the 6-month baseline period preceding cohort entry.
}Ambulatory prescriptions overlapping the index day.
#Gastroprotective drugs include H2-receptor antagonists, proton pump inhibitors, sucralfat, misoprostol, and gastrozepin.
COPD, chronic obstructive pulmonary disease; NSAID, non-steroidal anti inﬂammatory drug; ASA, acetylsalicylic acid; SSRI, selective serotonin reuptake
inhibitor; ICH, intracerebral hemorrhage.
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DISCUSSION
Phase 2 information on BMI and smoking behavior
added valuable information to the database study in-
vestigating phenprocoumon use and the risk of serious
bleedings. The phase 1 analysis revealed an increased
risk of serious bleedings associated with current phen-
procoumon use that decreased with increasing age.
The risk of bleeding rose with increasing age among
non-users, whereas the effect of age nearly vanished
among phenprocoumon users. Because the study only
included patients below 75, the observed age effect
should not be extrapolated to an elderly population
above 75 years.
The effect of sex estimated in the full phase 1 model
was not signiﬁcant, although the results implied a higher
risk of bleeding for male subjects in general and a higher
risk of bleeding associated with phenprocoumon use for
female subjects. Few studies examined the effect of sex
on bleeding risk and particularly on anticoagulant-
related bleeding because most studies were adjusted
for sex by matching or stratiﬁcation. Results of other
studies, in which a signiﬁcant effect of sex was detected,
were consistent with our results.13–15 If not adjusted for
BMI, an observed higher risk for anticoagulant-related
bleeding in female subjects also could be related to their
lower BMI. However, the two-phase analysis, which
was adjusted for BMI also indicated male sex as an
independent risk factor for bleeding, whereas female
sex was a risk factor for bleeding for phenprocoumon
users. Furthermore, we did not observe an interaction
between phenprocoumon use and BMI in the two-phase
analysis. These results imply that consideration of
information on BMI did not alter the risk for bleeding
associated with phenprocoumon use estimated from
phase 1 data without adjusting for BMI.
Additional knowledge on BMI and smoking was
gained from the two-phase analysis. The two-phase anal-
ysis revealed an increased bleeding risk for patients with
a high BMI. This ﬁnding is consistent with the literature.
A prospective cohort study conducted by Strate et al. in
47 228 male health professionals demonstrated that
Table 2. Additional information in phase 2
Phase 2 sample*
Cases Controls
N = 156 N= 346
BMI#
Mean (SD) 28.6 (5.9) 28.1 (6.8)
Minimum–maximum 16–48 13–69
Q1–Median–Q3 25–28–32 24–28–30
BMI categories#
Severe underweight (<16 kg/m²) 0 (0.0%) 1 (0.3%)
Underweight (16–< 18.5 kg/m²) 2 (1.3%) 11 (3.2%)
Normal weight (18.5–< 25 kg/m²) 42 (26.9%) 96 (27.7%)
Overweight (25–< 30 kg/m²) 56 (35.9%) 141 (40.8%)
Severe overweight (≥ 30 kg/m²) 56 (35.9%) 96 (27.7%)
Smoking status$
Never smoked 45 (28.8%) 121 (35.0%)
Past smoker 49 (31.4%) 128 (37.0%)
Current smoker 61 (39.1%) 95 (27.5%)
Packyears of smoking}
Never smoked 45 (28.8%) 121 (35.0%)
> 0–10 packyears 21 (13.5%) 61 (17.6%)
> 10–20 packyears 25 (16.0%) 40 (11.6%)
> 20 packyears 62 (39.7%) 122 (35.3%)
*Information shown for phase 2 sample was obtained from the survey data.
#BMI was not observed for one control.
$Assessed at cohort entry. For one case and two controls, no smoking status
was recorded.
}Information on packyears was missing for three cases and three controls.
BMI, body mass index.
Table 3. Adjusted odds ratios and 95% conﬁdence intervals for serious
bleedings based on phase 1 data
Multivariable model Adjusted
odds
ratio#
95%CI# Wald
test
(N= 26208) p-value
Phenprocoumon exposure 3.93} 2.75–5.61 < 0.001
Age (centered at 55 years) 1.04 1.03–1.04 < 0.001
Interaction:
age phenprocoumon exposure
0.97 0.94–0.99 0.015
Female sex 0.89 0.79–1.01 0.072
Interaction:
sex phenprocoumon exposure
1.33 0.83–2.15 0.235
Comorbid conditions
Diabetes mellitus 1.27 1.07–1.52 0.008
Hypertension 1.13 0.97–1.32 0.118
Ischemic heart disease 1.05 0.84–1.32 0.670
Ischemic cerebral infarction 1.28 0.78–2.11 0.333
Epilepsy 1.67 1.09–2.56 0.018
Cancer 1.26 0.96–1.64 0.096
Liver diseases 1.31 1.07–1.61 0.009
Renal failure 1.83 1.23–2.71 0.003
COPD 0.96 0.74–1.25 0.775
Alcohol dependence 3.42 2.69–4.35 < 0.001
Diverticular disease 1.37 0.89–2.11 0.149
Gastrointestinal diseases 1.37 1.09–1.73 0.008
History of serious bleeding 9.45 4.91–18.19 < 0.001
Current use of the following:
Platelet aggregation inhibitors 2.74 1.60–4.71 < 0.001
Heparin 5.88 3.27–10.60 < 0.001
NSAIDs 1.44 1.16–1.78 < 0.001
ASA 1.75 1.33–2.29 < 0.001
SSRIs 1.78 1.03–3.09 0.039
Diuretics 1.23 1.04–1.45 0.016
Corticosteroids 1.77 1.27–2.45 < 0.001
Statins 0.90 0.71–1.14 0.389
Gastroprotective drugs* 1.77 1.46–2.14 < 0.001
}Adjusted odds ratio for phenprocoumon exposure refers to a 55-year-old
male patient.
#Adjusted for all covariates included in the table and for two-way interac-
tions for phenprocoumon use with age and sex.
*Gastroprotective drugs include H2-receptor antagonists, proton pump
inhibitors, sucralfat, misoprostol, and gastrozepin.
NSAID, non-steroidal anti inﬂammatory drug; ASA, acetylsalicylic acid;
SSRI, selective serotonin reuptake inhibitor.
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obesity is a risk factor for diverticulitis and diverticular
bleeding.16 Furthermore, BMI ≥ 30kg/m² was associ-
ated with an increased risk of hemorrhagic stroke in a
study by Kurth et al. who analyzed a cohort of 21 414
US male physicians.17 In addition, current smoking
was associated with an increased bleeding risk in the
two-phase analysis. The effect of smoking on the bleed-
ing risk is discussed controversially in the literature. On
the one side, smoking has been identiﬁed as an
independent risk factor for bleeding in several studies.
Kaplan et al. observed a twofold increased risk for upper
gastrointestinal bleeding in a case–control study includ-
ing 1020 members of an American health maintenance
organization who were treated with speciﬁc anti-
hypertensive medications.18 A similar increase in risk
was detected in two studies by Kurth et al. exploring
the association between smoking and hemorrhagic
stroke in men and in women.19,20 Kurth et al. suggested
Table 5. Results of the two-phase analyses
Multivariable model} Two-phase analysis Two-phase analysis
(n= 498#) (n= 498#)
Phase 1 analysis Stratiﬁcation A$ Stratiﬁcation A$
(N = 26 208) Model without smoking interaction Model with smoking interaction
ln OR} OR} (95%CI) ln OR} OR} (95%CI) ln OR} OR} (95%CI)
Phenprocoumon exposure 1.42 4.14 (2.95–5.81) 1.60 4.96 (2.91–8.45) 2.00 7.40 (3.31–16.54)
Age (centered at 55 years) 0.043 1.044 (1.039–1.049) 0.062 1.064 (1.051–1.077) 0.063 1.065 (1.051–1.080)
Interaction between phenprocoumon and age 0.04 0.96 (0.94–0.99) 0.03 0.97 (0.94–1.00) 0.05 0.95 (0.91–0.99)
Female sex 0.21 0.81 (0.72–0.92) 0.14 0.87 (0.74–1.03) 0.13 0.88 (0.74–1.04)
Interaction between phenprocoumon and sex 0.46 1.59 (1.01–2.49) 0.56 1.75 (1.07–2.86) 0.44 1.55 (0.93–2.56)
BMI≥ 30 kg/m² — — 0.45 1.57 (1.00–2.47) 0.46 1.58 (1.00–2.49)
Interaction between phenprocoumon and BMI — — 0.39 0.68 (0.25–1.82) 0.43 0.65 (0.24–1.75)
Current smoker — — 0.83 2.30 (1.50–3.53) 0.96 2.61 (1.63–4.17)
Interaction between phenprocoumon and smoking — — — — 0.99 0.37 (0.10–1.36)
#One control without information on BMI and one case and two controls without information on smoking were excluded from the analysis.
}ORs also are adjusted for the comorbid conditions hypertension and diabetes mellitus.
$Stratiﬁcation A includes information on age (three categories), sex, and phenprocoumon exposure.
ln, natural logarithm.
Table 6. Comparison of different stratiﬁcations in the two-phase analyses
Multivariable model Two-phase analyses
(n= 498*)
Stratiﬁcation A$ Stratiﬁcation B# Stratiﬁcation C}
OR (95%CI) OR (95%CI) OR (95%CI)
Phenprocoumon exposure 4.96 (2.91–8.45) 4.92 (3.02–8.04) 5.67 (3.44–9.35)
Age (centered at 55 years) 1.06 (1.05–1.08) 1.07 (1.05–1.08) 1.06 (1.05–1.07)
Interaction between phenprocoumon and age 0.97 (0.94–1.00) 0.97 (0.94–1.00) 0.96 (0.93–0.99)
Female sex 0.87 (0.73–1.03) 0.85 (0.72–1.01) 0.86 (0.73–1.02)
Interaction between phenprocoumon and sex 1.75 (1.07–2.85) 1.77 (1.09–2.87) 1.69 (1.02–2.78)
BMI≥ 30 kg/m² 1.57 (1.00–2.47) 1.64 (1.07–2.51) 1.56 (1.00–2.42)
Interaction between phenprocoumon and BMI 0.68 (0.25–1.82) 0.67 (0.28–1.61) 0.47 (0.18–1.25)
Current smoker 2.30 (1.50–3.53) 2.47 (1.64–3.72) 2.24 (1.47–3.42)
Comorbid conditions
Hypertension 1.22 (0.80–1.88) 1.30 (1.06–1.59) 1.24 (0.82–1.87)
Diabetes mellitus 1.16 (0.72–1.89) 1.10 (0.68–1.77) 1.53 (1.22–1.91)
$Stratiﬁcation A includes information on age (three categories), sex, and phenprocoumon exposure.
#Stratiﬁcation B includes information on age (three categories), sex, phenprocoumon exposure, and hypertension.
}Stratiﬁcation C includes information on age (three categories), sex, phenprocoumon exposure, and diabetes mellitus.
*One control without information on BMI and one case and two controls without information on smoking were excluded from the analysis.
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that the structural damage of the arterial wall caused by
smoking could be the mechanism by which smoking
increases the bleeding risk. On the other side, it is
suspected that smoking has a short-term effect of reduc-
ing blood ﬂow, which may result in a negative interac-
tion with anticoagulant use. The results of a case–control
study investigating the effect of lifestyle and diet on
overanticoagulation supported this hypothesis.21 In our
study, we also observed a negative but non-signiﬁcant
interaction between smoking and phenprocoumon use.
From a methodological point of view, the study
results demonstrated that the precision of the OR
estimates in two-phase analyses depends on the chosen
stratiﬁcation. Stratiﬁcation on phase 1 variables incor-
porates the information of these variables into the two-
phase analysis. If, for example, age is not used in the
stratiﬁcation, the age distribution in phase 1 would be
ignored in the two-phase analysis leading to imprecise
estimates for age. This point is illustrated in Table 6;
although the effects of hypertension and diabetes
mellitus were not signiﬁcant when using stratiﬁcation
A, both effects became signiﬁcant when using the
alternative stratiﬁcations B and C, which incorporate
the respective phase 1 distributions.
Database studies have several strengths including the
large sample size and the availability of a multitude of
covariates and potential confounders. In our study, the
lack of important confounder information, for example,
BMI, was rectiﬁed using additional data from a health
survey in a two-phase approach. Because BMI and
smoking behavior were self-reported in the survey, there
is a potential for misclassiﬁcation error. However,
because only rough categorizations of BMI and
smoking were used in the analyses, we do not expect
that results were biased by the misclassiﬁcation error.
We did not include survey data on OTC use of pain
killers in our analysis because a comparison of survey
data with claims data with respect to prescribed pain kill-
ers revealed a large amount of reporting error. We also
could not account for the intensity of anticoagulation.
However, we do not expect major bias because the tar-
get international normalized ratio (INR) is between
2.0 and 3.0 for most indications of phenprocoumon
and between 2.0 and 3.5 only for mechanical heart
valve replacement.22 Increases in bleeding risk were
reported for INR values above 3.0, with the greatest
increase for INR values of more than 4.0.14,23 The
prescribed dose of phenprocoumon also was not avail-
able in our study, which might lead to misclassiﬁcation
of the exposure status at the index day. Sensitivity anal-
yses involving different deﬁnitions of phenprocoumon
exposure revealed similar risk estimates for all exposure
measures.1 A further limitation of our two-phase analy-
sis was certainly the small sample size of phase 2, pre-
cluding more informative stratiﬁcations and inclusion
of further covariates in the two-phase analysis. Because
we could not include the full set of covariates, the two-
phase analyses can only be deemed as sensitivity analy-
ses. Further research will address how to include a
maximum of phase 1 information on multiple risk
factors in the two-phase analysis.
In conclusion, the phase 2 sample, although very
small, added valuable information on the role of
smoking and BMI. Hence, the two-phase approach can
Figure 1. Risk of bleeding associated with phenprocoumon use estimated from phase 1 and phase 2 models using different stratiﬁcations
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be useful even with small phase 2 samples to cope with
missing confounder information. Conversely, it is reas-
suring that phase 1 results did not change dramatically
when phase 2 information on BMI was added because
it often is not possible to collect supplemental informa-
tion for database studies.
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KEY POINTS
• Two-phase methodology can be used to include
missing confounder information in database
studies.
• The two-phase analysis revealed that high BMI
and smoking are risk factors for serious bleedings;
information on both factors was lacking in the
claims data but obtained via patient interviews.
• The pure phase 1 analysis and the two-phase
analysis yielded similar risk estimates for phen-
procoumon use and bleeding.
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APPENDIX A
DEFINITION OF SERIOUS BLEEDINGS:
The following ICD-10 GM codes were used to identify
serious bleedings from the main discharge diagnosis:
• Gastrointestinal bleedings: K25.0, K25.2, K25.4,
K25.6, K25.8, K26.0, K26.2, K26.4, K26.6, K26.8,
K27.0, K27.2, K27.4, K27.6, K27.8, K28.0, K28.2,
K28.4, K28.6, K28.8, K29.0, I85.0, K22.6, K31.82,
K55.22, K57.01, K57.03, K57.11, K57.13, K57.21,
K57.23, K57.31, K57.33, K57.41, K57.43, K57.51,
K57.53, K57.81, K57.83, K57.91, K57.93, K62.5,
K92.0, K92.2
• Cerebral bleedings: I60.-, I61.-, I62.-
• Urogenital bleedings: N02.-, N42.1, N83.6, N85.7,
N89.7, N93.-, N95.0, R31
• Other bleedings: D68.3, D69.8, D69.9, H11.3,
H21.0, H31.3, H35.6, H43.1, H92.2, I31.2, J94.2,
K66.1, M25.0, R04.-, R23.3, R58
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DEFINITION OF RISK FACTORS AND
POTENTIAL CONFOUNDERS FROM CLAIMS
DATA:
Risk factors and potential confounding factors were
identiﬁed via ICD-10 GM codes from ambulatory and
inpatient diagnoses or ATC codes: diabetes mellitus
(ICD-10 codes E10 – E14 and prescriptions of antidia-
betic treatment: ATC codes A10A and A10B), alcohol
dependence (ICD-10 code F10 and prescriptions of
disulﬁram or acamprosate: ATC code N07BB), sys-
temic hypertension (ICD-10 codes I10–I15), ischemic
heart disease (ICD-10 codes I20–I25), liver diseases
(ICD-10 codes K70–K77, B15–B19), renal failure
(ICD-10 codes N17 – N19, P96.0), cancer s(ICD-10
codes C00-C97), epilepsy (ICD-10 code G40), ischemic
cerebral infarction (ICD-10 codes I63, I64), chronic
obstructive pulmonary disease (COPD) (ICD-10 code
J44), diverticular disease (ICD-10 codes K57, Q43,
K38.2), gastrointestinal disease (ICD-10 codes K20,
K21, K22.1, K25.1, K25.3, K25.5, K25.7, K25.9,
K26.1, K26.3, K26.5, K26.7, K26.9, K27.1, K27.3,
K27.5, K27.7, K27.9, K28.1, K28.3, K28.5, K28.7,
K28.9, K29.1, K29.3, K29.5, K29.7, K29.9), platelet
aggregation inhibitors (ATC codes B01AC04,
B01AC05), heparin (ATC code B01AB), non-steroidal
anti inﬂammatory drugs (NSAIDs) (ATC codes
M01A, M01BA), acetylsalicylic acid (ASA) (ATC
codes N02BA01, N02BA51, N02BA71, B01AC06)
selective serotonin reuptake inhibitors (SSRIs) (ATC
code N06AB), diuretics (ATC codes C02L, C03,
C07B-D, C08G, C09BA, C09DA ), corticosteroids
(ATC code H02), statins (ATC codes C10AA,
C10BA), and gastroprotective drugs (ATC codes
A02BA, A02BC, A02BX02, A02BB01, A01BX03).
Concomitant medications were identiﬁed by ambula-
tory prescriptions overlapping the index date or the
week before the index date. The duration of a prescrip-
tion was estimated under consideration of the amount
of prescribed substance and the DDD.
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Appendix E
Paper 4: Stratiﬁcation in two-phase
database studies with a rich phase 1
data set
Since this manuscript has not been published and most journals prohibit previous
publication of substantial parts of the manuscript, only the abstract and a selection
of tables and ﬁgures are included here.
Contribution to the manuscript I herewith certify that I conceived and de-
signed the research, performed all statistical analyses, interpreted the results, and
drafted the manuscript.
137
Stratiﬁcation in two-phase database studies with a rich phase 1
data set
Sigrid Behr, Walter Schill
Department of Biometry and Data Management, Leibniz Institute for Prevention Research and Epidemiology - BIPS,
Achterstr. 30, 28359 Bremen, Germany
Abstract
In logistic two-phase studies a dichotomous outcome and some covariate information are avail-
able for a large phase 1 data set whereas the full vector of covariates is only observed for a
subsample. Information on phase 1 covariates is utilized in the analysis of the phase 2 sample
via stratiﬁcation. Whereas in traditional two-phase studies only few phase 1 variables are col-
lected in a ﬁeld study, two-phase database studies encompass a multitude of covariates in phase
1. The traditional stratiﬁcation strategy, cross-classiﬁcation of all available phase 1 variables,
reaches its limits due to tremendously large numbers of strata. New stratiﬁcation strategies are
needed which account for relevant phase 1 covariates. In this work we propose to stratify on
percentiles of a disease score, which summarizes information on multiple phase 1 covariates.
The new approach is compared to cross-classiﬁcation in an empirical example of a two-phase
pharmacoepidemiological database study as well as by means of a simulation study based on the
empirical example.
Keywords: Database study, post stratiﬁcation, stratiﬁed sampling, study design, two-phase
methodology
Preprint submitted to XXX July 11, 2013
Figure E.1: Empirical distribution of the disease score in cases and controls. The
histogram in the background shows the marginal distribution. Vertical reference
lines correspond to the 50th and 95th percentile of the marginal distribution.
Figure E.2: Set-up of the simulation study. Phase 2 samples of sizes 500-10 000
are sampled according to four sampling schemes from each of the 1 000 phase 1 data
sets. Phase 2 data sets are analysed with respect to stratiﬁcations A-E and E*.
139
(a) Age
(b) Hypertension
Figure E.3: Bias in complete-case and two-phase analyses of phase 2 samples of
size 2 000. Vertical reference lines mark boxes showing bias in the complete-case
analysis, all other boxes refer to bias from the two-phase analysis. The numbers 1-4
denote the sampling scheme, where 4 refers to sampling according to stratiﬁcation
E*. Boxes are clipped if values exceed 10 times the interquartile range.
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Figure E.4: Eﬃciency of two-phase estimators for hypertension in phase 2 samples
of size 2 000. Stratiﬁcations are denoted by the capitals A-E. E* denotes the box
corresponding to the sample drawn and analysed with respect to stratiﬁcation E*.
Boxes are clipped if values exceed 10 times the interquartile range.
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Table E.1: Deﬁnition of stratiﬁcations applied in the empirical example and in the
simulation study
Name Stratiﬁed by... No of strata in the
empirical study simulation studya
A Phenprocoumon, age (<50, 50-<65, ≥65
years), sex
12 10
B Phenprocoumon, age (<50, 50-<65, ≥65
years), sex, hypertension
21 20
C Phenprocoumon, age (<50, 50-<65, ≥65
years), sex, diabetes
20 20
D Phenprocoumon, percentiles of the disease
score (50th, 75th, 90th, 95th, 99th %ile)
8 12
E Phenprocoumon, age (<50, 50-<65, ≥65
years), sex, 90th percentile of the disease
score
– 20
E* Phenprocoumon, age (<50, 50-<65, ≥65
years), sex, percentiles of the disease score
(90th, 95th %ile)
20 21(20-22)
F Phenprocoumon, age (<65, ≥65 years),
sex, percentiles of the disease score (50th,
75th, 90th, 95th, 99th %ile)
24 –
a If the number of strata varies, the median number of strata is presented with the quartiles Q1
and Q3 in parentheses.
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(0.31)
0.32
(0.21)
0.35
(0.21)
0.32
(0.16)
C
urrent
use
of:
N
SA
ID
s
0.37
0.36
(0.09)
0.37
(0.26)
0.38
(0.19)
0.37
(0.18)
0.37
(0.14)
A
SA
0.56
0.54
(0.12)
0.56
(0.31)
0.60
(0.26)
0.55
(0.24)
0.56
(0.16)
D
iuretics
0.21
0.21
(0.07)
0.22
(0.21)
0.22
(0.13)
0.21
(0.13)
0.21
(0.11)
Statins
-0.11
-0.11
(0.11)
-0.11
(0.30)
-0.13
(0.19)
-0.12
(0.18)
-0.11
(0.15)
G
astroprotective
drugs
0.57
0.55
(0.09)
0.56
(0.21)
0.58
(0.17)
0.59
(0.16)
0.57
(0.12)
P
hase
2
variables:
B
M
I≥
30kg/m
2
0.45
—
0.47
(0.22)
0.46
(0.11)
0.46
(0.11)
0.46
(0.11)
IA
:phen.×
B
M
I
-0.39
—
-0.39
(0.50)
-0.39
(0.27)
-0.39
(0.27)
-0.39
(0.27)
C
urrent
sm
oker
0.83
—
0.87
(0.19)
0.83
(0.10)
0.84
(0.10)
0.84
(0.10)
a
P
aram
eter
that
is
used
for
the
sim
ulation
of
the
disease
status.
b
P
aram
eter
estim
ate
and
standard
error
(SE
)
are
averaged
over
allsim
ulations.
c
A
ge
is
centred
around
55
years.
144
Bibliography
Aitchison, J. and Silvey, S. D. (1958). Maximum likelihood estimation of parameters
subject to restraints. Annals of Mathematical Statistics, 29(3): 813–828.
Allison, P. D. (2005). “Imputation of categorical variables with PROC MI”. SUGI
30 Proceedings.
Behr, S. and Schill, W. (2013). Stratiﬁcation in two-phase database studies with a
rich phase 1 data set. Unpublished manuscript.
Behr, S., Andersohn, F., and Garbe, E. (2010). Risk of intracerebral haemorrhage
associated with phenprocoumon exposure: a nested case-control study in a large
population-based German database. Pharmacoepidemiology and Drug Safety, 7(19):
722–730. doi: 10.1002/pds.1973.
Behr, S., Schill, W., and Pigeot, I. (2012). Does additional confounder information
alter the estimated risk of bleeding associated with phenprocoumon use - results
of a two-phase study. Pharmacoepidemiology and Drug Safety, 21(5): 535–545.
doi: 10.1002/pds.3193.
Breslow, N. E. and Cain, K. C. (1988). Logistic regression for two-stage case-control
data. Biometrika, 75(1): 11–20.
Breslow, N. E. and Chatterjee, N. (1999). Design and analysis of two-phase studies
with binary outcome applied to Wilms tumour prognosis. Applied Statistics,
48(4): 457–468.
Breslow, N. E. and Holubkov, R. (1997a). Maximum likelihood estimation of logistic
regression parameters under two-phase, outcome-dependent sampling. Journal of
the Royal Statistical Society B, 59(2): 447–461.
145
Breslow, N. E. and Holubkov, R. (1997b). Weighted likelihood, pseudo-likelihood
and maximum likelihood methods for logistic regression analysis of two-stage
data. Statistics in Medicine, 16(1): 103–116.
Breslow, N. E., McNeney, B., and Wellner, J. A. (2003). Large sample theory for
semiparametric regression models with two-phase, outcome-dependent sampling.
The Annals of Statistics, 31(4): 1110–1139.
Breslow, N. E., Amorim, G., Pettinger, M. B., and Rossouw, J. (2013). Using the
whole cohort in the analysis of case-control data. Statistics in Biosciences. doi:
10.1007/s12561-013-9080-2.
Charlson, M. E., Pompei, P., Ales, K. L., and MacKenzie, C. R. (1987). A new
method of classifying prognostic comorbidity in longitudinal studies: development
and validation. Journal of Chronic Diseases, 40: 373–383.
Collet, J., Schaubel, D., Hanley, J., Sharpe, C., and Boivin, J. (1998). Controlling
confounding when studying large pharmacoepidemiologic databases: a case study
of the two-stage sampling design. Epidemiology, 9(3): 309–315.
Deville, J. C., Särndal, C. E., and Sautory, O. (1993). Generalized raking procedures
in survey sampling. Journal of the American Statistical Association, 88: 1013–
1020.
Flanders, W. D. and Greenland, S. (1991). Analytic methods for two-stage case-
control studies and other stratiﬁed designs. Statistics in Medicine, 10(5): 739–
747.
Garbe, E., Kreisel, S., and Behr, S. (2013). Risk of subarachnoid hemorrhage and
early case fatality associated with outpatient antithrombotic drug use. Stroke.
doi: 10.1161/STROKEAHA.111.000811.
Gill, R. D., Vardi, Y., and Wellner, J. A. (1988). Large sample theory of empirical
distributions in biased sampling models. Annals of Statistics, 16: 1069–1112.
Groenbaek, H., Johnsen, S., Jepsen, P., Gislum, M., Vilstrup, H., Tage-Jensen, U.,
and Soerensen, H. (2008). Liver cirrhosis, other liver diseases and risk of hospi-
talisation for intracranial haemorrhage: a Danish population-based case-control
study. BMC Gastroenterology, 8: 16. doi: 10.1186/1471-230Y-8-16.
146
Haneuse, S., Saegusa, T., and Lumley, T. (2011). osDesign: An R package for the
analysis, evaluation, and design of two-phase and case-control studies. Journal of
Statistical Software, 43(11): 1–29.
Hein, L. and Schwabe, U. (2007). Antikoagulantien und Thrombozytenaggregation-
shemmer. Arzneiverordnungsreport. Ed. by U. Schwabe and D. Paﬀrath. Heidel-
berg: Springer Medizin Verlag: 425–438.
Hernandez-Diaz, S. and Rodriguez, L. Garcia (2002). Incidence of serious upper
gastrointestinal bleedings/perforation in the general population: Review of epi-
demiologic studies. Journal of Clinical Epidemiology, 55: 157–163.
Hirose, Y. and Lee, A. J. (2012). Reparametrization of the least favorable submodel
in semi-parametric multisample models. Bernoulli, 18(2): 586–605.
Holubkov, R. (1995). “Maximum likelihood estimation in two-stage case-control
studies”. PhD thesis. University of Washington.
Horvitz, D. and Thompson, D. (1952). A Generalization of Sampling Without Re-
placement from a Finite Universe. Journal of of the American Statistical Associ-
ation, 47(11): 663–685.
Hsieh, F. Y., Bloch, D. A., and Larsen, M. D. (1998). A simple method of sample
size calculation for linear and logistic regression. Statistics in Medicine, 17: 1623–
1634.
Jobski, K., Behr, S., and Garbe, E. (2011). Drug interactions with phenprocoumon
and the risk of serious haemorrhage: A nested case-control study in a large
population-based German database. European Journal of Clinical Pharmacology,
67(9): 941–951. doi: 10.1007/s00228-011-1031-6.
Johnsen, S., Pedersen, L., Friis, S., Blot, W., McLaughlin, J., Olsen, J., and So-
erensen, H. (2003). Nonaspirin nonsteroidal anti-inﬂammatory drugs and risk
of hospitalisation for intracerebral haemorrhage: a population-based case-control
study. Stroke, 34(2): 387–391. doi: 10.1161/01.STR.0000054057.11892.5B.
Korﬀ, M. von, Wagner, E. H., and Saunders, K. (1992). A chronic disease score from
automated pharmacy data. Journal of Clinical Epidemiology, 45: 197–203.
147
Kreuter, F., Mueller, G., and Trappmann, M. (2010). Nonresponse and measurement
error in employment research - Making use of administrative data. Public Opinion
Quarterly, 74(5): 880–906.
Lavori, P. W., Dawson, R., and Shera, D. (1995). A multiple imputation strategy for
clinical trials with truncation of patient data. Statistics in Medicine, 14: 1913–
1925.
Lee, A. J. (2007). On the semiparametric eﬃciency of the Scott-Wild estimator
under choice-based and two-phase sampling. Journal of Applied Mathematics and
Decision Sciences. Article ID 86180.
Little, R. J. A. and Rubin, D. B. (2002). Statistical analysis with missing data.
Second. New Jersey: John Wiley & Sons.
Lumley, T. (2004). Analysis of complex survey samples. Journal of Statistical Soft-
ware, 9: 1–19.
March, S., Rauch, A., Thomas, D., Bender, S., and Swart, E. (2012). Procedures
according to data protection laws for coupling primary and secondary data in a
cohort study: the lidA study. Gesundheitswesen. doi: 10.1055/s-0031-1301276.
Martel, M., Rey, E., Malo, J., Perreault, S., Beauchesne, M., Forget, A., and Blais,
L. (2009). Determinants of the incidence of childhood asthma: a two-stage case-
control study. American Journal of Epidemiology, 169(2): 195–205.
Marti, H. and Chavance, M. (2011). Multiple imputation analysis of case-cohort
studies. Statistics in Medicine, 30: 1595–1607.
Myers, J. A. and Louis, T. A. (2007). Optimal propensity score stratiﬁcation. Working
papers Working Paper 155. Johns Hopkins University, Dept. of Biostatistics.
Neyman, J. (1938). Contribution to the theory of sampling human populations.
Journal of the American Statistical Association, 33(201): 101–116.
Pigeot, I. and Ahrens, W. (2008). Establishment of a pharmacoepidemiological
database in Germany: Methodological potential, scientiﬁc value and practical
limitations. Pharmacoepidemiology and Drug Safety, 3(17): 215–223. doi: 10.
1002/pds.1545.
148
Prentice, R. L. and Pyke, R. (1979). Logistic disease incidence models and case-
control studies. Biometrika, 66(3): 403–411.
Reilly, M. and Pepe, M. S. (1995). A mean score method for missing and auxiliary
covariate data in regression models. Biometrika, 82(2): 299–314.
Reilly, M. and Pepe, M. (1997). The relationship between hot-deck multiple impu-
tation and weighted likelihood. Statistics in Medicine, 16: 5–19.
Robins, J. M., Rotnitzky, A., and Zhao, L. P. (1994). Estimation of regression coef-
ﬁcients when some regressors are not always observed. Journal of the American
Statistical Association, 89: 846–866.
Rosenbaum, P. R. and Rubin, D. B. (1983). The central role of the propensity score
in observational studies for causal eﬀects. Biometrika, 70(1): 41–55.
Rubin, D. B. (1978). “Multiple imputations in sample surveys”. Proceedings of the
Survey Research Methods Section, American Statistical Association: 20–34.
– (1987). Multiple imputation for nonresponse in surveys. New York: John Wiley.
– (1996). Multiple imputation 18+ years. Journal of the American Statistical As-
sociation, 91(434): 473–489.
Rudolph, H. and Trappmann, M. (2007). Design und Stichprobe des Panels "Ar-
beitsmarkt und Soziale Sicherung" (PASS). IAB Forschungsbericht, 12/2007: 60–
101.
SAS/STAT 9.2 User’s Guide (2008). SAS Institute Inc. Cary, NC.
Schafer, J. L. (1999). Multiple imputation: a primer. Statistical Methods in Medical
Research, 8(1): 3–15.
Schaubel, D., Hanley, J., Collet, J., Boivin, J., Sharpe, C., Morrison, H. I., and
Mao, Y. (1997). Two-stage sampling for etiologic studies. American Journal of
Epidemiology, 146(5): 450–458.
Schill, W. and Drescher, K. (1997). Logistic analysis of studies with two-stage sam-
pling: a comparison of four approaches. Statistics in Medicine, 16: 117–132.
149
Schill, W. and Wild, P. (2006). Minmax designs for planning the second phase in a
two-phase case-control study. Statistics in Medicine, 25: 1646–1659.
Schill, W., Joeckel, K.-H., Drescher, K., and Timm, J. (1993). Logistic analysis in
case-control studies under validation sampling. Biometrika, 80(2): 339–352.
Schill, W., Enders, D., and Drescher, K. (2013). sas-twophase-package: A SAS-
package for logistic two-phase studies. Journal of Statistical Software. submitted.
Scott, A. J. and Wild, C. J. (1991). Fitting logistic regression models in stratiﬁed
case-control studies. Biometrics, 47: 497–510.
– (1997). Fitting regression models to case-control data by maximum likelihood.
Biometrika, 84(1): 57–71.
– (2001). Maximum likelihood for generalised case-control studies. Journal of Sta-
tistical Planning and Inference, 96(1): 3–27.
– (2006). Calculating eﬃcient semiparametric estimators for a broad class of missing-
data problems. Festschrift for Tarmo Pukkila on his 60th birthday. Ed. by E. P.
Liski, J. Isotalo, J. Niemelae, S. Putanen, and G. P. H. Styan. University of
Tampere: 301–314.
– (2011). Fitting regression models with response-biased samples. Canadian Jour-
nal of Statistics, 39: 519–536.
Scott, A. J., Lee, A. J., and Wild, C. J. (2007). On the Breslow-Holubkov estimator.
Lifetime Data Analysis, 13: 545–563.
Sharpe, C., Collet, J., McNutt, M., Boivin, J., and Hanley, J. (2000). Nested case-
control study of the eﬀects of non-steroidal anti-inﬂammatory drugs on breast
cancer risk and stage. British Journal of Cancer, 83(1): 112–120.
Vaart, A. van der and Wellner, J. A. (2001). Consistency of semiparametric max-
imum likelihood estimators for two-phase sampling. The Canadian Journal of
Statistics, 29(2): 269–288.
Walker, A. M. (1982). Anamorphic analysis: Sampling and estimation for covariate
eﬀects when both exposure and disease are known. Biometrics, 38(4): 1025–1032.
150
White, J. E. (1982). A two stage design for the study of the relationship between
a rare exposure and a rare disease. American Journal of Epidemiology, 115(1):
119–128.
Whittemore, A. S. (1981). Sample size for logistic regression with small response
probability. Journal of the American Statistical Association, 76(373): 27–32.
Wild, C. J. and Jiang, Y. Description of the "missreg" library. Accessed on 2013-
01-12. url: http://www.stat.auckland.ac.nz/~wild/software.html.
151
CURRICULUM VITAE
Sigrid Behr
Leibniz Institute for Prevention Research and Epidemiology - BIPS
Department of Biometry and Data Manangement
Achterstr. 30, 28309 Bremen, Germany
Phone: +49 421 218-56951
Email: behr@bips.uni-bremen.de
EDUCATION
2007-present Ph.D. candidate in Statistics, Bremen University
1998-2004 Diploma in mathematics, RWTH Aachen
PROFESSIONAL POSITIONS
2007-present Research associate at BIPS
2004-2007 Statistician at Bayer Healthcare, Wuppertal, Germany
PUBLICATIONS
Peer-reviewed publications
2013 E. Garbe, S. Kreisel, and S. Behr. Risk of subarachnoid hemorrhage and early
case fatality associated with outpatient antithrombotic drug use. Stroke, 2013. doi:
10.1161/STROKEAHA.111.000811
2012 S. Behr, W. Schill, and I. Pigeot. Does additional confounder information alter
the estimated risk of bleeding associated with phenprocoumon use - results of a
two-phase study. Pharmacoepidemiology and Drug Safety, 21(5):535–545, 2012. doi:
10.1002/pds.3193
K. Jobski, U. Schmid, S. Behr, F. Andersohn, and E. Garbe. 3-year prevalence
of alcohol-related disorders in German patients treated with high-potency opioids.
Pharmacoepidemiology and Drug Safety, 21(10):1125 – 1129, 2012. doi: 10.1002/
pds.3268
2011 K. Jobski, S. Behr, and E. Garbe. Drug interactions with phenprocoumon and the
risk of serious haemorrhage: A nested case-control study in a large population-based
german database. European Journal of Clinical Pharmacology, 67(9):941–951, 2011.
doi: 10.1007/s00228-011-1031-6
2010 S. Behr, F. Andersohn, and E. Garbe. Risk of intracerebral haemorrhage associated
with phenprocoumon exposure: a nested case-control study in a large population-
based german database. Pharmacoepidemiology and Drug Safety, 7(19):722–730,
2010. doi: 10.1002/pds.1973
Other publications
2011 R. Mikolajczyk, S. Behr, and E. Garbe. Re: ”Auswirkungen leitlinienkonformer
Therapie auf das berleben von Patientinnen mit primrem Mammakarzinom - Ergeb-
nisse einer retrospektiven Kohortenstudie.” by R. Wolters, A. Wockel, M. Wis-
chnewsky and R. Kreienberg (Z Evid Fortbild Qual Gesundhwes 2011;105(6):468-
475). Zeitschrift fr Evidenz, Fortbildung und Qualitt im Gesundheitswesen, 105(6):
468–475, 2011. doi: doi:10.1016/j.zefq.2011.10.010. Letter to the editor
2008 S. Behr. New drug development: Design, methodology, and analysis by J. R. Turner.
Biometrics, 64(1):313–314, 2008. doi: 10.1111/j.1541-0420.2008.00962 6.x. Book
review
